

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.
OM protein - protein search, using sw model
Run on: October 29, 2003, 16:06:23 ; Search time 15.1588 Seconds
(without alignments)
2045.935 Million cell updates/sec
Title: US-09-832-129-35_COPY_34_766
Perfect score: 3902
Sequence: 1 AVSDQKATSPFDLSDKGP.....QAFNAKLPTMDYETKJCS 733
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5
Searched: 328717 seqs, 42310358 residues

Total number of hits satisfying chosen parameters: 328717

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:
1: /cgn2_6/ptodata/2/iaa/5A_COVB pep.*
2: /cgn2_6/ptodata/2/iaa/5B_COVB pep.*
3: /cgn2_6/ptodata/2/iaa/6A_COVB pep.*
4: /cgn2_6/ptodata/2/iaa/6B_COVB pep.*
5: /cgn2_6/ptodata/2/iaa/PCFUS_COVB pep.*
6: /cgn2_6/ptodata/2/iaa/backfiles1 pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	115.5	3.0	990	4	US-09-627-376-7
2	114.5	2.9	320	4	US-09-183-861-22
3	114.5	2.9	320	4	US-09-183-861-55
4	114.5	2.9	320	4	US-09-322-765-22
5	114.5	2.9	320	4	US-09-322-765-55
6	114.5	2.9	320	4	US-09-551-974A-22
7	114.5	2.9	320	4	US-09-551-974A-55
8	104.5	2.7	3461	4	US-09-334-220-2
9	103.5	2.7	1038	3	US-09-541-782-4
10	103.5	2.7	1038	4	US-09-723-820-4
11	103	2.6	744	1	US-08-179-481-2
12	102.5	2.6	1032	4	US-09-914-259-26
13	102	2.6	1817	4	US-09-004-838-125
14	101.5	2.6	907	3	US-08-930-996A-7
15	101.5	2.6	993	3	US-08-183-211-2
16	101.5	2.6	993	5	PCT-US95-00176A-2
17	101.5	2.6	4654	3	US-08-476-815A-84
18	101.5	2.6	4655	3	US-08-652-877-84
19	101.5	2.6	4655	3	US-08-652-877-86
20	101.5	2.6	4655	3	US-08-652-877-88
21	101.5	2.6	4655	3	US-08-652-877-90
22	100.5	2.6	560	2	US-08-559-492-5
23	100.5	2.6	1193	3	US-09-245-041-31
24	100.5	2.6	1198	4	US-09-734-236-3
25	100.5	2.6	1350	3	US-09-245-041-17
26	100.5	2.6	1429	3	US-09-245-041-30
27	100.5	2.6	2787	3	US-09-245-041-15

28 99.5 2.5 1170 1 US-08-313-288B-20 Sequence 20, Appl
29 99.5 2.5 1211 4 US-09-124-001C-4820 Sequence 4820, Ap
30 97.5 2.5 993 1 US-08-222-239-4 Sequence 4, Appl
31 97.5 2.5 993 2 US-08-434-878-4 Sequence 4, Appl
32 97.5 2.5 993 5 PCT-US95-03718-4 Sequence 4, Appl
33 97 2.5 557 1 US-08-313-288B-16 Sequence 16, Appl
34 96.5 2.5 1073 3 US-09-541-782-6 Sequence 6, Appl
35 96.5 2.5 1073 4 US-09-723-820-6 Sequence 6, Appl
36 96.5 2.5 480 3 US-09-191-647-7 Sequence 7, Appl
37 96.5 2.5 480 3 US-09-540-245A-7 Sequence 7, Appl
38 96.5 2.5 480 3 US-09-540-153-7 Sequence 7, Appl
39 96.5 2.5 480 4 US-09-182-034A-5 Sequence 5, Appl
40 96.5 2.5 480 5 PCT-US91-09055-2 Sequence 2, Appl
41 95.5 2.4 885 2 US-08-310-912A-2 Sequence 2, Appl
42 95.5 2.4 885 3 US-08-841-089-2 Sequence 2, Appl
43 95.5 2.4 885 3 US-09-301-085-2 Sequence 2, Appl
44 95.5 2.4 885 5 PCT-US95-04570-2 Sequence 2, Appl
45 95.5 2.4 995 5 PCT US95-04599-2 Sequence 2, Appl

ALIGNMENTS

RESULT 1
US-09-627-376-7
; Sequence 7, Application US/09427376
; Patent No. 6342385
; GENERAL INFORMATION:
; APPLICANT: Qi, Fengxia Caulfield, Page Chen, Ping
; TITLE OF INVENTION: MUTACIN : BIOSYNTHESIS GENES AND PROTEINS
; FILE REFERENCE: CAB-17402/22
; CURRENT APPLICATION NUMBER: US/09/627,376
; CURRENT FILING DATE: 2001-05-30
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: Patent version 3.0
; SEQ ID NO 7
; LENGTH: 990
; TYPE: PRT
; ORGANISM: Streptococcus mutans
US-09-627-376-7

Query Match 3.0%; Score 115.5; DB 4; Length 990;
Best Local Similarity 18.9%; Pred. No. 0.072;
Matches 154; Conservative 125; Mismatches 270; Indels 265; Gaps 42;

QY 86 TFCQITENLIXYG-----THF LLSSATGGESLTFVDRKLSKRAEGSSTNS 136
DB 139 TLKVANNALQKSNDFWCLDTRSHFGLMNSRD:REDITV-----KSNQLIDYVNC 190
QY 137 SS--VTLETHQLAASYFIDRDSTLRLHHQIASTAIK---VTETRTGPGCSNYDK- 189
DB 191 TTEP:SYQTLDDIAEKFSQSSDDVK-----EYLGLIKEEFILTELKPSLID----DKP 241
QY 190 LBSVSVLVQSPENKIQGL---QVLLPDYQERFVQAALSYIACNSEEFTCKEN----243
DB 242 LDWF-NILERCQNNSELLEKLEIKAMQDYTDNRIGEGNSILALENKKMSQIVKANAYL 301
QY 244 --DCHCHGCKPPECNCPNMD:QAMEENLRLITETW-KAYNSDFESSEFKLFMKR---- 296
DB 302 RVDLDYDHAEFLKLAQHTKSSL-----QNLKVLSSFSFSAVNSQKIKNYHEKFIAPYGYE 355
QY 297 --LENNYFLNTST:WHLMTMDSNFORRYEOLB-NEMKQLFLKAOKIVHKL---FSLSKAC 350
DB 356 QLVPLQLLJNS-----TSLGFPKGYGQTEVSKNNEDSKNQKIIFFLQPKFEALRD 408
QY 351 HKQPLISPRQRTSTY-WLTRIQSFLYCNEN-----GLLGSFSEEHSCTC 395
DB 409 GKELLSODDLKDLNFDTEQQISGLYCFYFKSKKLELVSLGVQMLGNTGRHS-KL 467
QY 396 PNDQVWCTAF:PCTVGDASACLTCPDNTRTCGTNTGY-----XLSQGCCKEVEAES 448
DB 468 PN-----TIVTKNKNKTE:FTEAYPNTIITQLNEVPYFGSGGNIVISNLS-KSHQLEL 520

QY 449 TCRVIGFETDLDL-----EMKYLCKTDRRIEVRHAIPTSNQWRLNSKFDSEWPKZML 501
DB 521 RNYTTKMSINDIYVRATSEELFYKVKYKRV-----IFVNMNM--FNWNGSKLRLFD 574
QY 502 LTLKSNKYKSLVHMILGL-----SIQICLTK 528
DB 575 LEVNSDPQ-NITFITLGLSDSNHVPAILYKDIILIKPETWNIKSEAKTLDLSLKWLT- 632
QY 529 NSTLEPVL-----AVYNEFGGSHESWPNVNSF-----PDWERTKLDL 570
DB 633 NNWVPFVRMKYTDQIYVLDL-SRTIDLTMLPQSIKHSFIQLDVRHSVCTNDFEILELVV 602
QY 571 PL-----OCYKXWTLTL-----GKWKTFETVH-----VLR- 597
DB 693 PFRSDVNAHQIYHQAQNIYTLSDSGSEKFIYAKIYVNIKQRTSFQKEYPDLKLYKRL 782
QY 598 -----SRIKSGPNNGNE-----SYEPLEFIDPSRLNGYMKINNIQVFG 637
DB 753 PENLQWFIYRYKDDCKDSIRLIRYVEDKQLVQVYSRFIEWATKAR-----KNIGISG 805
QY 638 YSM-HFOPEAR-----DILQLDYPYTOGSDSALLQLLEIDR 676
DB 806 YEISEY-PESARYGKKYSSIIHSFFYYDSLDLLQ-----KKAQOTIEVRS 854
QY 677 VN-----KLSPGGRRL--DLFSCLEHRLK 700
DB 855 LSIIRFLMLKSLQDCKLXNFDG--KHLKX 886

RESULT 2

US-09-183-861-22
; Sequence 22, Application US/09/83861
; Patent No. 6365165
; GENERAL INFORMATION:
; APPLICANT: Reed, Steven G.
; APPLICANT: Campos-Neto, Antonio
; APPLICANT: Webb, John R.
; APPLICANT: Dillon, David C.
; APPLICANT: Skeiky, Yasir A.W.
; TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE THERAPY AND
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 630C Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/183,861
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/022,765
; FILING DATE: 12-FEB-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Yaki, David J.
; REGISTRATION NUMBER: 31,392
; REFERENCE/DOCKET NUMBER: 210121.420C3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 622-6031
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 320 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein

US-09-183-861-22
Query Match 2.3%; Score 114.5; DB 4; Length 320;
Best Local Similarity 32.3%; Pred. No. 0.013;
Matches 30; Conservative 8; Mismatches 40; Indels 15; Gaps 3;
QY 350 CHKQPLISLPRQRTSYWLTIRIQSLFYCHNGLGSEETHSCTCPNDQVCTAFPLPCT 409
DB 176 CRUSDACSVNCKKCTGT-SRL-----CAECTGYSLSADATSCSPTTQ-----PCE 223
QY 410 VGDASACLTCAPDNRTRCGTCTNTGYWLSQGLCK 442
DB 224 V-----ESQNTGVNGDSTRCAVCNTGYVWSDGKCK 255

RESULT 3

US-09-183-861-55
; Sequence 55, Application US/09183861
; Patent No. 6365165
; GENERAL INFORMATION:
; APPLICANT: Reed, Steven G.
; APPLICANT: Campos-Neto, Antonio
; APPLICANT: Webb, John R.
; APPLICANT: Dillon, David C.
; APPLICANT: Skeiky, Yasir A.W.
; TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE THERAPY AND
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 630C Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/183,861
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/022,765
; FILING DATE: 12-FEB-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Yaki, David J.
; REGISTRATION NUMBER: 31,392
; REFERENCE/DOCKET NUMBER: 210121.420C3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 55:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 320 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FRAGMENT TYPE: internal
; US-09-183-861-55

Query Match 2.3%; Score 114.5; DB 4; Length 320;
Best Local Similarity 32.3%; Pred. No. 0.013;
Matches 30; Conservative 8; Mismatches 40; Indels 15; Gaps 3;
QY 350 CHKQPLISLPRQRTSYWLTIRIQSLFYCHNGLGSEETHSCTCPNDQVCTAFPLPCT 409
DB 176 CRUSDACSVNCKKCTGT-SRL-----CAECTGYSLSADATSCSPTTQ-----PCE 223
QY 410 VGDASACLTCAPDNRTRCGTCTNTGYWLSQGLCK 442

Db 224 V---EHCNTCVNGDSTRCAVCNTGYVYSDGKCK 253

RESULT 4

US-09-022-765-22
; Sequence 22, Application US/09022765
; Patent No. 6375955

GENERAL INFORMATION:

APPLICANT: Reed, Steven G.
APPLICANT: Campos-Neto, Antonio
APPLICANT: Webb, John R.
APPLICANT: Dillon, David C.
APPLICANT: Skeiky, Yasir A.W.

TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE THERAPY AND

NUMBER OF SEQUENCES: 87

CORRESPONDENCE ADDRESS:

ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
City: Seattle

STATE: Washington

COUNTRY: USA

ZIP: 98104-7092

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA: US/09/022,765

APPLICATION NUMBER: US/09/022,765

FILING DATE: 12-FEB-1998

CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:

NAME: Maki, David J.

REGISTRATION NUMBER: 31,392

REFERENCE/DOCKET NUMBER: 210121.420C3

TELECOMMUNICATION INFORMATION:

TELEPHONE: (206) 622-4900

TELEFAX: (206) 692-6031

INFORMATION FOR SEQ ID NO: 22:

SEQUENCE CHARACTERISTICS:

LENGTH: 320 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: Protein

US-09-022-765-22

Query Match

Best Local Similarity 2.9%; Score 114.5; DB 4; Length 320;

Mismatches 30; Conservative 5; Mismatches 40; Indels 15; Gaps 3;

QY 350 CHKQPLISLPQRTSTYKLTIRIQSLFYCNENGLLSFSEETHSCPCNDQVWCTAF.PCT 409

Db 176 CRLSDACSVNCKKCEGTGRSL-----CAECDTGYSLSDATSCSPSTG-----PCE 223

QY 410 VGDASACUCAPDNTRCTGTCNTGYVLSQGLCK 442

Db 224 V---EHCNTCVNGDSTRCAVCNTGYVYSDGKCK 253

RESULT 5

US-09-022-765-55

; Sequence 55, Application US/09022765

; Patent No. 6375955

GENERAL INFORMATION:

APPLICANT: Reed, Steven G.

APPLICANT: Campos-Neto, Antonio

APPLICANT: Webb, John R.

APPLICANT: Dillon, David C.

APPLICANT: Skeiky, Yasir A.W.

TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE THERAPY AND

NUMBER OF SEQUENCES: 87

CORRESPONDENCE ADDRESS:

ADDRESSEE: SEED and BERRY LLP

STREET: 6300 Columbia Center, 701 Fifth Avenue
City: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/022,765

FILING DATE: 12-FEB-1998

CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:

NAME: Maki, David J.

REGISTRATION NUMBER: 31,392

REFERENCE/DOCKET NUMBER: 210121.420C3

TELECOMMUNICATION INFORMATION:

TELEPHONE: (206) 622-4900

TELEFAX: (206) 632-6031

INFORMATION FOR SEQ ID NO: 55:

SEQUENCE CHARACTERISTICS:

LENGTH: 320 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: protein

FRAGMENT TYPE: Internal

US-09-022-765-55

Query Match

Best Local Similarity 32.3%; Score 114.5; DB 4; Length 320;

Mismatches 30; Conservative 8; Mismatches 40; Indels 15; Gaps 3;

QY 350 CHKQPLISLPQRTSTYKLTIRIQSLFYCNENGLLSFSEETHSCPCNDQVWCTAF.PCT 409

Db 176 CRLSDACSVNCKKCEGTGRSL-----CAECDTGYSLSDATSCSPSTG-----PCE 223

QY 410 VGDASACUCAPDNTRCTGTCNTGYVLSQGLCK 442

Db 224 V---EHCNTCVNGDSTRCAVCNTGYVYSDGKCK 253

RESULT 6

US-09-551-974A-22

; Sequence 22, Application US/09551,974A

; Patent No. 6500437

GENERAL INFORMATION:

APPLICANT: Reed, Steven G.

APPLICANT: Campos-Neto, Antonio

APPLICANT: Webb, John R.

APPLICANT: Dillon, David C.

APPLICANT: Skeiky, Yasir A.W.

TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE

FILE REFERENCE: 210121.420C5

CURRENT APPLICATION NUMBER: US/09/551,974A

CURRENT FILING DATE: 2000-04-14

NUMBER OF SEQ ID NOS: 101

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 22

LENGTH: 320

TYPE: PRT

ORGANISM: Leishmania major

US-09-551-974A-22

Query Match

Best Local Similarity 32.3%; Score 114.5; DB 4; Length 320;

Mismatches 30; Conservative 8; Mismatches 40; Indels 15; Gaps 3;

QY 350 CHKQPLISLPQRTSTYKLTIRIQSLFYCNENGLLSFSEETHSCPCNDQVWCTAF.PCT 409

```

DB 176 CR:SDACSVNCKKCTGTSRL-----CAECTGYSLSADATSCSSPTIQ-----PCE 223
QY 4:0 VGDASACVTCAPDNTRCGTNTGVMLSQGLCK 442
DB 224 V---EHCNTCVNGDSTRCAVCNTGYVSDGKCK 253

RESULT 7
US-09-551-974A-55
; Sequence 55, Application US/09551974A
; Patent No. 6500437
; GENERAL INFORMATION:
; APPLICANT: Reed, Steven G.
; APPLICANT: Campos-Nieto, Antonio
; APPLICANT: Webb, John R.
; APPLICANT: Dillon, David C.
; APPLICANT: Skeiky, Yasir A.W.
; TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE
; TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF LEISHMANIASIS
; FILE REFERENCE: 210121.420C5
; CURRENT APPLICATION NUMBER: US/09/551,974A
; CURRENT FILING DATE: 2000-04-14
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 55
; LENGTH: 320
; TYPE: PRT
; ORGANISM: Leishmania major
US-09-551-974A-55

Query Match 2.9%; Score 114.5; DB 4; Length 320;
Best Local Similarity 32.3%; Pred. No. 0.013;
Matches 30; Conservative 8; Mismatches 40; Indels 15; Gaps 3;

QY 350 CHKQPLSLPQRTSTYMLTRIQSLYCNENGLLOSFSEETHSCPCNDQVCTAFIPCT 409
DB 176 CR:SDACSVNCKKCTGTSRL-----CAECTGYSLSADATSCSSPTIQ-----PCE 223
QY 4:0 VGDASACVTCAPDNTRCGTNTGVMLSQGLCK 442
DB 224 V---EHCNTCVNGDSTRCAVCNTGYVSDGKCK 253

RESULT 8
US-09-334-220-2
; Sequence 2, Application US/09334220
; Patent No. 6923177
; GENERAL INFORMATION:
; APPLICANT: St. Jude's Children's Research Hospital
; APPLICANT: Curtan, Thomas
; APPLICANT: D'Arcangelo, Gabriella
; TITLE OF INVENTION: INTERACTION OF REELIN WITH VERY LOW
; TITLE OF INVENTION: DENSITY LIPOPROTEIN (VLDL) RECEPTOR FOR SCREENING AND
; TITLE OF INVENTION: THERAPIES
; FILE REFERENCE: 2427/CF704
; CURRENT APPLICATION NUMBER: US/09/334,220
; CURRENT FILING DATE: 1999-06-16
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 346;
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-334-220-2

Query Match 2.7%; Score 104.5; DB 4; Length 346;
Best Local Similarity 17.3%; Pred. No. 7.4;
Matches 129; Conservative 104; Mismatches 218; Indels 293; Gaps 37;

QY 40 TRYKIYR-----EFGKWKVNLAIV--ERRNFGSLPLPLAPEFFRNRLLSRRPTLQGIT 91
DB 1196 TRFRWKKVFGSDYDCWAVDQIILISEKQ---QVIVV-----NPTLPQ---1238

```

```

QY 92 ENLIKKGTFHLLSATLGGESLTIIVDKRKLKRAEGSDSTNSSSYTLETLHCLAASY 151
DB 1239 -NFEKPAFTYPMK-----QNSVLMJANEGMAKN-QSECATTPSAMVFGKS---DGDRE 1288
QY 152 FIDRSTLRRLHHIGASTAKVTETRTGTPGSCNVNLDSSVSVLVQSPENKICLOGSQ 211
DB 1289 AVTRDCLTLAGGVLOFELN-----IGCTS--QFSSTAPVLLQYSHD-----1327
QY 212 VILPDYQSRFYQAALSYIACNSEGEFCCKEKDCKCHCKPKEFCNCPSCYDQAMEENL 271
DB 1328 -----AGXSW-----FLKEG-CF-----PASAAGCEGNER 1353
QY 272 RITETWKAVNSDPEESDEKLEKALPNYPFNTSTIMELWTWDSNFORYRYCLENSMQ 331
DB 1354 ELSEPTVYVIGDFEETRTITIA:PR-----SLASSKTRFEW-QEASSQKNVPF-----1401
QY 332 LFLKAQKIVHKLPFSKRCRKQPLISLPRQRTSTYMLTRIQSLYCNENGLLOSFSEETH 391
DB 1402 -----FGLDGVYISEPCPS-----YCSHG-----1421
QY 392 SOTCPNDQVCTAFIPCTVGDASA--CLTCAPDNR-----7 425
DB 1422 -----DCISGVCF--CDLGYTAAQGTCSVNTFNHSEMPDFEGKLP:WYK:ITGQVGT 1473
QY 426 RCGTNTGYML-SQGJCKPE-----VAESTD--HYIGFETDLQDLE 463
DB 1474 CGGTANDGRSLYFNGLGKREARTVPLDTRNISLVQFYIGISKTSGITVITPRAYEGLV 1533
QY 464 MKY-----LLQKTDRIEIVHAFISNDRLNS-----WFDPSWRKRL-----501
DB 1534 VQVSNENGILWHLRLDFMSFLEPQ:ISIDLPREAKTPATAFRMWQPOGHKHAQWAG 1593
QY 502 -----LTKSNKYKSSLVHMLGLSLOI-CLTXNSTLEPVLAVY 539
DB 1594 DVLIGNVDSSTQFOFKLQGS:DLQANWYR-----QGGQVDLCLSDMTAL-----1642
QY 540 VNPFGG-SSESFNPVNPVNSFPDWERTKLBPLOQ-----YKWTJTLGNKWT 587
DB 1643 TENIGHPRVAETWDPHVSRSSEFLNE-----MNMGCKPFGSAHG-CLOYSLNNGKDWOL 1697
QY 588 FFE-----TVH-----IYLRSR-KSNGPNONESIYYEPIEFIDPSRNLGYNKKN:Q 634
DB 1698 VTBECVPTIGCVHY:ESSYVTSERFQ---NWRRTVTVPLATNSPRTSPRAICTN---1750
QY 635 VFGYKHFDFEAIKDL:LCIDYFY 658
DB 1751 ---YTVGADSWAIDNVILASGCPN 177;

RESULT 9
US-09-541-782-4
; Sequence 4, Application US/09541782
; Patent No. 6284430
; GENERAL INFORMATION:
; APPLICANT: Nislow, Corey
; APPLICANT: Sakowicz, Roman
; APPLICANT: Beraud, Christophe
; TITLE OF INVENTION: Antifungal Assay
; FILE REFERENCE: 1015
; CURRENT APPLICATION NUMBER: US/09/541,782
; CURRENT FILING DATE: 2000-04-03
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 1038
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
US-09-541-782-4

Query Match 2.7%; Score 103.5; DB 3; Length 1038;
Best Local Similarity 20.5%; Pred. No. 1.2;
Matches 83; Conservative 76; Mismatches 167; Indels 79; Gaps 20;

```

```

6  HATSEFFWL-LSDXGPHR---SQEYTDVWRGRQGF5-TRIKVIRE---FGRWKYN--NL 56
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
363 HITNAMEGLNLLQGLXHQVASTPKMNFSSRSHITFT-TLYKKHQDEUFRISKMNVL 422
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
57  A-----VERRRFLGSPLP-AZEPFFNIRLLGRRT-LOOI-ENLIKKYGTHF-----L 103
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
423 AGSEINIRSGAKNORAKBAGSINGSLTJLGR-----VINALVOKSG-HIPRESKLTRE 475
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
154 LSATLGGREESLITFVDRKKLSKRAEGSDSTNSSSVLTLETHCQAASYT-DDDS-TLRSH 163
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
476 LQDSLGGNTKALJATISPAKVSEETCSLEVASKAKNKNPQLGSGT-KDILVKNI- 534
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
164 HIQIASTAIRKVTETRTGP---LGCNVDN-LDS-VSSVLVQSPENK-TLOOL-----QVLLP 216
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
535 TMEJAKIKSOLLSTSKEGIVMSCHYKKNLSOLESYKNEVQCKREISLSTJSGALLWK 594
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
216 DYLQERFVQAALSVIACNSEGEPTCKENDCWC-----HCSTKFEPCNCPNCTCA 265
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
595 DKLKSK-----ET-QSGN---COIESLKTTHLRAQLQOKHKTETESD 636
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
266 MEENLRITETWKAYNSDFE-----SDERKLF-----MKELPWYFNT-STYHUKTN-D 315
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
637 PNNK-LQKLETPMOMALHCYKKEEDLQCKREYHITRE-KLKSLETLQJLNTQCEGILCE 694
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
316 SNFORRYECLENSMMKOLFKAQKIVHKLFLSLSKRCXKQPLIS-LFR 360
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
697 TNOIPNIDMKIWEV-TLMTTMOEKALMY---KQCVAKIKINESPK 738
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

```

RESULT 13
US-09-723-820-4
; Sequence 4, Application US/0972392C
; Patent NO. 646876C
; GENERAL INFORMATION:
; APPLICANT: N:s:ow, Corey
; APPLICANT: Sakowicz, Roman
; APPLICANT: Beraud, Christophe
; TITLE OF INVENTION: Antifungal Assay
; FILE REFERENCE: 1015
; CURRENT APPLICATION NUMBER: US/09/723,820
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: 09/541,782
; PRIOR FILING DATE: 2000-04-03
; NUMBER OF SEQ ID NOS: 1C
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 1038
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
US-09-723-820-4

```

Query Match	2.7%	Score 103.5	DB 4	Length 1038
Best Local Similarity	20.5%	Pred. No. 1.2		
Matches	83	Conservative 76	Mismatches 167	Indels 79
Gaps	20			
QY	6	HATSPEDWL-LSDKGPFRH---	SOEYTFDVRDRCQFS-TRYKIVSE--FGAKVYN--NL	56
DB	363	HITNAGESNLQGLKRRQVASTKQDFFSRSHPTFTLTKGQGESFRISKXNVL	422	
QY	57	A-----VERNFILGSPLEAPEFFENIRLLGRPTLQQTENLKKYGTHTF-----	103	
DB	423	AGSEININRSGALNQRKEDAGSINOSLLTLGR-----VINALVDKSG-HIPRESKLTRL	475	
QY	104	LSATLGGSESTIFVDKKRLSKRAGSDSTTNASSVTLETGCGAASAYFIDRDSFLRH	163	
DB	476	LCSTLGGNTKATLTIATISPAKVTSEETCSLEVASKAKNKVPQGGSPIMKDIYKMI-	534	
QY	164	HQIASTAIKVTETRTGP---LGCSDNDKDS-VSSVLVQSPENKLCLOGL---	215	
DB	535	TNELAKISDLSLTSKKEGIYWSQCHYXNLNSDLESYKNEVTECKRETESLTSKXNALLVK	594	
QY	216	DYLQERFVQAAALSYIACNSGEPTICKNDWC-----HCGPKFFPCKPCPSYIQQA	265	

```

DB 595 DKLSK-----ETIQSON---COIESLKTTHDLRAQDKQHKTEIEISD 636
QY 266 MEENLRITETWKAYNSDFEE-----SDEFKLP-----MKRLPMNYFLNTSTIMHWTX-D 315
DB 637 FNNKLOKLTETACMAWCHDYKKRELDLNQKFEHHTXEEKKLXSTJFLQLNTWQOESLQE 696
QY 316 SNFORREYEQESNMKQCFLMAQKIVHKJFSLSKRCHKQPLSLPR 360
DB 697 TNPQNLDMIKNEVLTIMRTMQEKABLMY---KDCVKKILNESP 738

RESULT 11
US-08-179-481-2
: Sequence 2, Application US/08/79481
: Patent No. 5624815
: GENERAL INFORMATION:
: APPLICANT: CARRAWAY, KERMIT L.
: APPLICANT: CAROTHERS CAREWAY, CORALIE A.
: APPLICANT: FREGIEN, REVIS J.
: TITLE OF INVENTION: ONCOGENE PRODUCT LIGAND
: NUMBER OF SEQUENCES: 125
: CORRESPONDENCE ADDRESS:
: ADDRESS: CUSHMAN, DAREY & CUSHMAN
: STREET: 1100 NEW YORK AVENUE, N.W.
: CITY: WASHINGTON
: STATE: D.C.
: COUNTRY: U.S.A.
: ZIP: 20005-3918
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DO
: SOFTWARE: PatentIn Release #1.0, Version: #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/179,481
: FILING DATE: 28-DEC-1993
: CLASSIFICATION: 435
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: US 07/922,521
: FILING DATE: 30-JUL-1992
: ATTORNEY/AGENT INFORMATION:
: NAME: KOKULIS, PAUL N.
: REGISTRATION NUMBER: 16,773
: REFERENCE/DOCKET NUMBER: 200702/UM92-08CIP
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (202) 861-3300
: TELEFAX: (202) 822-0944
: TELEX: 6714627 CUSH
: INFORMATION FOR SEQ ID NO: 2:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 744 amino acids
: TYPE: amino acid
: TOPOLOGY: linear
: MOLECULE TYPE: protein
US-08-179-481-2

```

```

Query Match:      2.6%; Score 103; DB 1; Length 744;
Best Local Similarity 21.4%; Pred. No. 0.7%;
Matches          97; Conservative 66; Mismatches 163; Indels 128; Gaps 26.
QY   39 FSTRYKIYREFGAWKYNNAVERNFLGSLP-LPLAPEFFNIRL-----LGRRTFLQQIT 91
    |||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||
DB   286 YSSKIQAYKGROWPLRSPATLRMSVASPTSAVAFELFENGSHVTNIPRRTY----- 341
QY   92 ENLIKKYGTHTFLISAALGGESITIFVDKRKLKRAEGSDSTTNSSSVTLTLLHQLAASY 151
    |||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||
DB   342 EILARDVKTN--LSSVL-QPETVACFCSKEEQCLYNETSKEGNSSTEVT-----SC 389
QY   152 FTRDSTLRRLHHIQTASTAKTTERTPGLPGSGSYNDLSVSASVLYQSPEKNKIQAG-- 209
    |||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||
DB   390 KCGNSGFRCJCEHSK-----DLCTEP-C--FPNVDCIPCKGCOACPNNMTGDGRH 436
QY   210 LGVLLPDYQQRFP-VQAALSY:ACKNSEGEFCCKENDCCHCPCKPEKCNC----- 258

```

Db 437 CVAVEISECONHSCSWNYCYNHGHCDISGPPDCOPT---CTCAPAFONRCF.AGNHET 493
Qy 259 ---PSMD:CAMENLRLITEWKANYSDFEBSDEFKLFYKSLPKNYFJNTSTI----- 308
Db 494 PIYKELPLRTI---TLSAREENASNAOVNAS--VANVLENDVRAFLSNS:VELIPTS 548
Qy 309 ---MHLTYSNFORR-----YEULENSKQJFJ-----KAKK 338
Db 549 PGAPVLGKPIHKKVSHKYPKPGPLIHYLNNQLISAWYAFJLQARQERRKRSGEARK 608
Qy 339 IVHKLFSLSKCHKQPLISLPRGRTSTYLTLSQSLFYCNENSLGSSSEBHSCTCND 395
Db 609 NV-RFPIS-RADVQGMALN-----LSMDEYFTC--GYKG-----YHLVYSPQ 651
Qy 399 QNVCTAFPLPCTVG-----DASACLCA 420
Db 652 GVTCVS--PSEGYCHNGGCKHLPDGPQC-TCA 662

RESULT 12
US-09-914-259-26
; Sequence 26, Application US/09914259
; Patent No. 6495336
; GENERAL INFORMATION:
; APPLICANT: Makowski, Lee
; APPLICANT: Hymans, Paul
; APPLICANT: Williams, Mark
; TITLE OF INVENTION: STAGED ASSEMBLY OF NANOSTRUCTURES
; FILE REFERENCE: 9471-010-999
; CURRENT APPLICATION NUMBER: US/09/914,259
; CURRENT FILING DATE: 2000-11-22
; NUMBER OF SEQ ID NOS: 180
; SOFTWARE: FASTSEQ for Windows Version 4.0
; SEQ ID NO 26
; LENGTH: 1032
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-914-259-26

Query Match 2.68; Score 102.5; DB 4; Length 1032;
Best Local Similarity 17.68; Pred. No. 1.5;
Matches 130; Conservative 104; Mismatches 253; Indels 253; Gaps 27;

Qy 25 QYTDVTRRCQFSRYKIYRFGKVVANLAVERNFQSPJPLAPEFFKXILLQER 84
Db 344 KYEKEKEKKAKEETIAKLEALSWMNGENVPEERLAGEEALGAELECEFTWONS 403
Qy 85 PTLQOITENIKKYGHFLLSA:CGGESLTIYVKKLSKRAEGSDSTNSSVLTET 144
Db 404 SIYVIAPEERQY-----EESI-----RRLYKQDCKDEINQCSQLEK 445
Qy 145 HQ-----LAAGYFDROSTLRRLHHIOIASAIKVITERTPLGCSNYDHLDSVSVL 197
Db 446 KOXLDGEBLLVSTRGDNKVKVBSLHLOENDAAK-----DEKVEV- 487
Qy 198 VQSFENKIQGLVLPDYQLERFVQALSYIACNSGEFICKNDCKCHCPKPPEN 257
Db 488 -----LQALELAVAYDCK-----SOEVEKSSQNOJ-----LVQELS 520
Qy 258 CPSYDCAEMENLRITET-----WKAYNSEFEESDEEFKLYK-----RLPNYVJNT 305
Db 521 QKVATMUSLESELCRQJGVSHQKRIAEVLNG:MKDLSEFVSIVGNRG:KLIV----- 574
Qy 306 ST:MHLWTMPSNFORRYEULENSKQJFJKAQ-----KIVHKLFSLSKCHKQPL:SLPRQ 361
Db 575 -----EISGAIEEBFTVARLY:SKIRSEKSVVKSCRCQ----- 607
Qy 362 RTSTYVW:TR:CSFLYCNENSLGSPSEER:HSCTCPNDQVCTAFPLCTVGDASACLTAP 421
Db 608 -----LENLQVECHRKKEVYTGRE:SSQQLIS 634
Qy 422 DNRTRCGTCNTGVYVLSQGLCKPEVAESTDHYIGFETDQDLEKMYLLQKTDREIETHAIF 481

Db 635 QBEAKIRSL-TEYMSVELKKPHLEESYD-----SLSDELAKLQAOET-----VHEVA 661
Qy 482 ISK-----DYRLNSWFDPSWRKRMLT:KSNKYKSSJYHMLG:SLQ:CL 526
Db 692 LKXKEDPTQADENVKAEJQWESHREAHHQARLRDEINF-KOKT:DELKDUNKQ:CL 740
Qy 527 TKNSTLEPVLAVYVNPFGGSHSESWFYVNVNENSPFDWERTKLCL-----P:QCYNW 577
Db 741 ----ELEKQADYELKSEHEKSTKLQBLTFLYERHEQSKCDLKGLEETVAREJQ----- 792
Qy 578 TLTGKNWKTFFETVHLYLRSIKNG--PKNPSIYVEPLEFIDPSPNLYGMYKINN:Q 634
Db 793 --LHNLRLKLPQCV-----TTVRKSAEWEPEDSGGIHSQ-----KOKISFSE-NWLE 838
Qy 635 VFGYSMHFDPEAIRDLILQDYPYTCGSOCSALLQLEIRDRVNVKLSPPGQRRLDLPSC 694
Db 839 -----QLTKVHKQLYRDA-----DLRCELPK----- 860
Qy 695 LHRHLKJSTSEVVRIOALQ 714
Db 861 LEKRLRATAERYKALEGALK 880

RESULT 13
US-09-004-838-125
; Sequence 125, Application US/09004838
; Patent No. 6350933
; GENERAL INFORMATION:
; APPLICANT: Micheltore, Richard W.
; APPLICANT: Shen, Kathy
; APPLICANT: Meyers, Blake
; TITLE OF INVENTION: Procedures and Materials for
; TITLE OF INVENTION: Conferring Pest Resistance in Plants
; NUMBER OF SEQUENCES: 140
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Flippy disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/004,838
; FILING DATE: 09-JAN-1998
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/761,734
; FILING DATE: 12-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Eichen, Gregory P.
; REGISTRATION NUMBER: 38,440
; REFERENCE/DOCKET NUMBER: 023070-07881505
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 125:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1817 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: -
; LOCATION: 1..1817
; OTHER INFORMATION: /note= "RG2S deduced sequence"
US-09-004-838-125

```

Query Match      2.6%  Score 102; DB 4; Length 1817;
Best Local Similarity 18.9%  Pred No. 4.4;
Matches 188; Conservative 122; Mismatches 281; Indels 320; Gaps 45;

QY 8 TSPF-----DL-----LSDKGFPHSQEYTDVDSRSGFSTRYKRYIFRFGWKYKMA 57
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 215 TDFATCAIAADYLGICLNKTRPARADKLREFKKNSDGGKTFKFLVLC-DWKCL----269

QY 58 VERNLGSPLPAPBFR-----NIRLGR-----43
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 270 VLEEDIGLSPFPGVDFKVLTSRDSQVCTMMGVEANSINVCULTAEAGSLFQCFVE 329

QY 84 --RPTLCQITENLKKYGTGTHFLSATLGGESLTIIVDKRKLKRAEGSDSTNSSSVL 141
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 330 TSEFLQKIGEDIVKCC-----GPIAKTVACTURKRGKADKADA-----371

QY 142 ETJHQAASVIFDRDSTLRJHHIQAIASTAIKVTETRTPLGGSNYDNL---DSVSSVAV 199
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 372 -----LSRIEYDHNVAKVFET-----SYNNLQEEBETKSTFLX 404

QY 199 -----QSPENKIQLGQLOVLLPYLQ-----REFVQAALSYIACNSESE 237
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 407 CGLFFEDFDIPTBELXRYGKGLJCFRVTYTRRARTPLNTCIERJVTNL-----456

QY 238 FICKENDKC-----HCGPKPEPC-----NCPYDIOAVEELJRIETMKA 279
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 457 LIESDVGCVKXHDVRAVLGNFSEVENASIVHGNMPEWENDITSCKGISITCKS 515

QY 280 YNSDFEESDEFKLFMKLPMNYFNLTSTIMHLMTMSNF---QRRYEQLNSYKQFLKA 336
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 516 -----MSKFPDGFPPNLMILKLVHGKSLFFPQDFEGME-----551

QY 337 QKLVHKLPSLKCHKOPSLSLPRQTSYVWTRIOSFLYCHENGLLGSFSETHSCTC 395
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 552 -----KLHVISYDKMKYPLPLAPRCSTN-----IRVLHJTKC-----593

QY 396 -----PNDQVCTA-----PUPCTVG-----DASACLTCPADNTRCGTONTGYMLSC 438
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 594 IGNLSNLEVUSFANSRNEWLPSTVRNLUKLRLJLRLFC-----DGLRIEC 638

QY 439 GLCKPEVAESTDHYIGPETQLQLEMKYLLQKTRRIEVHAFISNDMRL-NEWFDPSWR 497
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 639 GV/LK-SLVKLEEFYIGNASGFIIDNCNEMASRDNLSALEFAFPNKAQVKNNSFENLER 697

QY 498 KRM-----LTLKNKYKSSLVHMILGLSLQCLTKXNSTLPEVIL-----AVYVN 541
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 698 FKISVGRSFDGINYSYSHYEN-----MLQVNTNKGVLDSKLGJFLKTVLFLS 748

QY 542 PFQSHSESFM-----PVNENSFPDWERTKLDLPLQC-----VYVWTLTLGNKKMKTFTETVH 593
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 749 VHGNDLEDYEVKSTHTPTOSSFCN-----LKVLIISKVELRYLFLKLNAN-----TJSRLER 812

QY 594 IYL-----RSRKSNQNGNIESIYEPJEFIDPSR---NLGYMKINIQVEGYGMHTEPEA 846
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 803 LEVCECENMBELHTGICGEETITFPCKLKLSLSQLPKJSLI-CHNYNIILG-----PHL 856

QY 647 IROLILQ-----LDYPTQSGCSA-----LQLLEIRAVN-----KLSFPGQ 665
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 857 V-DLILKIGPGFTVIYPQNLRITSLLKSEVWIPKJSTLQIDCMENJEEIWPCELAGSEX 915

QY 686 ---RRLDLFC-----LRRHLKLSLSEVVVRIOALCAPNAKL 720
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 916 VKLREIKVSSCDKUNLFPNFMNSLJLHHLBELKVNCGSES---LPIIDL 963

```

RESULT 14

```

US-08-930-996A-7
; Sequence 7, Application US/08933996A
; Patent No. 6100449
; GENERAL INFORMATION:
; APPLICANT: FLUHR, Robert
; APPLICANT: ESHED, Yuva;

```

```

APPLICANT: ORI, Naomi
APPLICANT: PARAN, Ilan
APPLICANT: ZAVIR, Daniel
TITLE OF INVENTION: A GENE FAMILY FROM THE 12 FUSARIUM RESISTANCE
TITLE OF INVENTION: LOCUS OF TOMATO AND USE THEREOF FOR TRANSFORMATION AND
TITLE OF INVENTION: SELECTIVE BREEDING OF TOMATO AND RELATED PLANTS
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: BROWDY AND NEWMARK
STREET: 419 Seventh Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/28/910,996A
FILING DATE: 29-DEC-1997
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/05272
FILING DATE: 15-APR-1996
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: IL 113,373
FILING DATE: 13-APR-1995
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 907 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-930-996A-7

```

Query Match 2.6% Score 101.5; DB 3; Length 907;

Best Local Similarity 18.0% Pred No. 1.5; 198; Indels 255; Gaps 30;

Matches 118; Conservative 83; Mismatches 198; Indels 255; Gaps 30;

```

QY 170 TAIVTETRTGPL-----GCSNYNDSDSVSVL-----197
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 75 SAVQTEIKTALLVFRPRRRCPTMRRLYLSCPCADYKLCCKYSAILKSGELPERSE 134

QY 198 -VCSPEKIQJGGLQVLLPDV--QERFVQAALSYIACNSE-----235
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 135 A-KTGGGSIQTCREIP-DSVVGN-TMMEQVLEF-JSEEEERGIIGVYGGVGYKTLNQS 194

QY 236 --GEFICKEND---CWCHCGPKPECKPC-----SMDIOAVEEN-----269
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 195 INNELITKHQYCVLWVQMSREFGCTIQAVGARJGLSWDEKETGENALKIYRLRQ 254

QY 270 ----LLRITETWKAYNSDFEESDEFKLFMR-----LPMNYFLNTSTYHLWTDNSFQRRY 322
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 255 KRFLLLDDVW-----EEDLEXTGVPRPDRENKCKVMFTTRSIALCNNGAGYKLRV 307

QY 323 EQJENSMK-QLF-----LKAQKLVHKLPSLKCHKQKQPL-----S-PRGATSTY 366
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 308 EFJEKKHAMELFCSKVKWRKDLLESSIRLAEILVSKCGJFLALITLGGAMAHRETEEE 367

QY 367 W-----LJR-----LQSFLYCN-ENGLLGS-----FSEETHSCCTCPN-- 397
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 368 NIHASEVLTTRPAEMKGMNYVPAJLKFSYDNLESJLRSCLFYCALFEE-HSIEBQLV 426

QY 398 DQVCTAFPLPCTVGDASACLTCPADNTRCGTONTGYMLSQGLCKPEVAESTDHYIGET 457
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 427 EYVWGEGLTSSHG-----VNTIYKGYFL-----450

QY 459 DIQDLEMKYLLQKTRRIEVHAFISNDMRLNSWF-----DPS-----495
   |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db 451 -IGDLKACLLTETGDEKTVKMKHNVRSFAL--WMASEQGYTYKE--LIVEPSNGHT-EAPKA 507

```

```
QY 496 --WRKRMULTKSNKYKSSLVHMLGSLQICLTKNSTLEPVJAVYVNPFGSSHSWPM 553
DB 508 ENWQALVISJDNRIOTLPKELCPKLTTLXLOQNSLXKI-----PTSFVH-----M 556
QY 554 P---VWNSFFDWERTKDLDP--LQYVNTLT-----LGNK----- 584
DB 557 PVLRLVDSFSITEPLSIKYLVELYHLSMSGTKISVLPDELGNLAKLKHLDLQRTQFL 616
QY 585 -----WMTFFTVHYIYRS---R-KSNQPNONESIYYEPJEFIDPSNKG 626
DB 617 QTIPTDA*CWLSKLEVLNLYSYAGWELCSFGEDAEELGPAD-EYLENLTTLG 670

RESULT 15
US-08-193-211-2
; Sequence 2, Application US/081832:1
; Patent No. 5618709
; GENERAL INFORMATION:
; APPLICANT: Alan M. Gewirtz, Donald Small, Curt I. Civin.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES
; TITLE OF INVENTION: SPECIFIC FOR STR-1 AND METHOD FOR
; TITLE OF INVENTION: INHIBITING EXPRESSION OF THE STR-1 PROTEIN
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEIDEL GONDA LAVORGNA & MONACO
; STREET: Suite 1800, Penn. Center Plaza
; CITY: Philadelphia
; STATE: Pennsylvania
; COUNTRY: U.S.A.
; ZIP: 19102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 720 KB
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/183,211
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Monaco, Daniel A.
; REGISTRATION NUMBER: 30,480
; REFERENCE/DOCKET NUMBER: 3957-15
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-8383
; TELEFAX: (215) 565-5549
; TELEX: No. 5618709e
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 993 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; US-08-183-211-2
```

```
Query Match 2.6%; Score 102.5; DB 1; Length 993;
Best Local Similarity 19.3%; Pred. No. 1.9;
Matches 119; Conservative 76; Mismatches 237; Indels 183; Gaps 29;

QY 136 SSSVLTETLHQLAAS---YFIDRDSFIRRHIIQ-----IASTAKVETRTGPEL--- 182
DB 86 SASITLQVLVDAPGNISCLWFKHSLNCPHFDLQNRGVWSWILKXTETGAGVLLP 145
QY 183 --GCSNYNDLSVS-----SVLVQSPENKIQGSLQVLLPDYLOERFVQAAALSYACKS 234
DB 146 QSEATNYTLTFTVSRNTLLYTLRRPYFRKVENQALVCISSEVPEIVE-----KVLQDS 201
QY 235 EQSFICKE-----NDCWCHCGPKF-----PECKCPKM 261
DB 202 QGE-SCKEESPAVVKKEKVLHELFGTDIRCCARNSLGRECFRLFTIDINOTFQTLTLPOL 260
```

```
QY 262 DIQWKEENLRLITE-----THKAYNSCFEESDEKFLPMKRLPMNYFLNTSITXHLW 312
DB 261 FLKVGGEPLWIRCKAVRNHGFQUTWELENKALEEKYFEM-----STYSTRTTWRILF 314
QY 313 TMSDNFQRR---YEQLNSMKQLFLKAQKIVHKLF-----SLSKRCHKQPLI 356
DB 315 AFVSSVARNDTGYTCSSSKHPSQSALVTIVKGFINATNSSEDEYIDCYEFCFSVRPK 374
QY 357 SLFPRQRTSTYWTQIOSFLYCNENGL-----LGSPSEETHS-----CTCPNDQVVTAF 405
DB 375 AVFQIRCT--WTFESRKSF-PCQKGLDNGYSISKFCNKHKQPGEVIFHAAENDDAQFTKV 431
QY 406 LPCTVGDASACLTCPDKRTRCGTCTNTGYMLS-----QGLCKPEVAESTDHYIGPE 456
DB 432 FTNIRRKFCVLAELASASQASC-FSDGYPLSWTWKKSCKSPNCTEETESVWN----- 484
QY 457 TDLQDLEMKYLLQKTDRR-EVHAIFISNDMRLNSWFPDSWRKRMJLTLK-SNRYKSSLYH 515
DB 485 -----RKANKKV-----FGQWVSSS-----TLNMSAINGFLVK 513
QY 516 MILGLSJQCLTKNS---TLEPVJAVYVNPFGSSHSWFMVNNNSFPDWERTKLDLPL 572
DB 514 -----CCAYNSLGTSCETILLNSPGFF-----PFIQDN*SFYATIGVCL-L 553
QY 573 QCVNWTLTGLNKKKTFEETVHIYJRSRIKSNQPNGNESIV-----VE PLEFIDPSNLC 626
DB 554 FIVLTLLICHYKKQFR--YESQJQVQVTSSSDNEFYVDFREYEDLKNEFPRENLE 611
QY 627 YMKINNIQVGYSMH 641
DB 612 FGKVLGSGAFGKWN 626
```

Search completed: October 29, 2003, 16:18:44
Job time : 17:1588 secs

Centore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OX protein - protein search, using sw model

Run on: October 29, 2003, 16:13:29 ; Search time 23.9656 Seconds
(without alignments)
5235.672 Million cell updates/sec

Title: US-09-832-129-35_COPY_34_766

Perfect score: 2902

Sequence: 1 AYSDCHATSPPDWLSDXGPHRSOEYDFVDRSGSGSTYKIYREGRKWNLAVER 60

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 3.5

Searched: 642350 seqs, 171146564 residues

Total number of hits satisfying chosen parameters: 642350

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:

- 1: /cgn2_6/prodata1/pubpaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/prodata1/pubpaa/PCR_NEW_PUB.pep.*
- 3: /cgn2_6/prodata1/pubpaa/US06_NEW_PUB.pep.*
- 4: /cgn2_6/prodata1/pubpaa/US06_PUBCOMB.pep.*
- 5: /cgn2_6/prodata1/pubpaa/PCRJS_PUBCOMB.pep.*
- 6: /cgn2_6/prodata1/pubpaa/PCRJS_PUBCOMB.pep.*
- 7: /cgn2_6/prodata1/pubpaa/US08_NEW_PUB.pep.*
- 8: /cgn2_6/prodata1/pubpaa/US08_PUBCOMB.pep.*
- 9: /cgn2_6/prodata1/pubpaa/US09_PUBCOMB.pep.*
- 10: /cgn2_6/prodata1/pubpaa/US09_PUBCOMB.pep.*
- 11: /cgn2_6/prodata1/pubpaa/US09_PUBCOMB.pep.*
- 12: /cgn2_6/prodata1/pubpaa/US09_NEW_PUB.pep.*
- 13: /cgn2_6/prodata1/pubpaa/US10_PUBCOMB.pep.*
- 14: /cgn2_6/prodata1/pubpaa/US10_PUBCOMB.pep.*
- 15: /cgn2_6/prodata1/pubpaa/US10_PUBCOMB.pep.*
- 16: /cgn2_6/prodata1/pubpaa/US10_NEW_PUB.pep.*
- 17: /cgn2_6/prodata1/pubpaa/US60_NEW_PUB.pep.*
- 18: /cgn2_6/prodata1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB ID	Description
1	3902	100.0	766	11	US-09-832-129-35
2	1550	39.7	378	9	US-09-864-761-4325-A
3	127.5	26.3	379	9	US-09-864-761-4322-A
4	327	8.4	78	9	US-09-864-761-3823-A
5	299.5	7.7	101	12	US-10-231-417-371
6	219	5.6	69	9	US-09-864-761-3813-A
7	123	3.2	709	9	US-09-874-923-121
8	123	3.2	709	10	US-09-991-496-121
9	117	3.0	617	15	US-10-142-143-2
10	115.5	3.0	990	14	US-10-947-676A-7
11	115	2.9	617	15	US-10-142-143-4
12	114.5	2.9	320	9	US-09-874-923-22
13	114.5	2.9	320	9	US-09-874-923-55
14	114.5	2.9	320	10	US-09-991-496-22
15	114.5	2.9	320	10	US-09-991-496-55

15	106.5	2.7	858	15	US-10-125-692-8	Sequence 8, Appli
17	105.5	2.7	1379	12	US-10-235-219-5	Sequence 5, Appli
18	104	2.7	501	15	US-10-142-143-17	Sequence 17, Appli
19	102.5	2.6	1032	12	US-10-085-608A-26	Sequence 26, Appli
20	102.5	2.6	4545	9	US-09-873-453-2	Sequence 2, Appli
21	102.5	2.6	1307	11	US-09-957-005-9	Sequence 9, Appli
22	100.5	2.6	1198	12	US-09-893-959-3	Sequence 3, Appli
23	100.5	2.6	1350	12	US-09-893-238-17	Sequence 17, Appli
24	120.5	2.6	2787	12	US-09-893-238-15	Sequence 15, Appli
25	100	2.6	681	12	US-10-354-358-34	Sequence 34, Appli
26	100	2.6	930	11	US-09-866-350A-63A	Sequence 63A, App
27	100	2.6	1548	13	US-13-180-923-2	Sequence 2, Appli
28	93.5	2.5	466	9	US-08-925-321-1047	Sequence 1047, Ap
29	93.5	2.5	1152	10	US-09-919-603-1	Sequence 1, Appli
30	93.5	2.5	1170	12	US-10-021-660-114	Sequence 114, App
31	93.5	2.5	1170	12	US-10-008-093-2	Sequence 2, Appli
32	93.5	2.5	1170	13	US-10-020-141-12	Sequence 12, Appli
33	93.5	2.5	1170	13	US-10-017-721-2	Sequence 2, Appli
34	99	2.5	930	11	US-09-866-050A-644	Sequence 644, App
35	99	2.5	1500	12	US-09-870-759-136	Sequence 136, App
36	99	2.5	1520	12	US-09-751-708A-136	Sequence 136, App
37	99	2.5	4128	12	US-10-205-194-1	Sequence 1, Appli
38	98	2.5	614	12	US-10-032-585-7669	Sequence 7669, Ap
39	98	2.5	798	10	US-09-978-349-8	Sequence 8, Appli
40	96.5	2.5	1480	12	US-10-289-776-7	Sequence 7, Appli
41	96.5	2.5	1480	14	US-10-011-064-5	Sequence 5, Appli
42	96	2.5	1591	9	US-09-864-761-37952	Sequence 37952, A
43	95.5	2.4	255	12	US-10-168-651-4	Sequence 4, Appli
44	95.5	2.4	255	12	US-10-264-171-2	Sequence 2, Appli
45	95.5	2.4	255	15	US-10-040-805-2	Sequence 2, Appli

ALIGNMENTS

RESULT 1
US-09-832-129-35
Sequence 35, Application US/0983129
Publication No. US2003027297A1
GENERAL INFORMATION:
APPLICANT: fscella et al.
TITLE OF INVENTION: 19 Human secreted proteins
FILE REFERENCE: P2045P1
CURRENT APPLICATION NUMBER: US/09/832.129
CURRENT FILING DATE: 2001-04-11
PRIOR APPLICATION NUMBER: PCT/US02/28664
PRIOR FILING DATE: 2001-10-17
PRIOR APPLICATION NUMBER: 60/163,085
PRIOR FILING DATE: 1999-11-02
PRIOR APPLICATION NUMBER: 60/172,411
PRIOR FILING DATE: 1999-12-17
NUMBER OF SEQ ID NOS: 70
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 35
TYPE: PCT
LENGTH: 766
ORGANISM: Homo sapiens
US-09-832-129-35

Query Match	100.0%	Score 3902	DB 11	Length 766
Post Local Similarity	100.0%	Pred. No. 0		
Matches 733	Conservative 0	Mismatches 0	Indels 0	Gaps 0
CY	1	AYSDCHATSPPDWLSDXGPHRSOEYDFVDRSGSGSTYKIYREGRKWNLAVER	60	
DB	34	AYSDCHATSPPDWLSDXGPHRSOEYDFVDRSGSGSTYKIYREGRKWNLAVER	93	
CY	61	RNFLGSPPLAPEPFRNRLGRRRTLOCITENLIKKGTHFLSATLGGESJTFVCK	120	
DB	94	RNFLGSPPLAPEPFRNRLGRRRTLOCITENLIKKGTHFLSATLGGESJTFVCK	153	
CY	121	RKLSKRAEGSGSTTKSSSVTLTLHQLAASVTFDRDSTDRRLHHIQASTAIKVTETRTG	180	


```
APPLICANT: Hanzel, David K.
APPLICANT: Chen, Wensheng
TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
TITLE OF INVENTION: GENE EXPRESSION ANALYSIS BY MICROARRAY
FILE REFERENCE: Aeomica-X-1
CURRENT APPLICATION NUMBER: US/09/864,761
CURRENT FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/180,312
PRIOR FILING DATE: 2000-02-04
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: US 09/632,366
PRIOR FILING DATE: 2000-08-03
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,697
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 09/608,408
PRIOR FILING DATE: 2000-06-10
PRIOR APPLICATION NUMBER: US 09/774,203
PRIOR FILING DATE: 2001-01-29
NUMBER OF SEQ ID NOS: 49117
SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
SEQ ID NO 43222
LENGTH: 379
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: MAP TO AC006239.5
OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 2.7
OTHER INFORMATION: SWISSPROT HIT: P4413, EVALUATION: 3.5e-09
OTHER INFORMATION: EST HUMAN HIT: BF348205.1, EVALUATION: 1.00e-114
us-09-864-761-43222
Query Match 26.3%; Score 1027.5; DB 3; Length 379;
Best Local Similarity 50.1%; Pred No 23e-67;
Matches 191; Conservative 71; Mismatches 106; Indels 13; Gaps 6;
Cy 363 TSTVWLPRIQSLVYCNENGLIGSFSETHSCFNCQVWTAFLPCTVGDASACACAPD 422
D 1 TIOQMLARVQSLYCNENGLIGSFSETHSCFNCQVWTAFLPCTVGDASACACAPD 422
Cy 423 NRTTCGTCTGYKXLSGSLCKPEVAES--TDHYIGFETDL--OLEKXVLLQKTDPIEYH 479
D 61 NLSLGCNCGYKLYRCRCPKVSERSEQFISFETDLQFQELKXVLLQKTDPIEYH 479
Cy 479 APTSDMRKNSWPDPSWRKRMKMLTKNSLVHVLGLSICNCLTKNTSLERVLAV 539
D 121 TTFISNIRLDTPDPWRKRMKMLTKNSLVHVLGLSICNCLTKNTSLERVLAV 539
Cy 539 VYVFPGGSHSESNFMPYKNSFPDWERTKJDLPLQCYNWTJLGNKWKTFETVHYLRS 599
```

4
3
2
4
5
5
2
0
1
1
5
1
2
2
5
4
1
2
2
5
4
1

```

; APPLICANT: Skeiky, Yasir A.W.
; APPLICANT: Skatia, Alay
; APPLICANT: Colek, Rhea
; APPLICANT: Probst, Peter
; APPLICANT: Brannon, Mark
; TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE
; FILE OF INVENTION: THERAPY AND DIAGNOSIS OF LEISHMANIASIS
; FILE REFERENCE: 210121.420C8
; CURRENT APPLICATION NUMBER: US/09/874.923
; CURRENT FILING DATE: 2001-06-04
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 121
; LENGTH: 709
; TYPE: PRT
; ORGANISM: Leishmania major and chagasi
US-09-874-923-121

Query Match          3.2%; Score 123; DB 9; Length 709;
Best Local Similarity 21.8%; Pred. No. 0.035;
Matches 75; Conservative 26; Mismatches 117; Indels 126; Gaps 16;

QY 170 TARKVTRTRGPGCS-----NYNLDSSVSVLQSPENKICLOGLQV 212
DB 354 TARKDPYTRYAYLGCSAGCTCFNETACLECRPSYEML-----PDYTCSLTGLQC 403
QY 213 LLPDY-----LQERFVQALSYIACNS--EGEFICK-----END 244
DB 404 TDPNCKTCTTYGQCTDCNDGYGLTSSVVCVRCVAGCKSPVDANVCKVCLGGSEPINNY 463
QY 245 CWCHCGPKFPEC-NCPs-----MD---IQAYEENLLRITETWKAYNSDFEE 286
DB 464 CPC-----TDPCASCPSDAGTCTCCANGYGLVAGACVCEPCFSC-----D 507
QY 287 SDEPKLPMKLPNRYFLN-----TSTIMLMTMSNFCRRYEOLENSMKQLFLAKK 338
DB 508 SDANK--CTQCAPNYLTPLTCSFVACNIEHCWQCDQPTFSRQCEVSP-----555
QY 339 IVHKLFSLSKCHQKPLISLPRQRTSYWLTRIQSFLYCNENGLGSEFSETHSCTCND 398
DB 556 --YVVDYDGLCLRLSDACSVNCKKCTGTGSR-----CAECDTGYSLSADATSCSPTT 608
QY 399 QVVTCTAFPLPCTVGDASACLTGAPDNRTFCGTGNTGYMLSGQLCK 442
DB 609 Q-----PCEV---EHCNTVNGDSTRCAVNTGYVYVSDGKCK 642

RESULT 8
US-09-991-496-121
; Sequence 121, Application US/9999:496
; Patent No. US20020165285A1
; GENERAL INFORMATION:
; APPLICANT: Reed, Steven G.
; APPLICANT: Campos-Neto, Antonio
; APPLICANT: Webb, John R.
; APPLICANT: Dillon, David C.
; APPLICANT: Skeiky, Yasir A.W.
; APPLICANT: Skatia, Alay
; APPLICANT: Colek, Rhea
; APPLICANT: Probst, Peter
; APPLICANT: Brannon, Mark
; TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE
; FILE OF INVENTION: THERAPY AND DIAGNOSIS OF LEISHMANIASIS
; FILE REFERENCE: 210121.420C9
; CURRENT APPLICATION NUMBER: US/09/991.496
; CURRENT FILING DATE: 2001-11-20
; NUMBER OF SEQ ID NOS: 137
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 121
; LENGTH: 709
; TYPE: PRT
; ORGANISM: Leishmania major and chagasi
US-09-991-496-121
```

```

Query Match          3.2%; Score 123; DB 10; Length 709;
Best Local Similarity 21.8%; Pred. No. 0.035;
Matches 75; Conservative 26; Mismatches 117; Indels 126; Gaps 16;

QY 170 TARKVTRTRGPGCS-----NYNLDSSVSVLQSPENKICLOGLQV 212
DB 354 TARKDPYTRYAYLGCSAGCTCFNETACLECRPSYEML-----PDYTCSLTGLQC 403
QY 213 LLPDY-----LQERFVQALSYIACNS--EGEFICK-----END 244
DB 404 TDPNCKTCTTYGQCTDCNDGYGLTSSVVCVRCVAGCKSPVDANVCKVCLGGSEPINNY 463
QY 245 CWCHCGPKFPEC-NCPs-----MD---IQAYEENLLRITETWKAYNSDFEE 286
DB 464 CPC-----TDPCASCPSDAGTCTCCANGYGLVAGACVCEPCFSC-----D 507
QY 287 SDEPKLPMKLPNRYFLN-----TSTIMLMTMSNFCRRYEOLENSMKQLFLAKK 338
DB 508 SDANK--CTQCAPNYLTPLTCSFVACNIEHCWQCDQPTFSRQCEVSP-----555
QY 339 IVHKLFSLSKCHQKPLISLPRQRTSYWLTRIQSFLYCNENGLGSEFSETHSCTCND 398
DB 556 --YVVDYDGLCLRLSDACSVNCKKCTGTGSR-----CAECDTGYSLSADATSCSPTT 608
QY 399 QVVTCTAFPLPCTVGDASACLTGAPDNRTFCGTGNTGYMLSGQLCK 442
DB 609 Q-----PCEV---EHCNTVNGDSTRCAVNTGYVYVSDGKCK 642

RESULT 9
US-10-142-143-2
; Sequence 2, Application US/10142143
; Publication No. US2003009967A1
; GENERAL INFORMATION:
; APPLICANT: DeAngelis, Paul
; TITLE OF INVENTION: HEPARIN/HEPAROSAN SYNTHASE FROM P. MULTOCIDA AND METHODS OF MAKI
; FILE REFERENCE: 5864.017
; CURRENT APPLICATION NUMBER: US/10/142,143
; CURRENT FILING DATE: 2002-05-08
; PRIOR APPLICATION NUMBER: 60/269,554
; PRIOR FILING DATE: 2001-05-08
; PRIOR APPLICATION NUMBER: 60/296,386
; PRIOR FILING DATE: 2001-06-04
; PRIOR APPLICATION NUMBER: 60/303,691
; PRIOR FILING DATE: 2001-07-06
; PRIOR APPLICATION NUMBER: 60/313,259
; PRIOR FILING DATE: 2001-08-17
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 617
; TYPE: PRT
; ORGANISM: Pasteurella multocida
US-10-142-143-2

Query Match          3.0%; Score 117; DB 15; Length 617;
Best Local Similarity 19.0%; Pred. No. 0.1;
Matches 130; Conservative 11; Mismatches 207; Indels 236; Gaps 39;

QY 71 APEFFNRLLCRRPRTLOQITENLKKYGTHTFLASATLG--GEESLTFVDRKLSKRAEG 129
DB 7 ATELEFS---QNYKCALTYENIKIYGSLSVYVNDICKNIT---QSKSNKIEED 58
QY 130 SDSTTNSSSVLTETLQOLAASYFIDRSTLRLLHHIQIASTAKVETRTGP-----182
DB 59 KSGENKFSVSIKDYK-----ELSNELGITKRLGAPPLVSIIM 99
QY 183 GCSNYDNL--DSVSSVYVCSPENKICLOGLQV-LFDYLCERFVCAAJ-----227
DB 100 TSINTEKFEASINSLL--CTVNN-----LEVIWVDYDSTDKTFQIAGRANSTSKVKT 153
```

```

QY 228 -----SYZACN-----SEGEF--CXENDCWCXGPKFEEC-----NCPSS 26:
DB 154 RLNSLNGTYFAKNTGILKSKGDIIFQUSDVCH-HERIERCVALLSNKNDINVRGAYS 212
QY 262 DIOAYEENLLRITE-----TWKAYNSDFEE-----SDEF-----KLFMKPL 297
DB 213 RINLETQNIKVNDKMYKLGTLGVYKVFNEGFNCTTKASDEFFHRIIAYYGNR 272
QY 298 PMNVFL-----NTS-----TIMH:WTNDSNFCR-----YEQLENSMKQ 332
DB 273 INNLFPLYYNTMRBDSJFSOMVEVDENN:KQKTSARQNYLHEFPKIHNRKJNELKE 332
QY 332 LFLKACKIVHKLFLSLSKRCH-KPLI-----SLPQRTSTYWLTRIQSFLYCNVGL 382
DB 333 IFSRPR--IHALPISKMSKLSNPK:PVYINISIP-----SRKOLQY--TIGV 379
QY 383 LGSFSEETHSTCPNQVCTAF:PCTYGDASACLTCPADNRTCGTNTQYMLSQGLCK 442
DB 380 LKQCDHPHIVLDGYPEV--PDIK-KLGNKATVINC--QKNESIRENGKFIILEKLIK 434
QY 443 PEVAESTHY-----LGFETDLOLEMKYLLCKTOR-RIEVHAIISINDXPLNSWFP 494
DB 435 -----ENKGGYITCDDIRYADYNTMIKKYNDKAAIGJHGVIFPS--RYKYFSS 488
QY 495 SWRKEMJLTLS-----NRYK-SLVHM-ILGSLGICLTKN 529
DB 489 D-----RIVNFKXPJENDTAVMLGTGTVAFRVS:FNKESLSDFHPGXVDIYFSLCKN 545
QY 530 STLEPVJAVYVPPFGGSHSKFMWPNENSFPDWERTKLDLPJCCYNWTLTGNKWTFF 589
DB 546 NILQVCI-----SRPSNKLTEDNKN-----TETLPHEFQNRD 577
QY 590 ETVHLYLESR-KSNGPNGNESYI 612
DB 578 E-----IQSKU::SNP:PWGYSYI 596

RESULT 10
US-10-047-676A-7
; Sequence 7, Application US:10047676A
; Publication No. US20020123165A1
; GENERAL INFORMATION:
; APPLICANT: Qi, Fengxia
; APPLICANT: Cai, Fengd, Page W.
; APPLICANT: Chen, Bing W.
; TITLE OF INVENTION: NUTRACIN 1 BIOSYNTHESIS GENES AND PROTEINS
; FILE REFERENCE: UAB-17403/22
; CURRENT APPLICATION NUMBER: US/10/047,676A
; PRIOR FILING DATE: 2002-03-21
; PRIOR APPLICATION NUMBER: US 09/627,376
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 7
; LENGTH: 990
; TYPE: PRT
; ORGANISM: Streptococcus mutans
US-10-047-676A-7

Query Match 3.0%; Score 115.5; DB 14; Length 990;
Best Local Similarity 18.9%; Pred. No. 0.3;
Matches 154; Conservative 125; Mismatches 270; Indels 265; Gaps 42;

QY 86 TJCQITENLKKYK-----THF-LLSATUGGESLTFVKKRKLKRAEGSGSTNS 136
DB 139 TUKVANNALQSNDFWLLDTRSHFGLMNSRSDIRDTIV-----KSNQLDIYVNC 190
QY 137 SS-VTLETHQLAAYFP:DRDSTLRRLHH:QIASTAK-----VTETATGSLGCSNYN- 189
DB 191 TEPSYQTLIDDIKESQSSDDVK-----EYLQTLKEEFLITELKPSID-----DNP 242
QY 190 LDSVSVLVQSPENKIQGL---QVLLPDYLCERFVCAA-SYIACNSEGEFICKEN--- 243

```

```

DB 242 LQWFNILERDQWSELLEKLTETKAWICQYTRNIGSGNNS:LALNKYYSQIVKAYNI 301
QY 244 --DCWCHGCFKPFECNCPNDY:QAMEENLLR:TTETW-KAYNSDFRHSDEFKLMKE----- 296
DB 302 RVGLYCHAEIKLAQHTKSS-----QNLKVLSSPSSAVNSQKSIKYHKEFIAFYGE 355
QY 297 --LPMVYFNTSTIKHWTYCSNFORRYECLE-NSMKOLF:KACKIVHKL---FSLSKRC 350
DB 356 QLVPLGLLNS-----TSG:GFPAKGYSCTEVSKQWNEOSKNQKILIEFQKFEKALRD 408
QY 351 HKQPLISLSPORTSTY-WLTRI:CSFLYCNEN-----GLJGSFSEETHSCTC 395
DB 409 GXEIIISDODLKDLNEDTQQ:SGE:LYCFNFKSKKLEVSLSGVSMQ:GNTGCRFIS-KL 467
QY 396 FNDQVCTAF:PCTYGDASACLTCPADNRTCGTNTGY-----M:SCGLCKPVAES 448
DB 468 PN-----TIV:KNVKNKTKETFEAYPN:TIITQJAEVYFGRGNIMINS:L-KSHQJEL 520
QY 449 TCHVIGFETDLOL-----EMKYLLOKTDRIE:VHAIFISNDXRLNSWFPDSMRKML 501
DB 521 RNTTKKMSINDIYVRA:TSBELYFYKKYKRV-----FVWNM--FNYKSKLLREF 574
QY 502 LFLKSKKYSKSLVHMLGL-----SQQ:CLTK 528
DB 575 LEVSNDFQ-NITPITLGLSLOSYNHVPA:IIYKDII:KPEWNIRKSEAKTLDSEKNWLT- 632
QY 529 NSTLEBYL-----AVYVPPFGGSHSKFMWPNENSF-----POWER:KLQJL 570
DB 633 NNVKVPFVPMKYITDIIYLLSERT:DLTMLFOSIKKHSFIQLDVHSVCTNDT:ELLEVY 692
QY 571 PL-----QCVNWLTD-----GNKWTFFETVHI-----YLR- 597
DB 693 PPTRSVNAHCIVHYAQN:YTLSDSGSKKPYFAYIKVANKQCTSFQKEYPLLLKYLKL 752
QY 598 -----SRKSNNGPNNE-----SYVEPLEFIDPSNGLGYMKNN:QVFG 637
DB 753 PENLQWFIYRYKDGKGSIRJIRYRYVEDKQVGLYSRF-EMATKAP-----KNQIQSG 805
QY 638 YSM-HFDPEAIR-----PL:ILCLDYPYTCGSOESALLQJLLEIR 676
DB 906 YEISEYIPESARYGKKYS::HSFFYYSILDLILQ-----KKABQTI:EVPTS 954
QY 677 VN-----KLSPFGCKRQ--DLFSCLLRHLK 700
DB 855 LSIIRFLNKLKSLQDQCKLKNLFDG--KRLK 856

RESULT 11
US-10-142-143-4
; Sequence 4, Application US:10142143
; Publication No. US20030099567A1
; GENERAL INFORMATION:
; APPLICANT: DeAngelis, Paul
; TITLE OF INVENTION: HEPARIN/HEPAROSAN SYNTHASE FROM P. MULTOCIDA AND METHODS OF MAKI
; TITLE OF INVENTION: US:NG SAME
; FILE REFERENCE: 5864, 017
; CURRENT APPLICATION NUMBER: US/10/142,143
; CURRENT FILING DATE: 2002-05-08
; PRIOR APPLICATION NUMBER: 60/289,554
; PRIOR FILING DATE: 2001-05-08
; PRIOR APPLICATION NUMBER: 60/296,186
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: 60/303,691
; PRIOR FILING DATE: 2001-07-06
; PRIOR APPLICATION NUMBER: 60/313,258
; PRIOR FILING DATE: 2001-08-17
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 4
; LENGTH: 617
; TYPE: PRT
; ORGANISM: Pasteurella multocida
US-10-142-143-4

```

Query Match 2.9% Score 115; DB 15; Length 617;
Best Local Similarity 19.0%; Pred. No. 0.16;
Matches 130; Conservative 111; Mismatches 207; Indels 236; Gaps 33;
QY 71 APFFRNIRLGRPTQQITENLIKYYTHPLSATLG-GESLIFVFKRKSKEAEG 129
DB 7 ATELFKS---GNKDALTYENIAKIYGESLVKNIDCKNIT---QSKNKIED 59
QY 130 SDSTTKSSSVTLERLHGLASVFFDRSTLRRHHQIATIAKVTETRG 182
DB 59 NISGENKFSVSKGLYN-----SISNSESGIKERLGAPELVSLIX 93
QY 183 GCSONYDL--DSVSSVLVQSPENKIQQGLQVL-LPDYLCERTVQAL 227
DB 100 TSHNTEKFASINSLLQYNN-----LEVVDYSDKTFCIASRANSTSKYKF 153
QY 228 -----SYTACN-----SSEGI-CENQCHCGRKFFEC----- 261
DB 154 RLSNLSLTYPAKTGILKSKGEIFFQCSDDVCH-HERERQVALLSKCNIAVWQAYS 212
QY 262 DICAMSENLRITE-----TWKANSDFEE-----SSEF----- 297
DB 213 RINLETOKILKANDKMYKSGSLGLGVYRKVPRFEGFNCTKASDSEFYHRIKYYGNER 272
QY 298 PKNYFL-----NTS-----TGHILWTHCSNFORR-----VEQLENSMKQ 331
DB 273 INNLFLPYNTYREDLSLFQKVEWVDENNIKOKTSDARQNYHEFQKINERKINEJRE 332
QY 332 FLKAQKIVKJFSLSKCHK--QPLI-----SLPQRTSTYWLTRIQSLFYCNENGL 382
DB 333 TFSFPR-IHDAUFIKEMSKLSNPKIEVYINICSP-----SRKQLOY--TIGV 379
QY 383 LGSFSETHSTCPNDQWCTALPCTVGSASCLTCAPENRTRGTCNTGYMLSQGLCK 442
DB 380 LKQOCDFHYLDQYPEV--PDFIK-KLGRKATVNC--QMKIES-RDKGKFIJSEKLIK 434
QY 443 PEVAESTHY-----IGFETDLQDJEKVLQKTDRIEYKA-FISNDMLNSWFOR 434
DB 435 -----ENKGGYIITCCDIRPACYININKINKYNDKAAIGLGHVFPSS--RVNKFSS 438
QY 495 SWRKRYLLTLKS-----NKYK-SSLVHM-ILGLSLQICLTEN 529
DB 489 D---RIVYNFQKPLENDTAVNLGTGVAFVSVFENKFS-SDPEHPQWVDIYFSLCKXN 545
QY 530 STEPLUAVYVNEGSHSSEWPNENSEFPPOWERTKJLPLQCYNWTJLGNKWKPTFF 559
DB 546 NILQVCI-----SRPSNWLTDNKN-----TEILPEEFQNRD 577
QY 590 ETVHYLRSR-IKSNQNGNESIV 612
DB 578 E-----QSKLLIISNPNFYSSIV 596

RESULT 12
US-09-874-923-22

Sequence 22, Application US/09874923
Patent No. US20020081320A1

GENERAL INFORMATION:

APPLICANT: Reed, Steven G.

APPLICANT: Campos-Neto, Antonio

APPLICANT: Webb, John R.

APPLICANT: Dillon, Davin C.

APPLICANT: Skeiky, Yasir A.W.

APPLICANT: Bhatia, Ajay

APPLICANT: Coler, Rhea

APPLICANT: Probst, Peter

APPLICANT: Brannon, Mark

TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE

TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF LEISHMANIASIS

FILE REFERENCE: 210121.420C8

CURRENT APPLICATION NUMBER: US/09/874.923

CURRENT FILING DATE: 2001-06-04

NUMBER OF SEQ ID NOS: 122
SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 22

LENGTH: 320

TYPE: PRT

ORGANISM: Leishmania major

US-09-874-923-22

Query Match 2.9% Score 114.5; DB 9; Length 320;

Best Local Similarity 32.3%; Pred. No. 0.061;

Matches 30; Conservative 8; Mismatches 40; Indels 15; Gaps 3;

QY 350 CHKQPLISLPQRTSTYWLTRIQSLFYCNENGLGSFSETHSTCPNDQWVCTAFLEPT 409

DB 176 CRLSDACSVPNCKKKEGTGSRJ-----CAECDTGYLSADATSCSSPTTC-----PCE 223

QY 410 VGDASACITCAEDNRTGCTGNTGYMLSQGLCK 442

DB 224 V---SHCNTVNGDSTRCAVNTGYVSDGKCK 253

RESULT 13

US-09-874-923-55

Sequence 55, Application US/09874923

Patent No. US20020081320A1

GENERAL INFORMATION:

APPLICANT: Reed, Steven G.

APPLICANT: Campos-Neto, Antonio

APPLICANT: Webb, John R.

APPLICANT: Dillon, Davin C.

APPLICANT: Skeiky, Yasir A.W.

APPLICANT: Bhatia, Ajay

APPLICANT: Coler, Rhea

APPLICANT: Probst, Peter

APPLICANT: Brannon, Mark

TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE

TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF LEISHMANIASIS

FILE REFERENCE: 210121.420C8

CURRENT APPLICATION NUMBER: US/09/874.923

CURRENT FILING DATE: 2001-06-04

NUMBER OF SEQ ID NOS: 122

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 55

LENGTH: 320

TYPE: PRT

ORGANISM: Leishmania major

US-09-874-923-55

Query Match 2.9% Score 114.5; DB 9; Length 320;

Best Local Similarity 32.3%; Pred. No. 0.061;

Matches 30; Conservative 8; Mismatches 40; Indels 15; Gaps 3;

QY 350 CHKQPLISLPQRTSTYWLTRIQSLFYCNENGLGSFSETHSTCPNDQWVCTAFLEPT 409

DB 176 CRLSDACSVPNCKKKEGTGSRJ-----CAECDTGYLSADATSCSSPTTC-----PCE 223

QY 410 VGDASACITCAEDNRTGCTGNTGYMLSQGLCK 442

DB 224 V---SHCNTVNGDSTRCAVNTGYVSDGKCK 253

RESULT 14

US-09-991-495-22

Sequence 22, Application US/09991496

Patent No. US20020169285A1

GENERAL INFORMATION:

APPLICANT: Reed, Steven G.

APPLICANT: Campos-Neto, Antonio

APPLICANT: Webb, John R.

APPLICANT: Dillon, Davin C.

APPLICANT: Skeiky, Yasir A.W.

APPLICANT: Bhatia, Ajay

APPLICANT: Coler, Rhea

APPLICANT: Probst, Peter

APPLICANT: Brannon, Mark

TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE

TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF LEISHMANIASIS

FILE REFERENCE: 210121.420C8

CURRENT APPLICATION NUMBER: US/09/874.923

CURRENT FILING DATE: 2001-06-04

```

; APPLICANT: Probst, Peter
; APPLICANT: Brannon, Mark
; TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE
; FILE REFERENCE: 210121.420C9
; CURRENT APPLICATION NUMBER: US/09/991,496
; CURRENT FILING DATE: 2001-11-20
; NUMBER OF SEQ ID NOS: 137
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 320
; TYPE: PRT
; ORGANISM: Leishmania major
US-09-991-496-22

Query Match      2.9% Score 114.5; DB 10; Length 320;
Best Local Similarity 32.3%; Pred. No. 3.061;
Matches 30; Conservative 8; Mismatches 40; Indels 15; Gaps 3;

QY 350 CHKQPLISLPRQRTSTVWLTRIQSFLYCNENGLGSPSEETHSCTCPNDQVWCTAFLEPCT 409
Db 176 CRUSDACSVPNCKKCEGTGSRLE-----CAECDGYSLSADATSCSSEFTTQ-----PCE 223
CY 410 VGDASACLTCPDNRTRCGTCTGYMLSGGLCK 442
Db 224 V---EHCNTCVNGDSTRCAVCNTGYVYSDGKCK 253

RESULT 15
US-09-991-496-55
; Sequence 55, Application US/09991496
; Patent No. US20020169285A1
; GENERAL INFORMATION:
; APPLICANT: Reed, Steven G.
; APPLICANT: Campos-Neto, Antonio
; APPLICANT: Webb, John R.
; APPLICANT: Dillot, Davin C.
; APPLICANT: Skeiky, Yasir A.W.
; APPLICANT: Bhatia, Ajay
; APPLICANT: Coley, Rhea
; APPLICANT: Probst, Peter
; APPLICANT: Brannon, Mark
; TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE
; FILE REFERENCE: 210121.420C9
; CURRENT APPLICATION NUMBER: US/09/991,496
; CURRENT FILING DATE: 2001-11-20
; NUMBER OF SEQ ID NOS: 137
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 55
; LENGTH: 320
; TYPE: PRT
; ORGANISM: Leishmania major
US-09-991-496-55

Query Match      2.9% Score 114.5; DB 10; Length 320;
Best Local Similarity 32.3%; Pred. No. 3.061;
Matches 30; Conservative 8; Mismatches 40; Indels 15; Gaps 3;

QY 350 CHKQPLISLPRQRTSTVWLTRIQSFLYCNENGLGSPSEETHSCTCPNDQVWCTAFLEPCT 409
Db 176 CRUSDACSVPNCKKCEGTGSRLE-----CAECDGYSLSADATSCSSEFTTQ-----PCE 223
QY 410 VGDASACLTCPDNRTRCGTCTGYMLSGGLCK 442
Db 224 V---EHCNTCVNGDSTRCAVCNTGYVYSDGKCK 253

```

Search completed: October 29, 2003, 16:24:46
Job time : 25.9606 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 29, 2003, 16:06:23 Search time 15.8412 Seconds
(without alignment)
2045.935 Million cells updates/sec

Title: US-09-832-129-35

Perfect score: 4081

Sequence: 1 MWRSSAGALFSLMALKEW.....CAPKAKLPKDYCTTKLCS 766

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searches: 328717 seqs, 42310858 residues

Total number of hits satisfying chosen parameters: 328717

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: Issued Patents MA.*
1: /cgn2_6/ptodata/2/1aa/5A_COM3.pep.*
2: /cgn2_6/ptodata/2/1aa/5B_COM3.pep.*
3: /cgn2_6/ptodata/2/1aa/5A_COM3.pep.*
4: /cgn2_6/ptodata/2/1aa/5B_COM3.pep.*
5: /cgn2_6/ptodata/2/1aa/PTJUS_COM3.pep.*
6: /cgn2_6/ptodata/2/1aa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	115.5	2.8	930	4	US-09-627-376-7
2	114.5	2.8	320	4	US-09-183-861-22
3	114.5	2.8	320	4	US-09-183-861-55
4	114.5	2.8	320	4	US-09-032-765-22
5	114.5	2.8	320	4	US-09-032-765-55
6	114.5	2.8	320	4	US-09-551-974A-22
7	114.5	2.8	320	4	US-09-551-974A-55
8	104.5	2.5	3461	4	US-09-334-283-2
9	103.5	2.5	1038	3	US-09-541-782-4
10	103.5	2.5	1038	4	US-09-723-823-4
11	103	2.5	744	1	US-06-179-461-2
12	102.5	2.5	1032	4	US-09-914-259-26
13	102	2.5	1917	4	US-09-044-838-125
14	101.5	2.5	907	3	US-09-930-996A-7
15	101.5	2.5	993	1	US-08-183-211-2
16	101.5	2.5	993	5	PT-US95-00176A-2
17	101.5	2.5	4654	3	US-08-475-515A-84
18	101.5	2.5	4655	3	US-08-652-877-54
19	101.5	2.5	4655	3	US-08-652-877-86
20	101.5	2.5	4655	3	US-08-652-877-88
21	101.5	2.5	4655	3	US-08-652-877-90
22	100.5	2.5	560	2	US-08-553-492-5
23	100.5	2.5	1198	3	US-09-245-041-131
24	100.5	2.5	1198	4	US-09-794-236-3
25	100.5	2.5	1350	3	US-09-245-041-17
26	100.5	2.5	2429	3	US-09-245-041-130
27	100.5	2.5	2787	3	US-09-245-041-15

US-09-627-376-7
Sequence 1
US-09-627-376-7
Sequence 2
US-09-627-376-7
Sequence 3
US-09-627-376-7
Sequence 4
US-09-627-376-7
Sequence 5
US-09-627-376-7
Sequence 6
US-09-627-376-7
Sequence 7
US-09-627-376-7
Sequence 8
US-09-627-376-7
Sequence 9
US-09-627-376-7
Sequence 10
US-09-627-376-7
Sequence 11
US-09-627-376-7
Sequence 12
US-09-627-376-7
Sequence 13
US-09-627-376-7
Sequence 14
US-09-627-376-7
Sequence 15
US-09-627-376-7
Sequence 16
US-09-627-376-7
Sequence 17
US-09-627-376-7
Sequence 18
US-09-627-376-7
Sequence 19
US-09-627-376-7
Sequence 20
US-09-627-376-7
Sequence 21
US-09-627-376-7
Sequence 22
US-09-627-376-7
Sequence 23
US-09-627-376-7
Sequence 24
US-09-627-376-7
Sequence 25
US-09-627-376-7
Sequence 26
US-09-627-376-7
Sequence 27
US-09-627-376-7
Sequence 28
US-09-627-376-7
Sequence 29
US-09-627-376-7
Sequence 30
US-09-627-376-7
Sequence 31
US-09-627-376-7
Sequence 32
US-09-627-376-7
Sequence 33
US-09-627-376-7
Sequence 34
US-09-627-376-7
Sequence 35
US-09-627-376-7
Sequence 36
US-09-627-376-7
Sequence 37
US-09-627-376-7
Sequence 38
US-09-627-376-7
Sequence 39
US-09-627-376-7
Sequence 40
US-09-627-376-7
Sequence 41
US-09-627-376-7
Sequence 42
US-09-627-376-7
Sequence 43
US-09-627-376-7
Sequence 44
US-09-627-376-7
Sequence 45
US-09-627-376-7

ALIGNMENTS

US-09-627-376-7
Sequence 1
US-09-627-376-7
Sequence 2
US-09-627-376-7
Sequence 3
US-09-627-376-7
Sequence 4
US-09-627-376-7
Sequence 5
US-09-627-376-7
Sequence 6
US-09-627-376-7
Sequence 7
US-09-627-376-7
Sequence 8
US-09-627-376-7
Sequence 9
US-09-627-376-7
Sequence 10
US-09-627-376-7
Sequence 11
US-09-627-376-7
Sequence 12
US-09-627-376-7
Sequence 13
US-09-627-376-7
Sequence 14
US-09-627-376-7
Sequence 15
US-09-627-376-7
Sequence 16
US-09-627-376-7
Sequence 17
US-09-627-376-7
Sequence 18
US-09-627-376-7
Sequence 19
US-09-627-376-7
Sequence 20
US-09-627-376-7
Sequence 21
US-09-627-376-7
Sequence 22
US-09-627-376-7
Sequence 23
US-09-627-376-7
Sequence 24
US-09-627-376-7
Sequence 25
US-09-627-376-7
Sequence 26
US-09-627-376-7
Sequence 27
US-09-627-376-7
Sequence 28
US-09-627-376-7
Sequence 29
US-09-627-376-7
Sequence 30
US-09-627-376-7
Sequence 31
US-09-627-376-7
Sequence 32
US-09-627-376-7
Sequence 33
US-09-627-376-7
Sequence 34
US-09-627-376-7
Sequence 35
US-09-627-376-7
Sequence 36
US-09-627-376-7
Sequence 37
US-09-627-376-7
Sequence 38
US-09-627-376-7
Sequence 39
US-09-627-376-7
Sequence 40
US-09-627-376-7
Sequence 41
US-09-627-376-7
Sequence 42
US-09-627-376-7
Sequence 43
US-09-627-376-7
Sequence 44
US-09-627-376-7
Sequence 45
US-09-627-376-7

Query Match 2.8% Score 115.5 DB 4 Length 990
Best Local Similarity 18.9% Pred. No. 0.113
Matches 194 Conservative 125 Mismatches 270 Indels 265 Gaps 42
QY 119 TQQITENLIKXG-----THP-LLSAT-IGRES-TIFVCKRKLKSRAGSGSTMS 169
DB 139 TLKVANNALQKSNDFWJLGRSHFGLMNSPSDIEDTV-----KSNQLIDYVINC 190
QY 170 SS--VTLETHQLAASYFDROST-RLRHHQIASTAIK---VTETRTGPGCGSNYDN- 222
DB 191 TTEPISYQTLIDIAEKTSQSDDYK-----EYLQTL-KEEPLITELKFLSD----DNF 241
QY 223 LUSVSGLVCSNENKIQOGL--CVLLPDYLCERFVQAALSYIACNBEGEFICKEN--- 276
DB 242 LKWFILNLDQNNSELLEKLEIKAMIQDYTDNIGEGNNSILALENKMISOIVKANAYL 301
QY 273 --DCHCHOPKPEPCSCSMQCNKEENLRITETK-KAYNSDFEESDEPKFYKAR--- 429
DB 302 RVLLVDHAEKKACHTKSSL-----QMLKVLSSFSFAVNSOKIKNYHEKFIARYGVF 355
QY 330 --LPMNYFLNTSTIMELNTMDSNFORRYEQLE-NMKKQLP-KAKQIVHKJ----FSLSKEC 383
DB 356 GLVPJQLLNS-----TSGLGPFGYQSVTVSKQNNEDSKNQXIIIFLQCKPEKALRD 409
QY 384 HKQPLISLPROPTSY-MLTRIQSFLYCNEN-----GLGSPSESETHSTCC 429
DB 409 GKEIILSDDDLKDLAFDTEQQISGLYGFVAFKSKKLELVSSILGVSONLGNIFGRPHS-KI 467
QY 429 EKDQVCTAFLEPCTVGDASACLTCPDNTRCGTCNTGY-----MLSCGCKCKEVAES 481
DB 468 PR-----TIVTKNKNYKKEFTPEAYPNTI-TCQINEVYFGRGGKNIVISNEL-KSHQLEL 520

QY 452 TDYXGFTDLOQJ-----EMKYLLOKTDRIEVAHIFPNDOMEFLNSKEDPSKREME 534
Db 521 ANVTTKKMSINDIYVRATSEEDFYSKKPKRV-----IFWNNKX--FNYNGSKLLLEFL 594
QY 535 JTKSNKYKSSLMHMLGI-----AVVNVFPGGSHSSWMPNENEF-----PWERTKJDL 603
Db 575 LEVNSDQJ-NITPTUGSLDSYNHVPALIKYKDI--KPEFNIRKSEAKT--DSLKNWLT- 632
QY 562 NSTLEPV-----AVVNVFPGGSHSSWMPNENEF-----PWERTKJDL 603
Db 633 NNWPPFVRMYKTDQIIYDLRSRTDLYLFSQKKHSFICILDMHSVCTNDEILELV 692
QY 604 EL-----QYKMWLT-----GNKWKTFEEVHI-----YLR- 630
Db 693 PFTSDVNAHQIYHVAQNIYLEDSSGSEKFIYAKIYVYKQOTSFLOKEYPDLKLYK 752
QY 631 -----SRIKSGFNGNE-----SYVERLEFIDPSRNLGYMKNNIOVFG 670
Db 753 FENLQWFIYKDKGKDSIRLRIRYVEDKQLVQVYSREIWAUKAR-----KNIO:SG 805
QY 672 YSM-HFDPEAR-----ELILOLDYPTQSGDSALJQILERDR 709
Db 806 YEISEYIPESARYGKKYSS:HSFPYVDSLELLQ-----KKAECTIEVRTS 854
QY 730 VN-----KLSPPGQRRLL--DLFSCLLRHKK 733
Db 855 LSIIRMFYMLSLDQOKLKNLEFG--KHKZK 866

RESULT 2

US-09-183-861-22
; Sequence 22, Application US/09-83961
; Patent No. 6365165
; GENERAL INFORMATION:
; APPLICANT: Reed, Steven G.
; APPLICANT: Campos-Neto, Antonio
; APPLICANT: Webb, John R.
; APPLICANT: Dillon, David C.
; APPLICANT: Skeiky, Vasil A.W.
; TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USEIN THE THERAPY AND
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/183,861
; FILING DATE:

CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 39/022,765
; FILING DATE: 12-FEB-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Makl, David J.
; REGISTRATION NUMBER: 31,392
; REFERENCE/DOCKET NUMBER: 210121-42CC3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 320 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein

US-09-183-861-22

Query Match: 2.8%; Score 114.5; DB 4; Length 320;
Best Local Similarity 32.3%; Pred. No. 0.025;
Matches 30; Conservative 8; Mismatches 40; Indels 15; Gaps 3;
QY 383 CHKQPLISLPRORTSTYKWTPIQSFLYCNENGLGSPSEETHSCPCPNQVVTAFLEPCT 442
Db 176 CRJSDACSVNCKKCEGTGSRLE-----CAECTGYLSADATSCSPTTQ-----PCE 223
QY 443 VGDASACLTCAPENRTRCOTNTGYMLSQGLCK 475
Db 224 V-----EHQNTCVNGDSTRCAVCTGYVSDGCK 253

RESULT 3

US-09-183-861-55
; Sequence 55, Application US/09-83861
; Patent No. 6365165
; GENERAL INFORMATION:
; APPLICANT: Reed, Steven G.
; APPLICANT: Campos-Neto, Antonio
; APPLICANT: Webb, John R.
; APPLICANT: Dillon, David C.
; APPLICANT: Skeiky, Vasil A.W.
; TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USEIN THE THERAPY AND
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/183,861
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 39/022,765
; FILING DATE: 12-FEB-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Makl, David J.
; REGISTRATION NUMBER: 31,392
; REFERENCE/DOCKET NUMBER: 210121-42CC3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 55:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 320 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FRAGMENT TYPE: internal
; US-09-183-861-55

Query Match: 2.8%; Score 114.5; DB 4; Length 320;
Best Local Similarity 32.3%; Pred. No. 0.025;
Matches 30; Conservative 8; Mismatches 40; Indels 15; Gaps 3;

QY 383 CHKQPLISLPRORTSTYKWTPIQSFLYCNENGLGSPSEETHSCPCPNQVVTAFLEPCT 442
Db 176 CRJSDACSVNCKKCEGTGSRLE-----CAECTGYLSADATSCSPTTQ-----PCE 223
QY 443 VGDASACLTCAPENRTRCOTNTGYMLSQGLCK 475

Db 224 V---EHCNTCVNGSDSTRCAVCNTGYVYVSDGKCK 253

RESULT 4

US-09-022-765-22

Sequence 22, Application: US/09022765

Patent No. 6375955

GENERAL INFORMATION:

APPLICANT: Reed, Steven G.

APPLICANT: Campos-Neto, Antonio

APPLICANT: Webb, John R.

APPLICANT: Dillon, David C.

APPLICANT: Skeiky, Yasir A.W.

TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE THERAPY AND

NUMBER OF SEQUENCES: 87

CORRESPONDENCE ADDRESS:

ADDRESSEE: SEED AND BERRY LLP

STREET: 6300 Columbia Center, 701 Fifth Avenue

CITY: Seattle

STATE: Washington

COUNTRY: USA

ZIP: 98104-7092

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent-In Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/022,765

FILING DATE: 12-FEB-1998

CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:

NAME: Maki, David J.

REGISTRATION NUMBER: 31,392

REFERENCE/DOCKET NUMBER: 21021-420C3

TELECOMMUNICATION INFORMATION:

TELEPHONE: (206) 622-4900

TELEFAX: (206) 682-6031

INFORMATION FOR SEQ ID NO: 22:

SEQUENCE CHARACTERISTICS:

LENGTH: 320 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: protein

US-09-022-765-22

Query Match

Best Local Similarity 2.8%; Score 114.5; DB 4; Length 320;

Matches 30; Conservative 8; Mismatches 40; Indels 15; Gaps 3;

QY

383 CHKQPLISLPQRTSTYKLTQISFLYCNENGLGSGSEETHSCPCPDQVYCTAFLPCT 442

Db 176 CRUSDACSVNCKKCEGTGSR-----CAECDGYSLSDATSCSSPTTQ-----PCE 223

QY

443 VGSASACLTCAPDNTRCTGTCNTGYMLSGGLCK 475

Db 224 V---EHCNTCVNGSDSTRCAVCNTGYVYVSDGKCK 253

RESULT 5

US-09-022-765-55

Sequence 55, Application: US/09022765

Patent No. 6375955

GENERAL INFORMATION:

APPLICANT: Reed, Steven G.

APPLICANT: Campos-Neto, Antonio

APPLICANT: Webb, John R.

APPLICANT: Dillon, David C.

APPLICANT: Skeiky, Yasir A.W.

TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE THERAPY AND

NUMBER OF SEQUENCES: 87

CORRESPONDENCE ADDRESS:

ADDRESSEE: SEED AND BERRY LLP

STREET: 6300 Columbia Center, 701 Fifth Avenue

CITY: Seattle

STATE: Washington

COUNTRY: USA

ZIP: 98104-7092

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent-In Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/022,765

FILING DATE: 12-FEB-1998

CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:

NAME: Maki, David J.

REGISTRATION NUMBER: 31,392

REFERENCE/DOCKET NUMBER: 21021-420C3

TELECOMMUNICATION INFORMATION:

TELEPHONE: (206) 622-4900

TELEFAX: (206) 682-6031

INFORMATION FOR SEQ ID NO: 55:

SEQUENCE CHARACTERISTICS:

LENGTH: 320 amino acids

TYPE: amino acid

STRANDEDNESS:

TOPOLOGY: linear

MOLECULE TYPE: Protein

FRAGMENT TYPE: Internal

US-09-022-765-55

Query Match

Best Local Similarity 2.8%; Score 114.5; DB 4; Length 320;

Matches 30; Conservative 8; Mismatches 40; Indels 15; Gaps 3;

QY

383 CHKQPLISLPQRTSTYKLTQISFLYCNENGLGSGSEETHSCPCPDQVYCTAFLPCT 442

Db 176 CRUSDACSVNCKKCEGTGSR-----CAECDGYSLSDATSCSSPTTQ-----PCE 223

QY

443 VGSASACLTCAPDNTRCTGTCNTGYMLSGGLCK 475

Db 224 V---EHCNTCVNGSDSTRCAVCNTGYVYVSDGKCK 253

RESULT 6

US-09-551-974A-22

Sequence 22, Application: US/09551-974A

Patent No. 6503437

GENERAL INFORMATION:

APPLICANT: Reed, Steven G.

APPLICANT: Campos-Neto, Antonio

APPLICANT: Webb, John R.

APPLICANT: Dillon, David C.

APPLICANT: Skeiky, Yasir A.W.

TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE

TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF LEISHMANIASIS

FILE REFERENCE: 21021-420C5

CURRENT APPLICATION NUMBER: US/09/551,974A

CURRENT FILING DATE: 2000-04-14

NUMBER OF SEQ ID NOS: 101

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 22

LENGTH: 320

TYPE: PR

ORGANISM: Leishmania major

US-09-551-974A-22

Query Match

Best Local Similarity 2.8%; Score 114.5; DB 4; Length 320;

Matches 30; Conservative 8; Mismatches 40; Indels 15; Gaps 3;

QY

383 CHKQPLISLPQRTSTYKLTQISFLYCNENGLGSGSEETHSCPCPDQVYCTAFLPCT 442

Db 176 CRUSDACSVNCKKCEGTGSR-----CAECDGYSLSDATSCSSPTTQ-----PCE 223

```

Db 176 CRUSDACSVPCKKCTGTSRL-----CAEDTGYSLSDA--SCSPTTQ-----PCE 223
QY 443 VGDASACLTCAPDNRRCGTCTGTYMWSGLCK 475
Db 224 V----EHCNCTVNGDSTRCAVNTGYVVSCKK 253

RESULT 7
US-09-551-974A-55
; Sequence 55, Application US/09551974A
; Patent No. 6500437
; GENERAL INFORMATION:
; APPLICANT: Reed, Steven G.
; APPLICANT: Campos-Neto, Antonio
; APPLICANT: Webb, John R.
; APPLICANT: Dillon, David C.
; APPLICANT: Skeiky, Yasar A.W.
; TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE
; TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF LEISHMANIASIS
; FILE REFERENCE: 210121.420C5
; CURRENT APPLICATION NUMBER: US/09/551,974A
; CURRENT FILING DATE: 2000-04-14
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 55
; LENGTH: 320
; TYPE: PRT
; ORGANISM: Leishmania major
US-09-551-974A-55

Query Match 2.8%; Score 114.5; DB 4; Length 320;
Best Local Similarity 32.3%; Pred. No. 0.025;
Matches 30; Conservative 8; Mismatches 40; Indels 15; Gaps 3;

QY 383 CHKQPLISPRQRTSTYWCRIQSFYCNENGLGFSFEETHSCFCNDQVYCTAFLECT 442
Db 176 CRUSDACSVPCKKCTGTSRL-----CAEDTGYSLSDA--SCSPTTQ-----PCE 223
QY 443 VGDASACLTCAPDNRRCGTCTGTYMWSGLCK 475
Db 224 V----EHCNCTVNGDSTRCAVNTGYVVSCKK 253

RESULT 8
US-09-334-220-2
; Sequence 2, Application US/09234220
; Patent No. 6323177
; GENERAL INFORMATION:
; APPLICANT: St. Jude's Children's Research Hospital
; APPLICANT: Curran, Thomas
; APPLICANT: D'Arcangelo, Gabriella
; TITLE OF INVENTION: INTERACTION OF RECEPTOR WITH VERY LOW
; TITLE OF INVENTION: DENSITY LIPOPROTEIN (VLDL) RECEPTOR FOR SCREENING AND
; TITLE OF INVENTION: THERAPIES
; FILE REFERENCE: 2427/GF704
; CURRENT APPLICATION NUMBER: US/09/334,220
; CURRENT FILING DATE: 1999-06-16
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 346;
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-334-220-2

Query Match 2.6%; Score 104.5; DB 4; Length 346;
Best Local Similarity 17.3%; Pred. No. 12;
Matches 129; Conservative 104; Mismatches 218; Indels 293; Gaps 37;

QY 73 TRYKIYV-----EFGRWKYNLAV--ERRNFGSPLPAPAEPRNIRLGRPTLQQT 124
Db 1196 TRFRWKPVSFGSDYDQWAVDDIIILSEKQK---QVIPV-----NFTLPQ-- 1238

```

```

QY 125 ENLIKKYGTFFLSATLGGERSLTIFFVKRKLKRAEGSDSTTRSSSVTLTETHCIAASY 184
Db 1233 -NPEKPAFDYPMW-----QNSVWLNLANEGMAKN--DSFCATTFSAMVFGKS---GGDEF 1289
QY 185 FIDRSTLRLHHIQIASTA:KYTETRGPLGCSNYDN:DSVSSVLVQSPENKIKLQSLQ 244
Db 1289 AVTRDLTLAGYVJQFKL-----IGCTG--QFSSTAPVLJQYSHD----- 1327
QY 245 VLLPYLQRFYQAAISVIACNSEGEFICKENDCHCHGPKFPFECNCPMDIQAEMEKL 304
Db 1328 -----AGYSW-----FLKES-CF-----FASAAKCGEGNSR 1353
QY 305 RITETWAYNSDFEESDEPKLPMKRLPMNYFNTSTINHLWTMDSNFORRVEQLGNSKK 364
Db 1354 ELSEPTVVYTGDFEETRTTIAEPR-----SLASSKTRFRWIOESSQKQVFP----- 1401
QY 365 LFLKAOKIVKELFSLSKRCHKQP:SLRQRTSTVWLRIOSFLYCNENGLGFSFEETH 424
Db 1402 -----FGLGVVISSEPCPS-----FCSGRG----- 1421
QY 425 SCTCPNDQVYCTAFLPCTVGDASA---CTCAPDKR----- 458
Db 1422 -----DCISGVCF--CDLGYTAAOGTCVSN--PNHSEMPDRFEGKLSPLWKYITGGVGT 1473
QY 459 RCGTCTGYML--SCGLCKPE-----VAESTD--HYISFETLDQLE 496
Db 1474 GCGTLNDRGSJYFNGLGKREKTVFLDTRN:SLVOFY:QIGSKTSGITYITFRARYESLV 1533
QY 497 MKY-----LICKTERRIEVHAIFISNDMLAS-----WFDSPWKPXYL----- 534
Db 1534 VOVSNDNGILKHLSELDFMSFLEFCILSIDLPRAKT:PAATAFRANQPHGKHSQWALG 1593
QY 535 -----LTKSNYKSSLVHMILGSLQ:CLTKNSTLEPLVAVY 572
Db 1594 DVLIGVNDSSQTGFQOKLQGS:CLQANWYR-----IQGGVCIDCLSMDFAL----- 1642
QY 573 VNPFGG--SSSESMFMPVNSFEDWERTKLDLPLOC-----YNNWTJLGNKKKT 620
Db 1643 TENIGPRYAEWDFRVNSSEFQWE-----NMGCKPFPSSAHG:QLOYSLNKGDWOL 1697
QY 621 FPF-----TVH-----IYLRRIKSNKNGPNNS:YVEPLEF:DPERNLJYVKNNIQ 667
Db 1698 VTECVPTIGCVHVTFSSTYTSERPO-----NWRVTVVLPJATNSPRTFRWICTN--- 1750
QY 669 VQGYSMHFPDEAR:ROL:LDLYPY 691
Db 1751 ---YTVGADSWAIDKRVILASGCFW 1771

PESCT 9
US-09-541-782-4
; Sequence 4, Application US/09541782
; Patent No. 6264480
; GENERAL INFORMATION:
; APPLICANT: Nislow, Corey
; APPLICANT: Sakowicz, Roman
; APPLICANT: Berard, Christophe
; TITLE OF INVENTION: Antifungal Assay
; FILE REFERENCE: 1015
; CURRENT APPLICATION NUMBER: US/09/541,782
; CURRENT FILING DATE: 2000-04-03
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 1038
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
US-09-541-782-4

Query Match 2.5%; Score 103.5; DB 3; Length 1038;
Best Local Similarity 20.5%; Pred. No. 2;
Matches 83; Conservative 76; Mismatches 167; Indels 79; Gaps 20;

```

```

QY 39 HATSPFDWL-LSDKGFPHR---SCEYTDVDRSQGFS-TRYKIYRE--FCRAKVN--NL 69
DB 363 HITNAMEGJNLQKGLKHQVASTKMDFFSRSH:FTILYKXQDELFRISKANLVOL 422
QY 90 A-----VERRNFAGSPLPLAEPFRNRLGRPTLQQTENLKKYGFHF-----D 136
DB 423 AGSEINRSGALNORAKESGINSGLTLGR-----VINALVKSG-HIFFRESKUTRL 475
QY 137 LSATLGGESLTIIVCKRKLKRAEGSDSTNSSVLTLELHQAAAYFDRDSTLRRJH 136
DB 476 LQDSGGNTKTAJLATTISPAKVTSEETCSLEYASKAKNKKAPOLGSPFKKIDLVANI 534
QY 197 HQIATAIKVETRTGP---LGSSVNDLDS-VSSVLVQSPENKIQLOG---QVLAP 248
DB 535 TMLAKIKSDLSLTSKKEGYKSDHYKXNLNSDLESYNEVQCKRRIEILTAKNALVUK 594
QY 249 DYLOERFVQAAJSYIACNSEGEFTKENDWC-----SCEPKLF---YKRLPMNYFJNTSTIMLWY-D 348
DB 595 DKLKSK-----ETIOSQN---CQIESLKTTHLRAQLDKOKHTEISD 696
QY 299 MEENLRJRTETWKAYNSDFEE-----SDEPKLF---YKRLPMNYFJNTSTIMLWY-D 348
DB 637 FNNKLOKLTETVQMAHDYKXRELNLCKPEMHITKEKKLSTLFLQNTMQGESLQOE 696
QY 349 SNFORVEQLENSMKQJFLKAKIYVHKJFSLSKSKCHKQPLISLPR 393
DB 697 TTIQPNLDMIKNEVLTJXRTWQKAEALMY---KOCVKKILNESPK 736
QY 39 HATSPFDWL-LSDKGFPHR---SCEYTDVDRSQGFS-TRYKIYRE--FCRAKVN--NL 69
DB 363 HITNAMEGJNLQKGLKHQVASTKMDFFSRSH:FTILYKXQDELFRISKANLVOL 422
QY 90 A-----VERRNFAGSPLPLAEPFRNRLGRPTLQQTENLKKYGFHF-----D 136
DB 423 AGSEINRSGALNORAKESGINSGLTLGR-----VINALVKSG-HIFFRESKUTRL 475
QY 137 LSATLGGESLTIIVCKRKLKRAEGSDSTNSSVLTLELHQAAAYFDRDSTLRRJH 136
DB 476 LQDSGGNTKTAJLATTISPAKVTSEETCSLEYASKAKNKKAPOLGSPFKKIDLVANI 534
QY 197 HQIATAIKVETRTGP---LGSSVNDLDS-VSSVLVQSPENKIQLOG---QVLAP 248
DB 535 TMLAKIKSDLSLTSKKEGYKSDHYKXNLNSDLESYNEVQCKRRIEILTAKNALVUK 594
QY 249 DYLOERFVQAAJSYIACNSEGEFTKENDWC-----SCEPKLF---YKRLPMNYFJNTSTIMLWY-D 348
DB 595 DKLKSK-----ETIOSQN---CQIESLKTTHLRAQLDKOKHTEISD 696
QY 299 MEENLRJRTETWKAYNSDFEE-----SDEPKLF---YKRLPMNYFJNTSTIMLWY-D 348
DB 637 FNNKLOKLTETVQMAHDYKXRELNLCKPEMHITKEKKLSTLFLQNTMQGESLQOE 696
QY 349 SNFORVEQLENSMKQJFLKAKIYVHKJFSLSKSKCHKQPLISLPR 393
DB 697 TTIQPNLDMIKNEVLTJXRTWQKAEALMY---KOCVKKILNESPK 736

```

RESULT 10

US-09-723-820-4

Sequence 4, Application US/09723820

Patent No. 6468760

GENERAL INFORMATION:

APPLICANT: Nislow, Corey

APPLICANT: Sakowicz, Roman

APPLICANT: Berard, Christophe

TITLE OF INVENTION: Antifungal Assay

FILE REFERENCE: 1015

CURRENT APPLICATION NUMBER: US/09/723,820

CURRENT FILING DATE: 2000-11-28

PRIOR APPLICATION NUMBER: 09/541,782

PRIOR FILING DATE: 2000-04-03

NUMBER OF SEQ ID NOS: 10

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 4

LENGTH: 1038

TYPE: PRT

ORGANISM: Saccharomyces cerevisiae

US-09-723-820-4

Query Match 2.5%; Score 103.5; DB 4; Length 1038;
Best Local Similarity 20.5%; Pred. No. 2;
Matches 83; Conservative 76; Mismatches 167; Indels 79; Gaps 20;

```

QY 39 HATSPFDWL-LSDKGFPHR---SCEYTDVDRSQGFS-TRYKIYRE--FCRAKVN--NL 89
DB 363 HITNAMEGJNLQKGLKHQVASTKMDFFSRSH:FTILYKXQDELFRISKANLVOL 422
QY 90 A-----VERRNFAGSPLPLAEPFRNRLGRPTLQQTENLKKYGFHF-----D 136
DB 423 AGSEINRSGALNORAKESGINSGLTLGR-----VINALVKSG-HIFFRESKUTRL 475
QY 137 LSATLGGESLTIIVCKRKLKRAEGSDSTNSSVLTLELHQAAAYFDRDSTLRRJH 136
DB 476 LQDSGGNTKTAJLATTISPAKVTSEETCSLEYASKAKNKKAPOLGSPFKKIDLVANI 534
QY 197 HQIATAIKVETRTGP---LGSSVNDLDS-VSSVLVQSPENKIQLOG---QVLAP 248
DB 535 TMLAKIKSDLSLTSKKEGYKSDHYKXNLNSDLESYNEVQCKRRIEILTAKNALVUK 594
QY 249 DYLOERFVQAAJSYIACNSEGEFTKENDWC-----SCEPKLF---YKRLPMNYFJNTSTIMLWY-D 348

```

```

DB 595 DKLKSK-----ETIOSQN---CQIESLKTTHLRAQLDKOKHTEISD 696
QY 299 MEENLRJRTETWKAYNSDFEE-----SDEPKLF---YKRLPMNYFJNTSTIMLWY-D 348
DB 637 FNNKLOKLTETVQMAHDYKXRELNLCKPEMHITKEKKLSTLFLQNTMQGESLQOE 696
QY 349 SNFORVEQLENSMKQJFLKAKIYVHKJFSLSKSKCHKQPLISLPR 393
DB 697 TTIQPNLDMIKNEVLTJXRTWQKAEALMY---KOCVKKILNESPK 736

```

RESULT 11

US-09-179-481-2

Sequence 2, Application US/087949a

Patent No. 564916

GENERAL INFORMATION:

APPLICANT: CARRAWAY, KERNIT L.

APPLICANT: CAROTHERS CARRAWAY, CORALIE A.

APPLICANT: FREGIEN, NEVIS L.

TITLE OF INVENTION: ONCOGENE PRODUCT LIGAND

NUMBER OF SEQUENCES: 125

CORRESPONDENCE ADDRESS:

ADDRESSER: CUSHMAN, DARBY & CUSHMAN

STREET: 1100 NEW YORK AVENUE, N.W.

CITY: WASHINGTON

STATE: D.C.

COUNTRY: U.S.A.

ZIP: 20005-3918

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Selectin Release 11.0, Version #1.25

CURRENT APPLICATION DATA: US/08/179,481

APPLICATION NUMBER: US/08/179,481

FILING DATE: 28-DEC-1993

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/922,521

FILING DATE: 30-JUL-1992

ATTORNEY/AGENT INFORMATION:

NAME: KOKULIS, PAUL N.

REGISTRATION NUMBER: 16,773

REFERENCE/DOCKET NUMBER: 200702/UM92-C8CIP

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202) 962-3000

TELEFAX: (202) 622-0944

TELEX: 5714627 CUSH

INFORMATION FOR SEQ ID NO: 2:

SEQUENCE CHARACTERISTICS:

LENGTH: 744 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: protein

US-09-179-481-2

Query Match 2.5%; Score 103; DB 1; Length 744;
Best Local Similarity 21.4%; Pred. No. 1,3; Mismatches 128; Gaps 26;
Matches 97; Conservative 66;

```

QY 71 FSTRYKIVAEFRGKVNVLAVERRNPLGSP-PLAPEFRNRL-----LGRPTLQQT 124
DB 266 YSSKIQAYKRGCEWPLRSPTLRMSVASPTSAVAFELFENGSLHVCNIPRTVL---- 341
QY 125 ENLKKYGFHFLLSLTGGESLTIIVCKRKLKRAEGSDSTNSSVLTLELHQAAAY 164
DB 342 ELIARDVKTN--LSSVL-QPTVACFCSEKQCLNYSKGNSTEV-----SC 389
QY 185 FDEEDSTLRLHIGLQASTAVKVTIRTGFLGCSNYDNLDSSVSVQSPENKIQLOG-- 242
DB 390 KDGNSFGRLCEHKK-----DCTEP--C--FPNVDCIPGKGCACPNMTGDSRH 436
QY 243 LQVLDPVY-QERF--VQAALSYIACNSEGEFTKENDWCWCHGCPKFEQNC----- 291

```

DB 437 CVAEISEFCQNSQPNVYCYNGHCD:SGPPDQPT-CTCAPATNCTCLAGNFT 432
QY 292 ----PSMD-CAMEENLRITETWKAVNSDFESDFKJFMKLEPMYPLNSTI- 341
DB 494 PIIYKEPLRTI- TLSREBENASNADYNAS-VANVLENCKKAPLSN:VELIATS 548
QY 342 ----MHJMTDSNFOR-VEQENSKQJFL- 343
DB 549 PGAPVLGKTHHMKVSHKYPGGLIHYLNQUSAWNEAFILQARCRKRSSEAK 608
QY 372 VHKLSKRGCHKOPJSLPRQSTYWT:QSPFYCHWENGLSGSSETHSCCPWD 431
DB 609 NV-RFPIS-RADVQGMALN-----LSVDEYFTC-DGYK3-----YHIVYSPD 652
QY 432 QNVCTAPLPCTVG-----DASACLICA 453
DB 652 GVTCVS--PCSEGYCHNGGCKHLPDGPQC-TCA 682

RESULT 12
US-09-914-259-26
; Sequence 26, Application US/09914259
; Patent No. 6495336
; GENERAL INFORMATION:
; APPLICANT: Makowski, Lee
; APPLICANT: Hyman, Paul
; APPLICANT: Williams, Mark
; TITLE OF INVENTION: STAGED ASSEMBLY OF NANOSTRUCTURES
; FILE REFERENCE: 8471-010-999
; CURRENT APPLICATION NUMBER: US/09/914,259
; CURRENT FILING DATE: 2000-11-21
; NUMBER OF SEQ ID NOS: 180
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26
; LENGTH: 1032
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-914-259-26

Query Match 2.58; Score 102.5; DB 4; Length 1032;
Best Local Similarity 17.68; Pred. No. 2.5;
Matches 130; Conservative 104; Mismatches 253; Index 253; Gap# 27;

QY 58 OBYTDFVDRSGFSPRYKYRFFGQKYNLAVERNF-ASP:R-LAPFFNRLIGER 117
DB 344 KYEKEKEK-KAKETIAKLEASLWNGENVPETERLAGBEAALGASLCBETPVNDS 403
QY 118 PTLQITEN:KKYGTHTFLLSA-LOGGES-TIFVDKRR-SKRAEGSDSTNSSSVLELT 177
DB 404 SIVVIAPEERQY-----EEE-----RLYKQLDNDKDSINQOSQLEKL 445
QY 178 HQ-----LAASYFIDRSTLRLLH:QIASRAIKVTTETRTGFLGCSNYNLLSVSL 230
DB 446 KQYLDGEEJVS:RGNEVYQBELSHLOENDAK-----DEYAEV- 487
QY 231 VQSPENRIQGGQVLLPYDQJGRFVQAAVSY-ACNSEGEFFICKDCKCHGKPKPKP 290
DB 488 -----QJAEELAVNYDCK-----SCVESEKSCQVQ-----LYDELS 520
QY 291 CPSMIOAMENLRITET-----WKAYNSDFESEDFFKFMK-----EYKMYNFT 536
DB 521 QKVATMLSESELQGVSGHOKRP:AEVUNGMLKDSFYSVGVNGEIKLPV----- 514
QY 339 STIMHJMTDSNFORVECLSENSKQJFLKAO---KIVHKLPSLSKRGCHKQJFLSPRQ 394
DB 575 -----EISGAIEEFTVARLYSKIKSEVSVYKRCQ----- 607
QY 395 RTSTYWT:RIQSPYCNENGLGFSSETHSCCPNDQVWCTAFPLRCTVGDASACTCAP 454
DB 608 -----LEN-QVECHRKMEVGTRE-SSCQLIIS 534
QY 455 DNRTRCGTNTGYMLSGCLCKPEVAESTDHYIOPETDLOJLEKXYLLQKTDRIEVAIF 514

DB 436 QHEAKIRSL-TEYKSVFJKKHEDESYD-----SUSDELAJQOJET-----WHEVA 481
QY 516 ISN-----CMKSNWFPDSWRKMKMUTLKSNKYKSSLYHMLJLSLQICL 559
DB 582 LKSNEDTQADQFVKAZELONESHREAHHRQLARJROFINE-KKTIJELKLNCKQL 740
QY 560 TKUSTTEPVLAVYVRFQSGHSESWPNVNSPPEWEATKUL-----PLOCYNK 610
DB 741 -----ELEKLOQVYKLSKSEHEKSTKJQELTFLYERHEGSKQDLKGLBETVARRIQ 792
QY 611 TLLGNKWTPTETVHYLRSRKSNG---PNGNSLYVEPLEFDPSENIGYKINRIQ 667
DB 793 --TDRKLRJFQCV-----TPYKSAEMEPDSGSHSQ-----KOKISFLE-NWDE 838
QY 668 VFGYSNHFDPEAIRD--LQJDXFYTGSSQDSASJGJLLEIRDPVNKLSPPQPRLDJFSC 727
DB 839 -----QJTKVHKOLVADNA-----DJRCPLPK----- 860
QY 728 LRHRLKLTSTSEVVRJSSALQ 747
DB 861 LEXRLRATAERVKALEGAJJK 880

RESULT 13
US-09-004-938-125
; Sequence 25, Application US/09004838
; Patent No. 6350933
; GENERAL INFORMATION:
; APPLICANT: Michemore, Richard W.
; APPLICANT: Sher, Kathy
; APPLICANT: Meyers, Blake
; TITLE OF INVENTION: Procedures and Materials for
; TITLE OF INVENTION: Conferring Pest Resistance in Plants
; NUMBER OF SEQUENCES: 140
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/004,838
; FILING DATE: 09-JAN-1998
; CLASSIFICATION: 603
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/781,734
; FILING DATE: 10-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Eichert, Gregory P.
; REGISTRATION NUMBER: 36,440
; REFERENCE/DOC# NUMBER: 023C70-078910US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 575-0300
; INFORMATION FOR SEQ ID NO: 125:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1817 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY:
; LOCATION: 1..1817
; OTHER INFORMATION: /note= "RG2S deduced sequence"
US-09-004-938-125

Query Match 2.5%: Score 102; DB 4; Length 1817;
Best Local Similarity 18.9%: Pred. No. 7.2;
Matches 168; Conservative 122; Mismatches 261; Indels 320; Gaps 45;
QY 41 TSPF-----DWJ-----LSDGGRHRSQVDFYDRGRQGFSTHYKYRFGKXVWJLA 90
DB 215 TDPFAICAIADYIGQLNEXTKARADKLREWKNSDGGTKFLVLP-DWQL----- 250
QY 91 VERNFLOSPULAPAFPR-----NIPLLGR----- 116
DB 270 VDLEIGLSPFNQVDFKVLTSRDSQVCTMGVEAKS-INVELLEAEAGSLFQGFVE 320
QY 117 --RPTLQOITENLKKYKTHYELLNATJGGBESLJIFVYDKRKLKRAEGSSSTNSSVTL 174
DB 330 TSEPLQIGEDIVKCC-----GJFIATKTAQCTLNRKKAWKRA----- 372
QY 175 BTLHGLAASYFIDRSTLRRHLHIQIASTAKVTETRGFLGSCNYNKL-----DSVSVVW 231
DB 372 -----LSRIEHYDINHVPKVFET-----SYHMQEESTKSTFLM 406
QY 232 -----CSBNKIQLOGVLLFDYLO-----EFVDAALSYACNSEGE 270
DB 407 CGLEFEDFDIPTIELRYXGWSKLFDRVYTPREARTPLNTEBVAQTNL----- 458
QY 271 FICKENDWC-----HCGKPFBC-----NCPSYGQIQAVERNLIETETWA 312
DB 457 -LIESCDVCCVKNHVLVAFVIGXSEVEHASIVNHNMPENTENDITDCKRLSTLCKS 515
QY 313 YNSDFEEDERKLEKRLPMKMYFLNTSTVHLWTMDSNF-----GRVYQDLSNKKQLFIKA 369
DB 516 -----YSKPFGBKPPNMLLXNHGDKSLRFPDPFYEGYE----- 551
QY 370 QKIVKLPFLSKRCHKQQLSL-PRORTSTWLTQIQLSYFLYONENGLJGSPSEETHCTC 428
DB 552 -----KLRVISTDMMKYPCLPLAPCSN-----EVJHLTXC-----SLKMFQCS 593
QY 429 -----PNDQVWCTA-----FLPTVQ-----DASACLTGAPDKTRGCTGNTGYKLSQ 471
DB 594 IONSLEVLSEFANSEIENLSTVNRKKAHLDLRF-----DGLRIBO 636
QY 472 GLCKPEVAESTDHYIGPTDQDLEKYLLOKTDRREVAHAFLISNMYRLNSWDFSNR 530
DB 639 GVJX-SLVKLEBYIGNASGFIDDCNEMABRSOKLSALEFAFNKAEVKNMSPFNLER 697
QY 531 KXKL-----JTKSNKYKSSJVMHILJLSLOICLTKNSTLRPLV-----AYVN 574
DB 698 FKISVGRSFGDNVXSSHYEN-----MLQVTKRGVLSKKNGLFKTKVLFLS 749
QY 575 PFGGSHSEWPN-----PVKNSEFPDWERTKLDLPQC-----VNMFLTLGNKKWTFETVH 626
DB 749 VHGMDLEDVEVKSTHPTOSSFCN-----LKVLIISKVELRYLFLKLNAN-----LSRLEH 802
QY 627 IVL-----RSRKSNKGNPNESYYEPLEFDPSR--NIGMKNNINIOVFYSNHPDEPA 679
DB 803 LEVCECENMEZHTGICGEEITTFPKLFUSLSQLPKJSSL-CHNVNIIGL-----PHL 956
QY 680 FRLITQ-----LDVPTGSGQDSAL-----LOLLETADRVN-----KLSPPGQ 718
DB 857 V-DLLIKGPGGTVIYPONKLTSSLSLKEEVVPKLETLCIDDNENBEIMPCELSGGEK 915
QY 719 ---RRDLFSC-----LJRHRLKJSTSEVVRIOQA-CAFNKL 753
DB 916 VKLEIKVSSCKLVNLPNPNVSLJHLEELKKNKCSIES---LPIIDL 963

RESULT 14

US-08-930-996A-7
; Sequence 7, Application US/08930996A
; Patent No. 6100449
; GENERAL INFORMATION:
; APPLICANT: FUJIRI, Robert
; APPLICANT: ESHED, Yuval

APPLICANT: ORI, Naomi
APPLICANT: PARAN, Ilan
APPLICANT: ZAMIR, Daniel
TITLE OF INVENTION: A GENE FAMILY FROM THE 12 FUSARIUM RESISTANCE
LOCUS OF TOMATO AND USE THEREOF FOR TRANSFORMATION AND
TITLE OF INVENTION: LOCUS OF TOMATO AND USE THEREOF FOR TRANSFORMATION AND
SELECTIVE BREEDING OF TOMATO AND RELATED PLANTS
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: BROWDY AND NEIMARK
STREET: 419 Seventh Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:
MEDIA TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/930,996A
FILING DATE: 09-DEC-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05272
FILING DATE: 15-APR-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: IL 113,373
FILING DATE: 13-APR-1995
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 907 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-930-996A-7

Query Match 2.5%: Score 101.5; DB 3; Length 907;

Best Local Similarity 18.0%: Pred. No. 2.5;

Matches 118; Conservative 93; Mismatches 198; Indels 255; Gaps 30;

QY 203 TAIVKTEITRTGJ-----GCSNYKMLDSVSSV----- 230
DB 75 SAVOVTEITKALLVRRFRRECRTEVRRY-SCFGCAQVKLCKKVSAILKSGELRERSE 134
QY 231 -VQSPENKQLOGLVLPDYL-QERFVCAALSYIACNSE----- 268
DB 135 AKTDGSGTQVTCREIPDSVVGNTTMMEQVLEFLUSEEEERGIICVYGGVGKTLNQS 194
QY 269 --GEPTICKEND---CWCHCGKPFECNCP-----SMQIQAEEN----- 302
DB 195 INNELITKGQYDVLIKVMSREFGECTIQAAGARGLGSKDEKETGENRALKIYRALRQ 254
QY 303 ---LRIETWKAYNSDFEESDEFKLFYKR---JPMNYFLNTSTIMHLWTNDSNFORRY 355
DB 255 KRFLLGLDDVW-----BEIDLEXTGVPRDREKCKVMFTTRISALCNMNGADYKLRV 307
QY 356 EGIENSMK-QLF-----KACKIVHKLPFLSKRCHKQPLI-----SLPRQRTSTY 399
DB 303 EFLEKKHAELECSKWRKDLLESSIRRLAEILVSKCGGLPLALITIGGAMAHRETSEE 367
QY 400 W-----JTR-----IOSELYCN-ENGLLOS-----FSEETHSCTCPN--- 430
DB 368 WIHASEVLFRFPAEMKGVNVPALLKFPSDYNLESOLLRSCLFLYCALPPEE-HSIEIBQLV 426
QY 431 DQVVTATFLPCTVGDASACLTGAPDRTRCTGTCNTGYM-SGOLCKPEVAESTDHYIGFET 490
DB 427 EYWGEGFLTSSHG-----VNTIYKGYFL----- 450
QY 491 DQDLEMYKYLKTDERR-EVHAIFISNDMLNSKF-----DPS----- 528
DB 451 -GDLKKAACLETSGEKTQVKXNVERSPAL---HWASEQGYKELJLVPSMGTETAPKA 507

QY 529 --WRKEMLLTKSNRYKSSLVHILGLSLGICLTKSTLEPLVAVYVNFSSSHSKWEN 586
DB 508 ENWQAGVSLSDNRITQLEPEKLIQKITTLEKQNSLKI -----PTREKH-----M 554
QY 587 P-----WNSEFEMWETKDLPL-LOCYNNWT-----LQNK----- 619
DB 557 PVLRLVLDSPSITIPISIKVLVSLHLSMGTAISVLPDSJNLRKLEHILQRTVFL 616
QY 618 -----WKTFFTVHRYERS-----RKSNQPNQNESIYEELHFFIDPSRLG 659
DB 617 QTPRDAICWLSKLEVLNIVSYAGWELQSGEDAEELGACILEYLENLTIG 670

RESULT 15
US-08-183-211-2
Sequence 2, Application US/08183211
Patent No. 5618709
GENERAL INFORMATION:
APPLICANT: Alan M. Gewirtz, Donald Small, Curt J. Givin.
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES
TITLE OF INVENTION: SPECIFIC FOR STR-1 AND METHOD FOR
TITLE OF INVENTION: INHIBITING EXPRESSION OF THE STR-1 PROTEIN
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSER: SEIDEL GONDA LABORATORIA & MONACO
STREET: Suite 1800, Penn Center Plaza
CITY: Philadelphia
STATE: Pennsylvania
COUNTRY: U.S.A.
ZIP: 19102
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 720 Kb
COMPUTER: IBM PS/2
OPERATING SYSTEM: MS-DOS
SOFTWARE: MergPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/183,211
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Vcnago, Daniel A.
REGISTRATION NUMBER: 30,480
REFERENCE/DOCKET NUMBER: 3957-15
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-5383
TELEFAX: (215) 568-5349
TELEX: No. 5618709e
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 993 amino acids
TYPE: amino acid
TOPOLOGY: linear
US-08-183-211-2

Query Match 2.5%; Score 101.5; DS 1; Length 993;
Best Local Similarity 19.3%; Prod. No. 2.0; Indels 183; Gaps 59;
Matches 119; Conservative 76; Mismatches 237;
QY 169 SSSVTLTLRLQAAS---VFIDRSTLRRLHICQ-----IATAIKVETFTGRC----- 215
DB 86 SASITQVLVDAPGN:SCULWVFKHSSLNCPHFDLQNRGVSWILKVTETQAGEVLLPI 145
QY 216 --GCSNYNLDVS-----SVLVSPENKIQ:QGLQVLLPDYLOSPFVQAAALSVIANG 267
DB 146 QSEATNYTLFTVIRNTLVYTLRRPYFRKMENQALVCISSEVPSPIVE-----WVLQDS 201
QY 268 EGEFICKE-----NDCWCHCGPKF-----PCNCRSM 294
DB 202 QGE-SCKEESPAVKKKEKVLHLPFTDIRCCARNEIGREC:RLFTIDLNQTPQTLFCJ 260

QY 235 DIOAKPENLRATE-----TWKAYNSDEESDEPKLFMKRLDMKVFELVTSITINHLM 345
DB 261 PLAVGEPJMPICKAVNRHSGPGTWELNKALEBGNYPEY-----SYSTNRVIRILF 314
QY 346 TMSNSFQPR---VEQDENSQKQFLKAQKIVHKLF-----SLSKSKCHKOPLI 389
DB 315 AFVSSVARNVNDTYTCCSSSKHPSQSALVIVKGFNATNSSSEDIYEDQYEFCSVRFK 374
QY 390 SFRQPSYWLTRIOSFYONENGL-----LGSFSEETHS-----CTCPNDQVCTAP 438
DB 375 AVPCIRCT--WTFSRKSP-PCBOKGLDNGYS:SKFCNKKHQPOEYIFHAAENDDAQPTKM 431
QY 439 LPCTVGDASACLTCAPONRTRCGTCNTGYMS-----CGLCKPEVAESTDHVIQGE 489
DB 432 FTNIRKFCVJAEASASQASC--FSGGYPLSNWTKKCSKSPKCTEETEGVKN----- 484
QY 490 TDQCLEMKYLQKTDRT:EVHAIFISNDVRLNSWFDPSWRKEMLLTLK-SNRKYSLSLVH 548
DB 485 -----PKAVRKV-----FGQWVSSS-----TLNMSALKGFIAVK 513
QY 549 MLLGLSLQICLTKNS---TLEPVJAVYVNFPGSGSHSESWFMPVNVNENSPDWERTKLDLPJ 605
DB 514 -----CCAYNSLGTSCETILLNSPGFF-----PFIQCNISFYATIGYCL-J 553
QY 606 QCYNWTLLTQNKWKTFEIVHIVLRSRKISNGNPNESY-----YE-PLER-DEPSRLG 659
DB 554 FIVVLTLLICHKYKKQPR--YESCLOMVOVTGSSONEYFYVDPREYED:KWEFFRENJE 611
QY 660 YKKNINQVFGYSMH 674
DB 612 FGKVLGSGAFGKVMN 626

Search completed: October 29, 2003, 16:18:42
Job time : 19.8412 secs

GenCore version 5.1.6
 Copyright (c) 1993 - 2003 CompuGen Ltd.
 CM protein - protein search, using sw model
 Run on: October 29, 2003, 16:13:29 ; Search time 25.0394 Seconds
 without alignments:
 5235.672 Million cell updates/sec

Title: US-09-832-129-35
 Perfect score: 4381
 Sequence: 1 MIKRSRAGAEFLSLVALNEW.....QAFNAKLPTXNDYDTTKLQS 766

Scoring table: BLOSUM62
 Gapop 10.0 , Gapext 0.5

Searched: 642050 seqs, 171146364 residues

Total number of hits satisfying chosen parameters: 642250

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database : Published Applications AA:
 1: /cgn2_6/ptodata1/pubpaa/US07_PUBCOMB.pep.*
 2: /cgn2_6/ptodata1/pubpaa/PCN_NEW_PUB.pep.*
 3: /cgn2_6/ptodata1/pubpaa/US06_NEW_PUB.pep.*
 4: /cgn2_6/ptodata1/pubpaa/US06_PUBCOMB.pep.*
 5: /cgn2_6/ptodata1/pubpaa/US07_NEW_PUB.pep.*
 6: /cgn2_6/ptodata1/pubpaa/PCNUS_PUBCOMB.pep.*
 7: /cgn2_6/ptodata1/pubpaa/US08_NEW_PUB.pep.*
 8: /cgn2_6/ptodata1/pubpaa/US08_PUBCOMB.pep.*
 9: /cgn2_6/ptodata1/pubpaa/US09_PUBCOMB.pep.*
 10: /cgn2_6/ptodata1/pubpaa/US09_PUBCOMB.pep.*
 11: /cgn2_6/ptodata1/pubpaa/US09C_PUBCOMB.pep.*
 12: /cgn2_6/ptodata1/pubpaa/US09C_PUBCOMB.pep.*
 13: /cgn2_6/ptodata1/pubpaa/US09C_PUBCOMB.pep.*
 14: /cgn2_6/ptodata1/pubpaa/US10_PUBCOMB.pep.*
 15: /cgn2_6/ptodata1/pubpaa/US10_PUBCOMB.pep.*
 16: /cgn2_6/ptodata1/pubpaa/US10C_PUBCOMB.pep.*
 17: /cgn2_6/ptodata1/pubpaa/US10C_PUBCOMB.pep.*
 18: /cgn2_6/ptodata1/pubpaa/US10C_PUBCOMB.pep.*

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Result No.	Score	Query Match	Length	DB ID	Description
1	4081	100.0	766	11	US-09-832-129-35
2	1550	38.0	378	9	US-09-864-761-43251
3	1027.5	25.2	379	9	US-09-854-761-43222
4	327	8.0	78	9	US-09-864-761-38031
5	299.5	7.3	101	12	US-10-231-47-371
6	219	5.4	69	9	US-09-864-761-38114
7	123	3.0	709	9	US-09-874-923-121
8	123	3.0	709	10	US-09-991-496-121
9	117	2.9	617	15	US-10-142-143-2
10	115.5	2.8	990	14	US-10-547-676A-7
11	115	2.8	617	15	US-10-142-143-4
12	114.5	2.8	320	9	US-09-874-923-22
13	114.5	2.8	320	9	US-09-874-923-55
14	114.5	2.8	320	10	US-09-991-496-22
15	114.5	2.8	320	10	US-09-991-496-55

SUMMARIES

Query	Score	Query Match	Length	DB ID	Description
QY	1	MIKRSRAGAEFLSLVALNEWIALSLHCVLVAVAVSQHATSPDWLLSKGPHRSQY 60			
DB	1	MIKRSRAGAEFLSLVALNEWIALSLHCVLVAVAVSQHATSPDWLLSKGPHRSQY 60			
QY	61	TFVDRSQSTGYKIYRFGKRVNLAVERNFGLCSPLAPPEFRNRLJGRPTL 120			
DB	61	TFVDRSQSTGYKIYRFGKRVNLAVERNFGLCSPLAPPEFRNRLJGRPTL 120			
QY	121	COITENLIKKGTHFLLSATCGSESITIFVCKSKSKRAEGSSTNSSSVTLTTLHOL 180			

ALIGNMENTS

RESULT 1	
US-09-832-129-35	
Sequence 35, Application US/09632129	
Publication No. US20030027297A1	
GENERAL INFORMATION:	
APPLICANT: Fiscella et al.	
TITLE OF INVENTION: 19 Human secreted proteins	
FILE REFERENCE: P2045P2	
CURRENT APPLICATION NUMBER: US/09/832.129	
CURRENT FILING DATE: 2000-04-12	
PRIOR APPLICATION NUMBER: PCT/US00/28664	
PRIOR FILING DATE: 2000-10-17	
PRIOR APPLICATION NUMBER: 60/163,085	
PRIOR FILING DATE: 1999-11-02	
PRIOR APPLICATION NUMBER: 60/172,411	
PRIOR FILING DATE: 1999-12-17	
NUMBER OF SEQ ID NOS: 70	
SOFTWARE: PatentIn Ver. 2.0	
SEQ ID NO 35	
LENGTH: 766	
TYPE: PR7	
ORGANISM: Homo sapiens	
US-09-832-129-35	

Query Match	100.0%	Score 4081	DB 11	Length 766
Best Local Similarity	100.0%	Prod. No. 0		
Matches 766	Conservative 3	Mismatches 0	Gaps 0	


```

; OTHER INFORMATION: MAP TO ALO22143.1
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 0.94
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 1.1
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.1
; OTHER INFORMATION: EXPRESSED IN PETAL LIVER, SIGNAL = 1.1
; OTHER INFORMATION: EXPRESSED IN BT474, SIGNAL = 0.99
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 0.99
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.3
; OTHER INFORMATION: EST HUMAN HIT: R-5490.1, EVALUE 5.04e-37
; OTHER INFORMATION: SWISSPROT HIT: P16561, EVALUE 6.60e-01
US-09-864-761-38031

Query Match      8.3%; Score 327; DB 3; Length 78;
Best Local Similarity 70.5%; Pred. No. 7.6e-23;
Matches 55; Conservative 10; Mismatches 13; Indels 0; Gaps 0;

CY 243 LQVLLPYLQERFVQALSYIACKSEGERCKENOCWCHGKFKFECNCPKSDICAKHEEN 102
DB 1 LQVLLPEYLERRVVALSVITSSGELYCKENDCWKCSFTFFECNCPKSDICAKHEEN 60

CY 303 LKRITETWKAYNSCFEES 320
DB 61 LQIQDSWATHNRQFEES 78

RESULT 5
US-10-231-417-371
; Sequence 371, Application US/10231417
; Publication No. US20030176681A1
; GENERAL INFORMATION:
; APPLICANT: Feng et al.
; TITLE OF INVENTION: 148 Human Secreted Proteins
; FILE REFERENCE: P20198;
; CURRENT APPLICATION NUMBER: US/10231417
; CURRENT FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: US/09/296,622
; PRIOR FILING DATE: 1999-04-23
; NUMBER OF SEQ ID NOS: 619
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 371:
; LENGTH: 101
; TYPE: PR
; ORGANISM: Homo sapiens
US-10-231-417-371

Query Match      7.3%; Score 299.5; DB 12; Length 101;
Best Local Similarity 76.3%; Pred. No. 4.4e-20;
Matches 58; Conservative 6; Mismatches 7; Indels 5; Gaps 1;

CY 70 GFSTRYKIYEFERKWKNNVAVERRNPUSPLDAPFEFFNRIILGRRPTIQOTTENLIK 129
DB 10 GFSP-----REPARKYNNVJALRKOPFSLPLAPFENFELIQRFPENLOCVTENIK 44

CY 130 KYGTHPLLSATLQGE 145
DB 65 KYGTHPLLSATLQKQ 80

RESULT 6
US-09-864-761-38134
; Sequence 38134, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharon G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; APPLICANT: Chen, Wensheng
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; FILE REFERENCE: Acotica-X-1
; CURRENT APPLICATION NUMBER: US/09/864,761
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 65/180,312

```

```

; PRIOR FILING DATE: 2000-12-04
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-03-26
; PRIOR APPLICATION NUMBER: US 09/632,366
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: GB 24261.6
; PRIOR FILING DATE: 2000-10-14
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 09/609,408
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: US 09/774,203
; PRIOR FILING DATE: 2001-01-29
; NUMBER OF SEQ ID NOS: 4317
; SOFTWARE: Annotax Sequence Listing Engine vers. 1.1
; SEQ ID NO 38134
; LENGTH: 69
; TYPE: PR
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO ALO22143.1
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 0.99
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.4
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.5
; OTHER INFORMATION: EXPRESSED IN BT474, SIGNAL = 1.6
; OTHER INFORMATION: EST_HUMAN HIT: 072943.1, EVALUE 5.00e-16
US-09-864-761-38134

Query Match      5.4%; Score 219; DB 9; Length 69;
Best Local Similarity 66.7%; Pred. No. 8.4e-13;
Matches 16; Conservative 10; Mismatches 7; Indels 6; Gaps 1;

CY 144 ESLLTFVCKKLSKRAEGSDST-----NSSSVTJETLHOJAASYPIRDESLRRJHH 197
DB 1 ESLLTFVCKKLGKTKTTGGASITGGSGNSTAVSLTTLHQJAASYPIRDESLRRJHH 60

CY 196 IOIASTAIK 206
DB 61 IOIASTAIK 69

RESULT 7
US-09-874-923-101
; Sequence 101, Application US/09874923
; Patent No. US20020081320A1
; GENERAL INFORMATION:
; APPLICANT: Reed, Steven G.
; APPLICANT: Campos-Neto, Antonio
; APPLICANT: Webb, John R.
; APPLICANT: Dillon, David C.

```

APPLICANT: Skeiky, Yasir A.W.
 APPLICANT: Bhatia, Ajay
 APPLICANT: Coler, Rhea
 APPLICANT: Probst, Peter
 APPLICANT: Brannon, Mark
 TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE
 FILE OF INVENTION: THERAPY AND DIAGNOSIS OF LEISHMANIASIS
 FILE REFERENCE: 210121.420C8
 CURRENT APPLICATION NUMBER: US/09/874,923
 CURRENT FILING DATE: 2001-06-04
 NUMBER OF SEQ ID NOS: 122
 SOFTWARE: FastSeq for Windows Version 4.0
 SEQ ID NO 121
 LENGTH: 709
 TYPE: PRT
 ORGANISM: Leishmania major and chagasi
 US-09-874-923-121

Query Match 3.0%; Score 123; DB 9; Length 709;
 Best Local Similarity 21.8%; Pred. No. 0.037;
 Matches 75; Conservative 26; Mismatches 117; Indels 126; Gaps 16;

QY 203 TAIKVTETRTPLGCS-----NYNLDSSVSVLVGSPENKIQGLQGV 245
 DB 354 TAIKVPDPTNAYVGLCSAGCTTCFNETACLECRPSYEML-----PMTCSLTSLQC 403
 QY 246 LLPDY-----LOERFVQAALSYIACNS--EGEFICK-----END 277
 DB 404 TDPKCKTCTTYGQCTTCNDGGLTSSSVGVCRCSVAGCKSPVDANVCKVGLGSEPINNM 463
 QY 278 CWHCGKFPKPC-KCFSS-----MD---LCAMEENLLRITETWKAYNSDFEE 319
 DB 464 CPC-----TDPNCASCPDSAGTCTCANGYGLVDGACVACQCFPCFSC----- 555
 QY 320 SDERKLEPKRLPMRYFLN-----TSTIMLWTMSNFORRYEQLENSYKOLFLKAKQ 371
 DB 508 SDANK--CTOCAPNYLTLLTCSFVACNIEHCWCCDPOTFSCQCEVSP----- 555
 QY 372 IVHKLFSLSKCHKQPLISLPRQRTSYWLTTRIQSFLYCNENGLGSSFBETHSCCTCPND 431
 DB 556 --YVDSVDEGLRLSDACSVNCKKCTGTGSR-----CABCDTGYLSADATSCSPTT 608
 QY 372 IVHKLFSLSKCHKQPLISLPRQRTSYWLTTRIQSFLYCNENGLGSSFBETHSCCTCPND 431
 DB 556 --YVDSVDEGLRLSDACSVNCKKCTGTGSR-----CABCDTGYLSADATSCSPTT 608
 QY 432 QWCTAFPLPCTVGDASACLTCAPONRTRCGTNTGYMLSGSLCK 475
 DB 609 Q-----PCEV---EHNTCNGDSTRCAVNTGYVVSQCKK 642

RESULT 8
 US-09-991-496-121
 Sequence 121, Application US/0999,496
 Patent No. US20020169285A
 GENERAL INFORMATION:
 APPLICANT: Reed, Steven G.
 APPLICANT: Campos-Neto, Antonio
 APPLICANT: Webb, John R.
 APPLICANT: Dillon, David C.
 APPLICANT: Skeiky, Yasir A.W.
 APPLICANT: Bhatia, Ajay
 APPLICANT: Coler, Rhea
 APPLICANT: Probst, Peter
 APPLICANT: Brannon, Mark
 TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE
 FILE OF INVENTION: THERAPY AND DIAGNOSIS OF LEISHMANIASIS
 FILE REFERENCE: 210121.420C9
 CURRENT APPLICATION NUMBER: US/09/991,496
 CURRENT FILING DATE: 2001-11-20
 NUMBER OF SEQ ID NOS: 137
 SOFTWARE: FastSeq for Windows Version 4.0
 SEQ ID NO 121
 LENGTH: 709
 TYPE: PRT
 ORGANISM: Leishmania major and chagasi
 US-09-991-496-121

Query Match 3.0%; Score 123; DB 10; Length 709;
 Best Local Similarity 21.8%; Pred. No. 0.037;
 Matches 75; Conservative 26; Mismatches 117; Indels 126; Gaps 16;

QY 203 TAIKVTETRTPLGCS-----NYNLDSSVSVLVGSPENKIQGLQGV 245
 DB 354 TAIKVPDPTNAYVGLCSAGCTTCFNETACLECRPSYEML-----PMTCSLTSLQC 403
 QY 246 LLPDY-----LOERFVQAALSYIACNS--EGEFICK-----END 277
 DB 404 TDPKCKTCTTYGQCTTCNDGGLTSSSVGVCRCSVAGCKSPVDANVCKVGLGSEPINNM 463
 QY 278 CWHCGKFPKPC-KCFSS-----MD---LCAMEENLLRITETWKAYNSDFEE 319
 DB 464 CPC-----TDPNCASCPDSAGTCTCANGYGLVDGACVACQCFPCFSC----- 555
 QY 320 SDERKLEPKRLPMRYFLN-----TSTIMLWTMSNFORRYEQLENSYKOLFLKAKQ 371
 DB 508 SDANK--CTOCAPNYLTLLTCSFVACNIEHCWCCDPOTFSCQCEVSP----- 555
 QY 372 IVHKLFSLSKCHKQPLISLPRQRTSYWLTTRIQSFLYCNENGLGSSFBETHSCCTCPND 431
 DB 556 --YVDSVDEGLRLSDACSVNCKKCTGTGSR-----CABCDTGYLSADATSCSPTT 608
 QY 432 QWCTAFPLPCTVGDASACLTCAPONRTRCGTNTGYMLSGSLCK 475
 DB 609 Q-----PCEV---EHNTCNGDSTRCAVNTGYVVSQCKK 642

RESULT 9
 US-10-142-143-2
 Sequence 2, Application US/10142,143
 Publication No. US2003039969A
 GENERAL INFORMATION:
 APPLICANT: DeAngelis, Paul
 TITLE OF INVENTION: HEPARIN/HEPARAN SYNTHASE FROM P. MULTOCIDA AND METHODS OF MAKING
 FILE OF INVENTION: USING SAME
 FILE REFERENCE: 5864,017
 CURRENT APPLICATION NUMBER: US/10/142,143
 CURRENT FILING DATE: 2002-05-08
 PRIOR APPLICATION NUMBER: 60/289,554
 PRIOR FILING DATE: 2001-05-08
 PRIOR APPLICATION NUMBER: 60/296,385
 PRIOR FILING DATE: 2001-06-08
 PRIOR APPLICATION NUMBER: 60/303,691
 PRIOR FILING DATE: 2001-07-06
 PRIOR APPLICATION NUMBER: 60/313,258
 PRIOR FILING DATE: 2001-08-17
 NUMBER OF SEQ ID NOS: 22
 SOFTWARE: PatentIn version 3.1
 SEQ ID NO 2
 LENGTH: 617
 TYPE: PRT
 ORGANISM: Pasteurella multocida
 US-10-142-143-2

Query Match 2.9%; Score 117; DB 15; Length 617;
 Best Local Similarity 19.0%; Pred. No. 0.011;
 Matches 130; Conservative 111; Mismatches 207; Indels 236; Gaps 39;

QY 104 APEFRNIRLLGRRTPLQITENIKKYGTHFLSLATLG-GEESLT-FVCKRLSKRAEG 162
 DB 7 ATELKPS---GNVKQALTVEN-AKIVGSLSVKNIDICKNIT---QSKSNKISED 58
 QY 143 SSTNTSSSVTLERHQAASVFDROSTLRRLHIQIASTAIKVETRTGP----- 215
 DB 59 NISGENKPSVS-KQVYN-----EISNSELGITKERLCAPPVSVIIM 99
 QY 216 GCSNYDNL--DSVSSVLVSPENKIQGLQGV--LPDYLERFVQAAL----- 260
 DB 100 TSHNTEKFEIASINSLLOTYNN-----LEVIWDDYSTDKTFQASRIANSTSKVKT 153

QY 261 ---SYACN-----SEGHFI-CKNDQCHGCPHPEPC-----KPSM 294
DB 154 RUNSLGTYFAKNTGILKSKGDIIFQSDUDVCH-HEIEPCQALLSKXGNIAPPCAYS 312
QY 295 DICAMEENLJLRT-----TWAYNSDFEE-----SDRP-----KLEKAL 333
DB 213 RINLETONTIKYNDKRYKLGILITGVYKRVFNEIGFENCITKADCEFYHILKYQAR 272
QY 331 PMNYFQ-----NTS-----TIMELWTMOSNFOR-----YEQFNSMKQ 364
DB 273 INKLFLPLYNTYREDLSFDVYVWVWENNKKQKSDARQYHLHFFQKHNERALNEAKS 332
QY 365 JFJKAQKIYHKLFSLSKCHK---QPSJ-----SLPQRTSTYWLTRICQFELFQENML 415
DB 333 JFSFPR--IHDAIPISKEMSKLSNKPYPVINCSP-----SPKQGVY---TGV 309
QY 416 LGSFSEHSCPCNDQVYCTAFJCTVGDASACLTCAPONRTPGTONTYMLSOGLCK 475
DB 380 LKQCQDHPHYLDGYPEV---PQPIK-KLONKATVINC--QKXHSIRPENGKATILEKLIK 434
QY 476 PEVASTCHY-----IGFTDQJLEKMYLLOKTUR RIEVHAIF-SNDYRLNSWPDF 527
DB 435 -----ENKQGYITCODDIRYPADYNTMIKKINKYNDKAAGLHGVIPPS--RVNKYPSS 498
QY 525 SNEKRVLLTKS-----NKYK-SSLAHV-ILGLSLQICUTKN 562
DB 489 D---RIVYNPQKPLENDTAVNLGTCTVAFVSI-FNKFSLSDPEHPGNVDIYFSLCKN 545
QY 563 STJEPYLAIVYVPPFGSHSESMPYNSFPDWERTKLDLPLOQYNNLTILGNKRWKTF 622
DB 546 NTLQVCI-----SRPSNLTEDNKN-----TETJPHFQNR 577
QY 623 ETVMHYLSR--KSNQPNQNESTY 645
DB 578 E-----IQSKLIISNPNWGYSSII 596

RESULT 10
US-10-047-676A-7
; Sequence 7, Application US/10047676A
; Publication No. US2002023105A1
; GENERAL INFORMATION:
; APPLICANT: Qi, Fengxia
; APPLICANT: Caulfield, Page W.
; APPLICANT: Chen, Ping W.
; TITLE OF INVENTION: MUTACIN I BIOSYNTHESIS GENES AND PROTEINS
; FILE REFERENCE: UNB-17431/22
; CURRENT APPLICATION NUMBER: US/10/047,676A
; CURRENT FILING DATE: 2002-03-21
; PRIOR APPLICATION NUMBER: US 05/627,376
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 7
; TYPE: PRF
; ORGANISM: Streptococcus mutans
US-10-047-676A-7

Query Match 2.88; Score 115.5; DB 14; Length 990;
Rest Local Similarity 18.96; Pred No 0.32;
Matches 154; Conservative 125; Mismatches 270; Indels 265; Gaps 42.

QY 119 TLOQITENLAKYQ-----TRF-LLSATLGGESLTIFFVKRLSKRSEGSTINS 169
DB 139 TLKVANNALQKSNDFWLLTRSHFGLMNSRSIDREDITY-----KSNQLEIYVNC 190
QY 170 SS--VTLESTHCLMAAFIDRSDTLRLHPIQIATAIK-----VTETRGPLCCSYCH- 222
DB 191 TEEPISYQTLCDIAEKFSOSSDVK-----EYQTLKEEPTJTSKPSLID----RNP 241
QY 223 LDSVSSVAVGSPENKICLOG-----QVLLPDYLOERFQAALSYVACKSEGETCKEN--- 276

DB 242 LWFINKILERDONNSELLEKUTEKAMIQDYTDNIGEGNNSIALENKMSOIVKANAYL 301
QY 277 ---CQCHCGPFFPCNCPSPMDIQAMEENLIRITETK-KAYNSDFEEDDFKLPYKR-- 329
EP 302 RVCLTCHAEALXLAQHTKSSL-----QNLKVJSSFSASVNSCKEIKNYHEKF-AAVGYE 355
QY 330 ---LPNNYFEN-STVHLWTMOSNFORRYEQLE-NSMKQJFJKAQKIYHKL-----FSLSKRC 383
DB 356 QVLP-QLLJNS-----TSLGFPKGYSTEVSKQNEEDSKNGKLIIEF-QRKEFKALRD 408
QY 384 HKQPLISLPRGTSY-KLTRI-QSPFYVYEN-----GLGSESEETHSTC 428
DB 409 GHEILSDDDLKOLNFDTEQGISSELYCFYNFKSKLLEVSLGVSONLGNTPFSPHS-KL 467
QY 429 PRQVYCTAFJCTVGDASACLTCAPONRTPGTONTGY-----VLSQJCKEFAVES 481
DB 466 PK-----TIVTKWNTKKEPTEAVPNTITOLNEVYFQRGGNIMISKSL-KSHQJEL 520
QY 482 THYIGFTDQDL-----EYKYLLOKTERRIEVHAIFISNDYRLNSWPDFSWKXKML 534
DB 521 RNYTTKEMSINDIYVRATSEELIYFYSKKYKRV-----IFNNNM--PNYNGSKLJREL 574
QY 535 LTKSNKYKSSLVHXYLGL-----GKWKTFEFTVHI-----SLQICLTK 561
DB 575 LEVNSDQF-NITPTTGLSLSYNHVPAILYKDIIRKETWNRKSEAKTLCSLKNWLT- 632
QY 562 NSTLEPV-----AVYVNFPGSHSESMPYNSF-----PWERTKLDL 603
DB 633 NNKVPFVRKMYTDGIIVLCUSRTTDLTMLFOSIKHUSFIQLLDVHVSCTVDTLELIV 692
QY 604 PL-----QYNNMTLT-----GKWKTFEFTVHI-----YLR- 630
DB 593 PFRSDVAHQIYHVAQNIYTLSDSGSKYFYAKIYVVKQRTSFLQKEYVPLKLYLK 752
QY 631 -----SRKSNQPNQNE-----SIYEPLEFIDPSNLYMKINNIQVFG 670
DB 753 PENLOWFYTRYKDCGKDSIRJERYVEDKQLVQVSRFIEWATKAR-----KHIQVSG 805
QY 671 YSM-HFDEPAIR-----DULQLDYPYVYTGQSQSALLGLEIRDR 709
DB 806 YEISEYTPESARYGKKYSSIIHSFPYVDSILDLLQ-----KKAECTIEVETS 854
QY 710 VN-----KLSPFGQRL--DLFSCLLRHRLK 733
DB 855 LSIIRVFLMWKLSLQCKQLERKLPDG--KHKLK 896

RESULT 11
US-10-142-143-4
; Sequence 4, Application US/10142143
; Publication No. US2003059957A1
; GENERAL INFORMATION:
; APPLICANT: DeAngelis, Paul
; TITLE OF INVENTION: HEPARIN/HEPARANS SYNTHASE FROM P. MULTOCIDA AND METHODS OF MAKI
; FILE REFERENCE: 5864, 627
; CURRENT APPLICATION NUMBER: US/10/142,143
; CURRENT FILING DATE: 2002-05-28
; PRIOR APPLICATION NUMBER: 60/289,554
; PRIOR FILING DATE: 2001-05-05
; PRIOR APPLICATION NUMBER: 60/296,386
; PRIOR FILING DATE: 2001-06-26
; PRIOR APPLICATION NUMBER: 47/103,691
; PRIOR FILING DATE: 2002-07-06
; PRIOR APPLICATION NUMBER: 60/313,258
; PRIOR FILING DATE: 2001-08-17
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 4
; LENGTH: 617
; TYPE: PRF
; ORGANISM: Pasteurella multocida
US-10-142-143-4

```
Query Match      2.8% Score 115; DB 15; Length 617;
Best Local Similarity 19.0% Pred. No. 0.17;
Matches 130; Conservative 111; Mismatches 267; Indels 236; Gaps 39;

QY 104 APEPRRLRLGRPTQQTENIKKYGTHFLLSATLG-GEESLTIFVCKRKLKSAEG 162
DB 104 APEPRRLRLGRPTQQTENIKKYGTHFLLSATLG-GEESLTIFVCKRKLKSAEG 162
QY 7 ATELFKS-----GNVKDALTYENIAKYGESLVKYNDICKNIT-----QSKNKEED 58
DB 7 ATELFKS-----GNVKDALTYENIAKYGESLVKYNDICKNIT-----QSKNKEED 58
QY 163 SDSSTINSSVTLETJHOLASFYDRDSTLRRLLHHIOIASTAIKVTETRTGP-----L 215
DB 163 SDSSTINSSVTLETJHOLASFYDRDSTLRRLLHHIOIASTAIKVTETRTGP-----L 215
QY 59 NISGENKFSVSIKOLYN-----EISNELGCIKERUGARPLYSIIV 93
DB 59 NISGENKFSVSIKOLYN-----EISNELGCIKERUGARPLYSIIV 93
QY 216 GCSNYDKL--DSVSLSVQSENKIQLOGLOVJ-LPDYJGERFVQAAI----- 249
DB 216 GCSNYDKL--DSVSLSVQSENKIQLOGLOVJ-LPDYJGERFVQAAI----- 249
QY 100 TSHNTKEFIASIRSLQTYNN-----LEVIIVDCYSYDKTFQJASRANSTSKVATP 153
DB 100 TSHNTKEFIASIRSLQTYNN-----LEVIIVDCYSYDKTFQJASRANSTSKVATP 153
QY 261 -----SYIACN-----SEGEFI-CKENDCMCHGPKFPEC-----NCPGM 294
DB 261 -----SYIACN-----SEGEFI-CKENDCMCHGPKFPEC-----NCPGM 294
QY 154 RNSNLGTYPANNGILASKGDIIFQDSDDVCH-HERIECNALLSNKON-AVGCAYS 212
DB 154 RNSNLGTYPANNGILASKGDIIFQDSDDVCH-HERIECNALLSNKON-AVGCAYS 212
QY 295 DIOAMEENLGRITE-----TWKYNNSDFEE-----SDFE-----KLFLYKEL 310
DB 295 DIOAMEENLGRITE-----TWKYNNSDFEE-----SDFE-----KLFLYKEL 310
QY 213 RINLETQNIKVNOKKYLGLTILGWKRVENEIGFNCITKAEDDFEYRIIKVYSKR 272
DB 213 RINLETQNIKVNOKKYLGLTILGWKRVENEIGFNCITKAEDDFEYRIIKVYSKR 272
QY 331 PNYVEL-----NTS-----TIMHLTMTDSNFQRR-----YEQJENSMKQ 364
DB 331 PNYVEL-----NTS-----TIMHLTMTDSNFQRR-----YEQJENSMKQ 364
QY 273 INNUFLPYNYKXREDSFSDMVWVDENNIRKQKTSARONYLHEFKIINERKALNEKE 312
DB 273 INNUFLPYNYKXREDSFSDMVWVDENNIRKQKTSARONYLHEFKIINERKALNEKE 312
QY 365 LFLKAQKIVHKJFSLSKRCHK--QPLI-----SLPRQSTYWLTRISFVYCNENGL 415
DB 365 LFLKAQKIVHKJFSLSKRCHK--QPLI-----SLPRQSTYWLTRISFVYCNENGL 415
QY 333 IFSFPR--IHOALPFSKMSKLSNPKIPVYINISIP-----SRIRQLQV--TIGV 379
DB 333 IFSFPR--IHOALPFSKMSKLSNPKIPVYINISIP-----SRIRQLQV--TIGV 379
QY 416 LOSPSEETHSCFCNQVQVCTAFIPCTVGDASACLTCAPDNRCTGTCNTGYVLSQGLCK 475
DB 416 LOSPSEETHSCFCNQVQVCTAFIPCTVGDASACLTCAPDNRCTGTCNTGYVLSQGLCK 475
QY 380 LKNOCDRPHYLOGYPEV--PQFK-KLGNKATVNC--QNKESIRCNKGKFIULENLIY 434
DB 380 LKNOCDRPHYLOGYPEV--PQFK-KLGNKATVNC--QNKESIRCNKGKFIULENLIY 434
QY 476 PEVAESTHY-----IGFSTDIQDLEMVYLLQKTSR-PIEVALFISMDMSANSEOP 527
DB 476 PEVAESTHY-----IGFSTDIQDLEMVYLLQKTSR-PIEVALFISMDMSANSEOP 527
QY 435 ----ENKQGVITCDDIRYADYINTKIRKINKYNDKAAIGCHWIFTS--RNKYPSS 498
DB 435 ----ENKQGVITCDDIRYADYINTKIRKINKYNDKAAIGCHWIFTS--RNKYPSS 498
QY 528 SMPKEMULTKSS-----NKKY-SSEVHM-ILGLESQICLTKN 562
DB 528 SMPKEMULTKSS-----NKKY-SSEVHM-ILGLESQICLTKN 562
QY 489 D--RIVYNEKPLENDTAVNIIIGTVAPVUSIFNKPFLSLPFRGWDVIYISILCKN 545
DB 489 D--RIVYNEKPLENDTAVNIIIGTVAPVUSIFNKPFLSLPFRGWDVIYISILCKN 545
QY 563 STLSVPJAVVYVPPGSHSSEWFEWNSFPDNRKLDJFLQYKNTLTGKXKWTFF 622
DB 563 STLSVPJAVVYVPPGSHSSEWFEWNSFPDNRKLDJFLQYKNTLTGKXKWTFF 622
QY 546 NIIQVCI-----SRESNKLTECNK-----TETLFEHQWRD 577
DB 546 NIIQVCI-----SRESNKLTECNK-----TETLFEHQWRD 577
QY 623 ETVH-YLASR-IKSKGPNGNESIY 645
DB 623 ETVH-YLASR-IKSKGPNGNESIY 645
QY 578 E-----IQSKJISNNPWGYSSIIY 596
DB 578 E-----IQSKJISNNPWGYSSIIY 596

RESULT 12
US-09-874-923-22
; Sequence 22, Application US/09874923
; Patent No. US20020081320A1
; GENERAL INFORMATION:
; APPLICANT: Reed, Steven G.
; APPLICANT: Campos-Neto, Antonio
; APPLICANT: Webb, John R.
; APPLICANT: Dillon, Davin C.
; APPLICANT: Skeiky, Yasir A.W.
; APPLICANT: Bhatia, Ajay
; APPLICANT: Colier, Rhea
; APPLICANT: Probst, Peter
; APPLICANT: Brannon, Mark
; TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE
; FILE REFERENCE: 2:0121.420C8
; CURRENT APPLICATION NUMBER: US/09/874.923
; CURRENT FILING DATE: 2001-06-04

Query Match      2.8% Score 114.5; DB 9; Length 320;
Best Local Similarity 32.3% Pred. No. 0.064;
Matches 30; Conservative 8; Mismatches 40; Indels 15; Gaps 3;

QY 383 CHKQPLJSLPRQSTYWLTRISQFLYCNENGLSGSSEETHSCFCNQVQVCTAFIPCT 442
DB 383 CHKQPLJSLPRQSTYWLTRISQFLYCNENGLSGSSEETHSCFCNQVQVCTAFIPCT 442
QY 176 CRISDAGSVNPKKCKETGTSRL-----CAECDGYSLSADATSCSPTTC-----PCE 223
DB 176 CRISDAGSVNPKKCKETGTSRL-----CAECDGYSLSADATSCSPTTC-----PCE 223
QY 443 VGDASACLTCAPDNRCTGTCNTGYVLSQGLCK 475
DB 443 VGDASACLTCAPDNRCTGTCNTGYVLSQGLCK 475
QY 224 V---EHCKTCVNGDSTRCAVNTGYVYSDGKCK 253
DB 224 V---EHCKTCVNGDSTRCAVNTGYVYSDGKCK 253

RESULT 14
US-09-991-496-22
; Sequence 22, Application US/09991496
; Patent No. US20020169285A1
; GENERAL INFORMATION:
; APPLICANT: Reed, Steven G.
; APPLICANT: Campos-Neto, Antonio
; APPLICANT: Webb, John R.
; APPLICANT: Dillon, Davin C.
; APPLICANT: Skeiky, Yasir A.W.
; APPLICANT: Bhatia, Ajay
; APPLICANT: Colier, Rhea
; APPLICANT: Probst, Peter
; APPLICANT: Brannon, Mark
; TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE
; FILE REFERENCE: 2:0121.420C8
; CURRENT APPLICATION NUMBER: US/09/874.923
; CURRENT FILING DATE: 2001-06-04
```


Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
August 1, 2003
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS 10 SEP 22 DIPPR file reloaded
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded
NEWS 12 SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced

NEWS EXPRESS OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:50:21 ON 30 OCT 2003

=> file medline, uspatful, dgene, embase, wpids, fsta, biosis		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 16:50:42 ON 30 OCT 2003

FILE 'USPATFULL' ENTERED AT 16:50:42 ON 30 OCT 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 16:50:42 ON 30 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 16:50:42 ON 30 OCT 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 16:50:42 ON 30 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 16:50:42 ON 30 OCT 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'BIOSIS' ENTERED AT 16:50:42 ON 30 OCT 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

=> e fiscella,m/au

E1	8	FISCELLA RICHARD/AU
E2	19	FISCELLA RICHARD G/AU
E3	0 -->	FISCELLA,M/AU
E4	1	FISCELLI NICOLINO/AU
E5	9	FISCELLI O/AU
E6	1	FISCELLS R/AU
E7	1	FISCENCO V/AU
E8	1	FISCER A G/AU
E9	1	FISCER J J/AU
E10	1	FISCFHER A/AU
E11	2	FISCH/AU
E12	203	FISCH A/AU

=> e wei, p/au

E1	1	WEI ZUO/AU
E2	1	WEI ZUO JUN/AU
E3	0 -->	WEI, P/AU
E4	1	WEI1 F/AU
E5	1	WEIAI SU/AU
E6	1	WEIAND C/AU
E7	1	WEIAND CLAUDIA/AU
E8	1	WEIAND D D/AU
E9	1	WEIAND DENNIS D/AU
E10	7	WEIAND F/AU
E11	3	WEIAND FRANK/AU
E12	20	WEIAND G/AU

=> e lafleur, d/au

E1	5	LAFLEUR W R/AU
E2	2	LAFLEUR WILLIAM R/AU
E3	0 -->	LAFLEUR, D/AU
E4	1	LAFLEUREZA J A/AU
E5	24	LAFLEURIEL J/AU
E6	2	LAFLEURIEL JACQUELINE/AU
E7	1	LAFLEURIEL M/AU
E8	18	LAFLEURIEL M T/AU
E9	1	LAFLEURIEL TH M/AU
E10	1	LAFLEURJUN P J/AU
E11	1	LAFLEY LINDA S/AU
E12	3	LAFLIN B/AU

=> e soppet, d/au

E1	2	SOPPET DANIEL P/AU
E2	112	SOPPET DANIEL R/AU
E3	0 -->	SOPPET, D/AU

E4	3	SOPPETT D/AU
E5	1	SOPPETT DAN/AU
E6	16	SOPPI A M/AU
E7	233	SOPPI E/AU
E8	10	SOPPI E T/AU
E9	13	SOPPI ESA/AU
E10	38	SOPPIMATH K S/AU
E11	5	SOPPIMATH KUMARESH S/AU
E12	1	SOPPIMATH S S/AU

=> e moore, p/au

E1	4	MOORE ZACK J/AU
E2	3	MOORE ZAKHIA/AU
E3	0 -->	MOORE, P/AU
E4	1	MOOREADIAN ARSHAG D/AU
E5	1	MOOREAU J/AU
E6	1	MOORECR J R/AU
E7	1	MOORECRAFT P/AU
E8	4	MOORECROFT B J/AU
E9	1	MOORED J A/AU
E10	1	MOORED J W/AU
E11	1	MOOREE J H/AU
E12	1	MOOREES C F/AU

=> e rosen, c/au

E1	2	ROSEN ZVI MICHAL/AU
E2	1	ROSEN ZWEIG JAMES/AU
E3	0 -->	ROSEN, C/AU
E4	1	ROSENA BRUCE R/AU
E5	1	ROSENABUM S/AU
E6	1	ROSENACKER A F/AU
E7	1	ROSENACKER ARTHUR F/AU
E8	4	ROSENADA CEPERO R/AU
E9	1	ROSENAGER L/AU
E10	1	ROSENAK B/AU
E11	49	ROSENAK B D/AU
E12	23	ROSENAK D/AU

=> e baker, k/au

E1	98	BAKER ZANDER S A/AU
E2	4	BAKER ZANDER SHARON A/AU
E3	0 -->	BAKER, K/AU
E4	1	BAKERAMMAR A/AU
E5	1	BAKERBB/AU
E6	1	BAKERBM J R/AU
E7	4	BAKERDC J R/AU
E8	1	BAKERDJIAN Z/AU
E9	1	BAKERDJIEV T/AU
E10	1	BAKERDZHIEVA D/AU
E11	2	BAKERDZHIEVA N T/AU
E12	2	BAKERENKOV A S/AU

=> e ruben, s/au

E1	1	RUBEN ZANCHETTA JOSE/AU
E2	2	RUBEN ZORRO/AU
E3	0 -->	RUBEN, S/AU
E4	7	RUBENACH B/AU
E5	8	RUBENACH BERNHARD/AU
E6	2	RUBENACH GERZ K/AU
E7	1	RUBENACH I/AU
E8	1	RUBENACH J/AU
E9	11	RUBENACH S/AU
E10	1	RUBENACH S E/AU
E11	3	RUBENACH SALLY/AU

E12 1 RUBENACH SALLY E/AU

=> s secreted protein () protein expression
3 FILES SEARCHED...

L1 0 SECRETED PROTEIN (W) PROTEIN EXPRESSION

=> s secreted protein () squamous carcinoma

L2 0 SECRETED PROTEIN (W) SQUAMOUS CARCINOMA

=> s renal cell carcinoma

L3 33636 RENAL CELL CARCINOMA

=> s secreted protein and l3

L4 504 SECRETED PROTEIN AND L3

=> s l4 and therapy

L5 488 L4 AND THERAPY

=> s l5 and ovarian cancer

L6 402 L5 AND OVARIAN CANCER

=> s l6 and skin cancer

L7 223 L6 AND SKIN CANCER

=> s l7 and bladder

L8 223 L7 AND BLADDER

=> s l8 and treatment

L9 223 L8 AND TREATMENT

=> s l9 and screening assay

L10 153 L9 AND SCREENING ASSAY

=> s l10 and method

L11 153 L10 AND METHOD

=> s l11 and fluorescent

L12 153 L11 AND FLUORESCENT

=> d l12 ti abs ibib 1-15

L12 ANSWER 1 OF 153 USPATFULL on STN

TI Nucleic Acids, Proteins, and antibodies

AB The present invention relates to novel **bladder** related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "**bladder** antigens," and the use of such **bladder** antigens for detecting disorders of the **bladder** system, particularly the presence of **bladder** cancer and **bladder** cancer metastases. More specifically, isolated **bladder** associated nucleic acid molecules are provided encoding novel **bladder** associated polypeptides. Novel **bladder** polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human **bladder** associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the **bladder**, including **bladder** cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2003:282665 USPATFULL
 TITLE: Nucleic Acids, Proteins, and antibodies
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199008	A1	20031023
APPLICATION INFO.:	US 2002-80254	A1	20020222 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764858, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)

US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)

US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 20702

L12 ANSWER 2 OF 153 USPATFULL on STN

TI Human cDNAs and proteins and uses thereof

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the **treatment** of GENSET-related disorders.

ACCESSION NUMBER: 2003:282611 USPATFULL
TITLE: Human cDNAs and proteins and uses thereof
INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003198954	A1	20031023
APPLICATION INFO.:	US 2001-1142	A1	20011114 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-IB1715	20010806
	US 2001-305456P	20010713 (60)
	US 2001-302277P	20010629 (60)
	US 2001-298698P	20010615 (60)
	US 2001-293574P	20010525 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL
 ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1,
 GAINESVILLE, FL, 326066669
 NUMBER OF CLAIMS: 13
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 4 Drawing Page(s)
 LINE COUNT: 25681

L12 ANSWER 3 OF 153 USPTFULL on STN

TI Polynucleotides encoding three novel human cell surface proteins with
 leucine rich repeats and immunoglobulin folds, BGS2, 3, and 4 and
 variants thereof
 AB The present invention provides novel polynucleotides encoding BGS-2, 3,
 and 4 polypeptides, fragments and homologues thereof. Also provided are
 vectors, host cells, antibodies, and recombinant and synthetic methods
 for producing said polypeptides. The invention further relates to
 diagnostic and therapeutic methods for applying these novel BGS-2, 3,
 and 4 polypeptides to the diagnosis, **treatment**, and/or
 prevention of various diseases and/or disorders related to these
 polypeptides. The invention further relates to screening methods for
 identifying agonists and antagonists of the polynucleotides and
 polypeptides of the present invention.

ACCESSION NUMBER: 2003:277136 USPTFULL
 TITLE: Polynucleotides encoding three novel human cell surface
 proteins with leucine rich repeats and immunoglobulin
 folds, BGS2, 3, and 4 and variants thereof
 INVENTOR(S): Wu, Shujian, Langhorne, PA, UNITED STATES
 Krystek, Stanley R., Ringoes, NJ, UNITED STATES
 Lee, Liana, North Brunswick, NJ, UNITED STATES
 Feder, John N., Belle Mead, NJ, UNITED STATES
 Cheng, Janet D., Lawrenceville, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003195163	A1	20031016
APPLICATION INFO.:	US 2002-193477	A1	20020711 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-304888P	20010711 (60)
	US 2002-372147P	20020412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Page(s)	
LINE COUNT:	19137	

L12 ANSWER 4 OF 153 USPTFULL on STN

TI Metalloproteinase ADAM 22
 AB The present invention relates to a novel metalloproteinase protein
 called ADAM 22. In particular, isolated nucleic acid molecules are
 provided encoding the human ADAM 22 proteins. ADAM 22 polypeptides are
 also provided as are vectors, host cells and recombinant methods for
 producing the same. The invention further relates to screening methods
 for identifying agonists and antagonists of ADAM 22 activity. Also
 provided are diagnostic methods for detecting cancer and therapeutic
 methods for cancer and other disorders characterized by an over or under
 production of this metalloproteinase.

ACCESSION NUMBER: 2003:276772 USPATFULL
TITLE: Metalloproteinase ADAM 22
INVENTOR(S): Young, Paul E., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003194797	A1	20031016
APPLICATION INFO.:	US 2002-156028	A1	20020529 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-487614, filed on 20 Jan 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-116927P	19990122 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	14391	

L12 ANSWER 5 OF 153 USPATFULL on STN

TI Transcription factor polynucleotides, polypeptides, antibodies, and methods based thereon

AB The present invention relates to newly identified human polynucleotides and the polypeptides encoded by these polynucleotides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human antigens. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human antigens.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:271690 USPATFULL
TITLE: Transcription factor polynucleotides, polypeptides, antibodies, and methods based thereon
INVENTOR(S): Barash, Steven C., Rockville, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003191298	A1	20031009
APPLICATION INFO.:	US 2002-112857	A1	20020402 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US30146, filed on 27 Sep 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-236803P	20001002 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18978	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 6 OF 153 USPATFULL on STN

TI 17 human secreted proteins

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:271104 USPATFULL
TITLE: 17 human secreted proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Komatsoulis, George A., Silver Spring, MD, UNITED STATES
Baker, Kevin P., Darnestown, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Wei, Ping, Brookeville, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Duan, D. Roxanne, Bethesda, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Choi, Gil H., Rockville, MD, UNITED STATES
Fiscella, Michele, Bethesda, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003190707	A1	20031009
APPLICATION INFO.:	US 2002-277802	A1	20021023 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-915582, filed on 27 Jul 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US1431, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-231968P	20000912 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 20847

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 7 OF 153 USPATFULL on STN

TI Polynucleotide encoding a novel human potassium channel beta-subunit, K+Mbeta1

AB The present invention provides novel polynucleotides encoding K+Mbeta1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+Mbeta1 polypeptides to the diagnosis, **treatment**, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:258658 USPATFULL
TITLE: Polynucleotide encoding a novel human potassium channel
beta-subunit, K+Mbeta1
INVENTOR(S): Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana M., Somerset, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Siemers, Nathan O., Pennington, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003181711	A1	20030925
APPLICATION INFO.:	US 2002-264171	A1	20021003 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-40805, filed on 1 Nov 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-245366P	20001102 (60)
	US 2000-257851P	20001221 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	11490	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 8 OF 153 USPATFULL on STN

TI 207 human secreted proteins

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:258639 USPATFULL
TITLE: 207 human secreted proteins
INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Hu, Jing-Shan, Mountain View, CA, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Kyaw, Hla, Frederick, MD, UNITED STATES
Fischer, Carrie L., Burke, VA, UNITED STATES

Ferrie, Ann M., Painted Post, NY, UNITED STATES
 Fan, Ping, Potomac, MD, UNITED STATES
 Feng, Ping, Gaithersburg, MD, UNITED STATES
 Endress, Gregory A., Florence, MA, UNITED STATES
 Dillon, Patrick J., Carlsbad, CA, UNITED STATES
 Carter, Kenneth C., North Potomac, MD, UNITED STATES
 Brewer, Laurie A., St. Paul, MN, UNITED STATES
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Zeng, Zhizhen, Lansdale, PA, UNITED STATES
 Greene, John M., Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 2003181692	A1	20030925
APPLICATION INFO.:	US 2001-933767	A1	20010822 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US5614, filed on 21 Feb 2001, PENDING		
	Continuation-in-part of Ser. No. US 1998-205258, filed on 4 Dec 1998, PENDING		

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2000-184836P	20000224 (60)
	US 2000-193170P	20000329 (60)
	US 1997-48885P	19970606 (60)
	US 1997-49375P	19970606 (60)
	US 1997-48881P	19970606 (60)
	US 1997-48880P	19970606 (60)
	US 1997-48896P	19970606 (60)
	US 1997-49020P	19970606 (60)
	US 1997-48876P	19970606 (60)
	US 1997-48895P	19970606 (60)
	US 1997-48884P	19970606 (60)
	US 1997-48894P	19970606 (60)
	US 1997-48971P	19970606 (60)
	US 1997-48964P	19970606 (60)
	US 1997-48882P	19970606 (60)
	US 1997-48899P	19970606 (60)
	US 1997-48893P	19970606 (60)
	US 1997-48900P	19970606 (60)
	US 1997-48901P	19970606 (60)
	US 1997-48892P	19970606 (60)
	US 1997-48915P	19970606 (60)
	US 1997-49019P	19970606 (60)
	US 1997-48970P	19970606 (60)
	US 1997-48972P	19970606 (60)
	US 1997-48916P	19970606 (60)
	US 1997-49373P	19970606 (60)
	US 1997-48875P	19970606 (60)
	US 1997-49374P	19970606 (60)
	US 1997-48917P	19970606 (60)
	US 1997-48949P	19970606 (60)
	US 1997-48974P	19970606 (60)
	US 1997-48883P	19970606 (60)
	US 1997-48897P	19970606 (60)
	US 1997-48898P	19970606 (60)
	US 1997-48962P	19970606 (60)
	US 1997-48963P	19970606 (60)
	US 1997-48877P	19970606 (60)
	US 1997-48878P	19970606 (60)
	US 1997-57645P	19970905 (60)
	US 1997-57642P	19970905 (60)
	US 1997-57668P	19970905 (60)
	US 1997-57635P	19970905 (60)
	US 1997-57627P	19970905 (60)

US 1997-57667P	19970905 (60)
US 1997-57666P	19970905 (60)
US 1997-57764P	19970905 (60)
US 1997-57643P	19970905 (60)
US 1997-57769P	19970905 (60)
US 1997-57763P	19970905 (60)
US 1997-57650P	19970905 (60)
US 1997-57584P	19970905 (60)
US 1997-57647P	19970905 (60)
US 1997-57661P	19970905 (60)
US 1997-57662P	19970905 (60)
US 1997-57646P	19970905 (60)
US 1997-57654P	19970905 (60)
US 1997-57651P	19970905 (60)
US 1997-57644P	19970905 (60)
US 1997-57765P	19970905 (60)
US 1997-57762P	19970905 (60)
US 1997-57775P	19970905 (60)
US 1997-57648P	19970905 (60)
US 1997-57774P	19970905 (60)
US 1997-57649P	19970905 (60)
US 1997-57770P	19970905 (60)
US 1997-57771P	19970905 (60)
US 1997-57761P	19970905 (60)
US 1997-57760P	19970905 (60)
US 1997-57776P	19970905 (60)
US 1997-57778P	19970905 (60)
US 1997-57629P	19970905 (60)
US 1997-57628P	19970905 (60)
US 1997-57777P	19970905 (60)
US 1997-57634P	19970905 (60)
US 1997-70923P	19971218 (60)
US 1998-92921P	19980715 (60)
US 1998-94657P	19980730 (60)
US 1997-70923P	19971218 (60)
US 1998-92921P	19980715 (60)
US 1998-94657P	19980730 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
 ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 10 Drawing Page(s)
 LINE COUNT: 32746
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 153 USPATFULL on STN

TI 186 human secreted proteins

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:251072 USPATFULL

TITLE: 186 human secreted proteins

INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Soppet, Daniel R., Centreville, VA, UNITED STATES
 Carter, Kenneth C., North Potomac, MD, UNITED STATES

Bednarik, Daniel P., Columbia, MD, UNITED STATES
 Endress, Gregory A., Florence, MA, UNITED STATES
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Ni, Jian, Germantown, MD, UNITED STATES
 Feng, Ping, Germantown, MD, UNITED STATES
 Young, Paul E., Gaithersburg, MD, UNITED STATES
 Greene, John M., Gaithersburg, MD, UNITED STATES
 Ferrie, Ann M., Painted Post, NY, UNITED STATES
 Duan, D. Roxanne, Bethesda, MD, UNITED STATES
 Hu, Jing-Shan, Mountain View, CA, UNITED STATES
 Florence, Kimberly A., Rockville, MD, UNITED STATES
 Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
 Fischer, Carrie L., Burke, VA, UNITED STATES
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
 Brewer, Laurie A., St. Paul, MN, UNITED STATES
 Moore, Paul A., Germantown, MD, UNITED STATES
 Shi, Yanggu, Gaithersburg, MD, UNITED STATES
 LaFleur, David W., Washington, DC, UNITED STATES
 Li, Yi, Sunnyvale, CA, UNITED STATES
 Zeng, ZhiZhen, Lansdale, PA, UNITED STATES
 Kyaw, Hla, Frederick, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175858	A1	20030918
APPLICATION INFO.:	US 2001-882171	A1	20010618 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-809391, filed on 16 Mar 2001, PENDING Continuation of Ser. No. US 1998-149476, filed on 8 Sep 1998, GRANTED, Pat. No. US 6420526 Continuation-in-part of Ser. No. WO 1998-US4493, filed on 6 Mar 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-190068P	20000317 (60)
	US 1997-40162P	19970307 (60)
	US 1997-40333P	19970307 (60)
	US 1997-38621P	19970307 (60)
	US 1997-40626P	19970307 (60)
	US 1997-40334P	19970307 (60)
	US 1997-40336P	19970307 (60)
	US 1997-40163P	19970307 (60)
	US 1997-47600P	19970523 (60)
	US 1997-47615P	19970523 (60)
	US 1997-47597P	19970523 (60)
	US 1997-47502P	19970523 (60)
	US 1997-47633P	19970523 (60)
	US 1997-47583P	19970523 (60)
	US 1997-47617P	19970523 (60)
	US 1997-47618P	19970523 (60)
	US 1997-47503P	19970523 (60)
	US 1997-47592P	19970523 (60)
	US 1997-47581P	19970523 (60)
	US 1997-47584P	19970523 (60)
	US 1997-47500P	19970523 (60)
	US 1997-47587P	19970523 (60)
	US 1997-47492P	19970523 (60)
	US 1997-47598P	19970523 (60)
	US 1997-47613P	19970523 (60)
	US 1997-47582P	19970523 (60)
	US 1997-47596P	19970523 (60)
	US 1997-47612P	19970523 (60)
	US 1997-47632P	19970523 (60)
	US 1997-47601P	19970523 (60)

US 1997-43580P	19970411 (60)
US 1997-43568P	19970411 (60)
US 1997-43314P	19970411 (60)
US 1997-43569P	19970411 (60)
US 1997-43311P	19970411 (60)
US 1997-43671P	19970411 (60)
US 1997-43674P	19970411 (60)
US 1997-43669P	19970411 (60)
US 1997-43312P	19970411 (60)
US 1997-43313P	19970411 (60)
US 1997-43672P	19970411 (60)
US 1997-43315P	19970411 (60)
US 1997-48974P	19970606 (60)
US 1997-56886P	19970822 (60)
US 1997-56877P	19970822 (60)
US 1997-56889P	19970822 (60)
US 1997-56893P	19970822 (60)
US 1997-56630P	19970822 (60)
US 1997-56878P	19970822 (60)
US 1997-56662P	19970822 (60)
US 1997-56872P	19970822 (60)
US 1997-56882P	19970822 (60)
US 1997-56637P	19970822 (60)
US 1997-56903P	19970822 (60)
US 1997-56888P	19970822 (60)
US 1997-56879P	19970822 (60)
US 1997-56880P	19970822 (60)
US 1997-56894P	19970822 (60)
US 1997-56911P	19970822 (60)
US 1997-56636P	19970822 (60)
US 1997-56874P	19970822 (60)
US 1997-56910P	19970822 (60)
US 1997-56864P	19970822 (60)
US 1997-56631P	19970822 (60)
US 1997-56845P	19970822 (60)
US 1997-56892P	19970822 (60)
US 1997-57761P	19970905 (60)
US 1997-47595P	19970523 (60)
US 1997-47599P	19970523 (60)
US 1997-47588P	19970523 (60)
US 1997-47585P	19970523 (60)
US 1997-47586P	19970523 (60)
US 1997-47590P	19970523 (60)
US 1997-47594P	19970523 (60)
US 1997-47589P	19970523 (60)
US 1997-47593P	19970523 (60)
US 1997-47614P	19970523 (60)
US 1997-43578P	19970411 (60)
US 1997-43576P	19970411 (60)
US 1997-47501P	19970523 (60)
US 1997-43670P	19970411 (60)
US 1997-56632P	19970822 (60)
US 1997-56664P	19970822 (60)
US 1997-56876P	19970822 (60)
US 1997-56881P	19970822 (60)
US 1997-56909P	19970822 (60)
US 1997-56875P	19970822 (60)
US 1997-56862P	19970822 (60)
US 1997-56887P	19970822 (60)
US 1997-56908P	19970822 (60)
US 1997-48964P	19970606 (60)
US 1997-57650P	19970905 (60)
US 1997-56884P	19970822 (60)
US 1997-57669P	19970905 (60)

US 1997-49610P 19970613 (60)
 US 1997-61660P 19971009 (60)
 US 1997-51926P 19970708 (60)
 US 1997-52874P 19970716 (60)
 US 1997-58785P 19970912 (60)
 US 1997-55724P 19970818 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
 ROCKVILLE, MD, 20850
 NUMBER OF CLAIMS: 23
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 2 Drawing Page(s)
 LINE COUNT: 26326
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 10 OF 153 USPATFULL on STN

TI Interferon Receptor HKAEF92
 AB The present invention relates to a novel Interferon receptor
 "INFR-HKAEF92" protein which is a member of the Interferon/IL-10
 receptor family. In particular, isolated nucleic acid molecules are
 provided encoding the human INFR-HKAEF92 protein. INFR-HKAEF92
 polypeptides are also provided as are vectors, host cells and
 recombinant methods for producing the same. The invention further
 relates to screening methods for identifying agonists and antagonists of
 INFR-HKAEF92 activity. Also provided are diagnostic methods for
 detecting immune system-related disorders and therapeutic methods for
 treating immune system-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:250992 USPATFULL
 TITLE: Interferon Receptor HKAEF92
 INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES
 Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175778	A1	20030918
APPLICATION INFO.:	US 2003-358281	A1	20030205 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-453569, filed on 2 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-326216, filed on 3 Jun 1999, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-88185P	19980605 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	12153	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L12 ANSWER 11 OF 153 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies
 AB The present invention relates to novel proteins. More specifically,
 isolated nucleic acid molecules are provided encoding novel
 polypeptides. Novel polypeptides and antibodies that bind to these
 polypeptides are provided. Also provided are vectors, host cells, and
 recombinant and synthetic methods for producing human polynucleotides
 and/or polypeptides, and antibodies. The invention further relates to

diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:250953 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175739	A1	20030918
APPLICATION INFO.:	US 2002-222020	A1	20020816 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-116016, filed on 5 Apr 2002, PENDING Continuation of Ser. No. US 2001-764848, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)

US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)

US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 20345
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 12 OF 153 USPATFULL on STN

TI Human chemokine beta-10 mutant polypeptides
AB Human Chemokine Beta-10 polypeptides and DNA (RNA) encoding such
chemokine polypeptides and a procedure for producing such polypeptides
by recombinant techniques is disclosed. Also disclosed are methods for
utilizing such chemokine polypeptides for the **treatment** of
leukemia, tumors, chronic infections, autoimmune disease, fibrotic
disorders, wound healing and psoriasis. Antagonists against such
chemokine polypeptides and their use as a therapeutic to treat
rheumatoid arthritis, autoimmune and chronic inflammatory and infective
diseases, allergic reactions, prostaglandin-independent fever and bone
marrow failure are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244905 USPATFULL
TITLE: Human chemokine beta-10 mutant polypeptides
INVENTOR(S): Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Li, Haodong, Gaithersburg, MD, UNITED STATES
Adams, Mark D., Rockville, MD, UNITED STATES
Gentz, Solange H.L., Belo Horizonte, BRAZIL

Alderson, Ralph, Gaithersburg, MD, UNITED STATES
Li, Yuling, Germantown, MD, UNITED STATES
Parmelee, David, Rockville, MD, UNITED STATES
White, John R., Coatesville, PA, UNITED STATES
Appelbaum, Edward R., Blue Bell, PA, UNITED STATES
Salcedo, Theodora, East Syracuse, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171319	A1	20030911
APPLICATION INFO.:	US 2002-263139	A1	20021003 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-125451, filed on 19 Apr 2002, PENDING Continuation-in-part of Ser. No. WO 2001-US18046, filed on 5 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1999-261201, filed on 3 Mar 1999, GRANTED, Pat. No. US 6458349 Continuation-in-part of Ser. No. US 1996-613822, filed on 23 Feb 1996, GRANTED, Pat. No. US 6174995 Continuation-in-part of Ser. No. US 1995-458355, filed on 2 Jun 1995, GRANTED, Pat. No. US 5981230 Continuation-in-part of Ser. No. WO 1994-US9484, filed on 23 Aug 1994, PENDING Continuation-in-part of Ser. No. WO 1994-US9484, filed on 23 Aug 1994, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209578P	20000606 (60)
	US 1999-115439P	19990108 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Page(s)	
LINE COUNT:	13207	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L12 ANSWER 13 OF 153 USPATFULL on STN
TI Human cDNAs and proteins and uses thereof
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the **treatment** of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:244219 USPATFULL
TITLE: Human cDNAs and proteins and uses thereof
INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003170628	A1	20030911
APPLICATION INFO.:	US 2001-999570	A1	20011114 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING		

NUMBER	DATE
--------	------

PRIORITY INFORMATION: WO 2001-IB1715 20010806
 US 2001-305456P 20010713 (60)
 US 2001-302277P 20010629 (60)
 US 2001-298698P 20010615 (60)
 US 2001-293574P 20010525 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL
 ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1,
 GAINESVILLE, FL, 326066669

NUMBER OF CLAIMS: 13
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 4 Drawing Page(s)
 LINE COUNT: 25549
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 14 OF 153 USPATFULL on STN
 TI 83 human secreted proteins
 AB The present invention relates to novel human secreted proteins and
 isolated nucleic acids containing the coding regions of the genes
 encoding such proteins. Also provided are vectors, host cells,
 antibodies, and recombinant methods for producing human secreted
 proteins. The invention further relates to diagnostic and therapeutic
 methods useful for diagnosing and treating diseases, disorders, and/or
 conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 ACCESSION NUMBER: 2003:238383 USPATFULL
 TITLE: 83 human secreted proteins
 INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
 Feng, Ping, Germantown, MD, UNITED STATES
 LaFleur, David W., Washington, DC, UNITED STATES
 Moore, Paul A., Germantown, MD, UNITED STATES
 Shi, Yanggu, Gaithersburg, MD, UNITED STATES
 Kyaw, Hla, Frederick, MD, UNITED STATES
 Li, Yi, Sunnyvale, CA, UNITED STATES
 Zeng, Zhizhen, Lansdale, PA, UNITED STATES
 Carter, Kenneth C., North Potomac, MD, UNITED STATES
 Endress, Gregory A., Florence, MA, UNITED STATES
 Wei, Ying-Fei, Berkeley, CA, UNITED STATES
 Fan, Ping, Potomac, MD, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED
 STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166541	A1	20030904
APPLICATION INFO.:	US 2002-160162	A1	20020604 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-236557, filed on 26 Jan 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US15949, filed on 29 Jul 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-295558P	20010605 (60)
	US 1997-54209P	19970730 (60)
	US 1997-54211P	19970730 (60)
	US 1997-54212P	19970730 (60)
	US 1997-54213P	19970730 (60)
	US 1997-54214P	19970730 (60)
	US 1997-54215P	19970730 (60)
	US 1997-54217P	19970730 (60)
	US 1997-54218P	19970730 (60)

US 1997-54234P	19970730 (60)
US 1997-54236P	19970730 (60)
US 1997-55968P	19970818 (60)
US 1997-55969P	19970818 (60)
US 1997-55972P	19970818 (60)
US 1997-56534P	19970819 (60)
US 1997-56543P	19970819 (60)
US 1997-56554P	19970819 (60)
US 1997-56561P	19970819 (60)
US 1997-56727P	19970819 (60)
US 1997-56729P	19970819 (60)
US 1997-56730P	19970819 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
 ROCKVILLE, MD, 20850
 NUMBER OF CLAIMS: 24
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 2 Drawing Page(s)
 LINE COUNT: 24088
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 15 OF 153 USPATFULL on STN

TI Polynucleotide encoding a novel human potassium channel beta-subunit,
 K+betaM8
 AB The present invention provides novel polynucleotides encoding K+betaM8
 polypeptides, fragments and homologues thereof. Also provided are
 vectors, host cells, antibodies, and recombinant and synthetic methods
 for producing said polypeptides. The invention further relates to
 diagnostic and therapeutic methods for applying these novel K+betaM8
 polypeptides to the diagnosis, **treatment**, and/or prevention of
 various diseases and/or disorders related to these polypeptides. The
 invention further relates to screening methods for identifying agonists
 and antagonists of the polynucleotides and polypeptides of the present
 invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:232051 USPATFULL
 TITLE: Polynucleotide encoding a novel human potassium channel
 beta-subunit, K+betaM8
 INVENTOR(S): Feder, John N., Belle Mead, NJ, UNITED STATES
 Lee, Liana M., North Brunswick, NJ, UNITED STATES
 Chang, Han, Princeton Junction, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003162251	A1	20030828
APPLICATION INFO.:	US 2002-234951	A1	20020904 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-317087P	20010904 (60)
	US 2001-329666P	20011016 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	16624	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

WEST**Freeform Search****Database:**

US Patents Full-Text Database ▲
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins ▼

L2 and l1

Term:**Display:** 10 **Documents in Display Format:** CIT **Starting with Number** 1**Generate:** ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show Numbers

Edit Numbers

Preferences

Help

Search History**DATE:** Thursday, October 30, 2003 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
---------------------------------	--------------	------------------	-------------------------------

DB=USPT; PLUR=YES; OP=OR

<u>L3</u>	L2 and l1	56935	<u>L3</u>
<u>L2</u>	cancer therapy	107591	<u>L2</u>
<u>L1</u>	secreted protein	143193	<u>L1</u>

END OF SEARCH HISTORY

FILE 'MEDLINE' ENTERED AT 16:29:46 ON 30 OCT 2003

FILE 'WPIDS' ENTERED AT 16:29:46 ON 30 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

=> s secreted protein
L1 4670 SECRETED PROTEIN

=> s cancer therapy
L2 19002 CANCER THERAPY

=> s l2 and l1
L3 7 L2 AND L1

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 7 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI Secretory production of recombinant urokinase kringle domain in *Pichia pastoris*.
AB Human urokinase kringle domain, sharing homology with angiostatin kringles, has been shown to be an inhibitor of angiogenesis, which can be used for the treatment of cancer, rheumatoid arthritis, psoriasis, and retinopathy. Here, the expression of the kringle domain of urokinase (UK1) as a **secreted protein** in high levels is reported. UK1 was expressed in the methylotrophic yeast *Pichia pastoris* GS115 by fusion of the cDNA spanning from Ser47 to Lys135 to the secretion signal sequence of alpha-factor prepro-peptide. In a flask culture, the secreted UK1 reached about 1 g/l level after 120 h of methanol induction and was purified to homogeneity by ion-exchange chromatography. Amino-terminal sequencing of the purified UK1 revealed that it was cleaved at the Stel3 signal cleavage site. The molecular mass of UK1 was determined to be 10,297.01 Da. It was also confirmed that the purified UK1 inhibited endothelial cell proliferation stimulated by basic fibroblast growth factor, vascular endothelial growth factor, or epidermal growth factor, in a dose-dependent manner. These results suggest that a *P. pastoris* system can be employed to obtain large amounts of soluble and active UK1.

ACCESSION NUMBER: 2003:490314 BIOSIS
DOCUMENT NUMBER: PREV200300492318
TITLE: Secretory production of recombinant urokinase kringle domain in *Pichia pastoris*.
AUTHOR(S): Kim Hyun-Kyung; Hong, Yong-Kil; Park, Hyo-Eun; Hong, Sung Hee; Joe, Young Ae [Reprint Author]
CORPORATE SOURCE: Cancer Research Institute, Catholic Research Institutes of Medical Sciences, Catholic University of Korea, Seoul, 137-701, South Korea
youngjoe@catholic.ac.kr
SOURCE: Journal of Microbiology and Biotechnology, (August 2003)
Vol. 13, No. 4, pp. 591-597. print.
ISSN: 1017-7825.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 22 Oct 2003
Last Updated on STN: 22 Oct 2003

L3 ANSWER 2 OF 7 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo.
AB Prostate cancer is one of the most common malignant tumors with increasing incidence rates in the aging male. Since locally advanced or metastatic prostate tumors are essentially incurable, identification of new target molecules and treatment strategies is of critical importance. Fibroblast growth factor-2 (FGF-2) acts as potent mitogen which is upregulated in

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 AUG 05 New pricing for EUROPAFULL and PCTFULL effective
August 1, 2003
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS 10 SEP 22 DIPPR file reloaded
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded
NEWS 12 SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced

NEWS EXPRESS OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:29:34 ON 30 OCT 2003

=> file biosis, medline, wpids

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'BIOSIS' ENTERED AT 16:29:46 ON 30 OCT 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

prostate cancers modulating cancer cell proliferation and development of an invasive phenotype. Normally it is tightly bound to the extracellular matrix that quenches its biological activity. The FGF-binding proteins (FGF-BP, HBp17) is a **secreted protein** which is able to mobilize and activate FGF-2 from the extracellular matrix. Here we show that FGF-BP is highly expressed in prostate tumor cells. To study the functional role of FGF-BP, we use a ribozyme-targeting approach to selectively deplete FGF-BP in prostate cancer cells achieving a more than 50% reduction of FGF-BP mRNA and protein levels in two mass-transfected cell lines. FGF-BP depletion reduces proliferation of the cells in vitro without changes in cell cycle distribution or apoptosis. Using cDNA microarrays, Northern blotting and RT-PCR, we show a complex pattern of changes in the gene expression profiles upon FGF-BP depletion. Most strikingly, ribozyme-mediated reduction of FGF-BP levels completely abolishes the ability of the highly metastatic PC-3 prostate carcinoma cells to grow tumors in an athymic nude mouse in vivo model which is far beyond the effects of FGF-BP ribozyme targeting observed previously in cells from other tumors in the same model. Taken together, our study identifies FGF-BP as a potential rate-limiting factor for prostate cancer growth and, due to its restricted expression pattern in adults, a potentially attractive target for prostate **cancer therapy**.

ACCESSION NUMBER: 2002:484632 BIOSIS
DOCUMENT NUMBER: PREV200200484632
TITLE: Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo.
AUTHOR(S): Aigner, Achim [Reprint author]; Renneberg, Heiner; Bojunga, Joerg; Apel, Juergen; Nelson, Peter S.; Czubayko, Frank
CORPORATE SOURCE: Department of Pharmacology and Toxicology, Philipps-University School of Medicine, Marburg, Germany aigner@mailier.uni-marburg.de
SOURCE: Oncogene, (22 August, 2002) Vol. 21, No. 37, pp. 5733-5742. print.
CODEN: ONCNES. ISSN: 0950-9232.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 18 Sep 2002
Last Updated on STN: 18 Sep 2002

L3 ANSWER 3 OF 7 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI Production process for recombinant human angiostatin in Pichia pastoris.
AB A pilot-scale production method of recombinant human angiostatin, a 38-kD fragment of plasminogen which has been reported to have antiangiogenic activity, has been successfully established by expressing the protein in the methylotrophic yeast Pichia pastoris. The **secreted protein** inhibited culture endothelial cell proliferation in vitro and Lewis lung carcinoma growth in mice. The fermentation process was carried out using an on-line methanol controller, administering methanol to the growing culture and keeping its concentration under 2 g L⁻¹. The fermentation lasted 90 h, of which 70 h were growth on methanol. During growth on methanol the culture volume increased 64%, from 7 L to 11.5 L, producing 200 mg angiostatin and 5 kg of biomass.

ACCESSION NUMBER: 2000:154528 BIOSIS
DOCUMENT NUMBER: PREV200000154528
TITLE: Production process for recombinant human angiostatin in Pichia pastoris.
AUTHOR(S): Lin, J.; Panigraphy, D.; Trinh, L. B.; Folkman, J.; Shiloach, J. [Reprint author]
CORPORATE SOURCE: Biotechnology Unit, NIH, Bldg 6 Rm B133, Bethesda, MD, 20892, USA
SOURCE: Journal of Industrial Microbiology and Biotechnology, (Jan., 2000) Vol. 24, No. 1, pp. 31-35. print.
ISSN: 1367-5435.

DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 26 Apr 2000
Last Updated on STN: 4 Jan 2002

L3 ANSWER 4 OF 7 MEDLINE on STN
TI Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo.
AB Prostate cancer is one of the most common malignant tumors with increasing incidence rates in the aging male. Since locally advanced or metastatic prostate tumors are essentially incurable, identification of new target molecules and treatment strategies is of critical importance. Fibroblast growth factor-2 (FGF-2) acts as potent mitogen which is upregulated in prostate cancers modulating cancer cell proliferation and development of an invasive phenotype. Normally it is tightly bound to the extracellular matrix that quenches its biological activity. The FGF-binding proteins (FGF-BP, HBp17) is a **secreted protein** which is able to mobilize and activate FGF-2 from the extracellular matrix. Here we show that FGF-BP is highly expressed in prostate tumor cells. To study the functional role of FGF-BP, we use a ribozyme-targeting approach to selectively deplete FGF-BP in prostate cancer cells achieving a more than 50% reduction of FGF-BP mRNA and protein levels in two mass-transfected cell lines. FGF-BP depletion reduces proliferation of the cells in vitro without changes in cell cycle distribution or apoptosis. Using cDNA microarrays, Northern blotting and RT-PCR, we show a complex pattern of changes in the gene expression profiles upon FGF-BP depletion. Most strikingly, ribozyme-mediated reduction of FGF-BP levels completely abolishes the ability of the highly metastatic PC-3 prostate carcinoma cells to grow tumors in an athymic nude mouse in vivo model which is far beyond the effects of FGF-BP ribozyme targeting observed previously in cells from other tumors in the same model. Taken together, our study identifies FGF-BP as a potential rate-limiting factor for prostate cancer growth and, due to its restricted expression pattern in adults, a potentially attractive target for prostate **cancer therapy**.

ACCESSION NUMBER: 2002418379 MEDLINE
DOCUMENT NUMBER: 22162915 PubMed ID: 12173043
TITLE: Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo.
AUTHOR: Aigner Achim; Renneberg Heiner; Bojunga Jorg; Apel Jurgen; Nelson Peter S; Czubayko Frank
CORPORATE SOURCE: Department of Pharmacology and Toxicology, Philipps-University School of Medicine, Marburg, Germany.. aigner@mailier.uni-marburg.de
SOURCE: ONCOGENE, (2002 Aug 22) 21 (37) 5733-42.
Journal code: 8711562. ISSN: 0950-9232.
PUB. COUNTRY: England; United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200209
ENTRY DATE: Entered STN: 20020813
Last Updated on STN: 20020911
Entered Medline: 20020910

L3 ANSWER 5 OF 7 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
TI Assessing the presence of ovarian cancers in humans, as well as efficacy of a **cancer therapy**, by determining the level of expression of ovarian cancer marker gene(s), e.g., mesothelin, matrix metalloproteinase.
AN 2003-361913 [34] WPIDS
AB US2003003479 A UPAB: 20030529
NOVELTY - Assessing whether a patient is afflicted with ovarian cancer by

comparing the level of expression of one or several ovarian cancer marker genes in a patient sample to a control subject not afflicted with ovarian cancer. At least one of the marker genes is from any of the 714 marker genes fully described in the specification, e.g. mesothelin, tryptophan hydroxylase, apoptosis-related protein PNAS-1, or leukemia-associated phosphoprotein p18.

DETAILED DESCRIPTION - Assessing whether a patient is afflicted with ovarian cancer comprises comparing:

(a) the level of expression of one or several ovarian cancer marker genes in a patient sample; and

(b) the normal level of expression of one or several of the marker genes in a sample from a control subject not afflicted with ovarian cancer.

At least one of the marker genes is from any of the 714 marker genes fully described in the specification, e.g. mesothelin (AI056417), brain-specific Na-dependent inorganic phosphate cotransporter (AA702627), tryptophan hydroxylase (tryptophan 5-monooxygenase) (AA702193), ariadne-2 (D. melanogaster) homolog (AA136879), FLJ20689 fis, KAIA2890 (AA448710), high density lipoprotein binding protein (vigilin) (T55446), apoptosis-related protein PNAS-1 (AA521316), or leukemia-associated phosphoprotein p18 (AA873060). A significant difference between the level of expression of one or several of the marker genes in the patient sample, and the normal level of the marker gene(s) is an indication that the patient is afflicted with ovarian cancer.

INDEPENDENT CLAIMS are also included for the following:

- (1) monitoring the progression of ovarian cancer in a patient;
- (2) assessing the efficacy of a test compound for inhibiting ovarian cancer in a patient;
- (3) assessing the efficacy of a therapy for inhibiting ovarian cancer in a patient;
- (4) selecting a composition for inhibiting ovarian cancer in a patient;
- (5) inhibiting ovarian cancer in a patient;
- (6) kits for assessing whether a patient is afflicted with ovarian cancer, the presence of ovarian cancer cells, the suitability of each of the compounds for inhibiting ovarian cancer in a patient, the presence of human ovarian cancer cells, or the ovarian cell carcinogenic potential of a test compound;
- (7) making an isolated hybridoma that produces an antibody for assessing whether a patient is afflicted with ovarian cancer;
- (8) an antibody produced by the hybridoma made by the method (7);
- (9) assessing the ovarian cell carcinogenic potential of a test compound;
- (10) inhibiting ovarian cancer in a patient at risk for developing ovarian cancer by inhibiting the expression of any of the marker genes cited above;
- (11) treating a patient afflicted with ovarian cancer by providing to the cells of the patient an antisense oligonucleotide complementary to a polynucleotide encoded by any of the marker genes cited above, or a segment of the polynucleotide;
- (12) determining whether ovarian cancer has metastasized in a patient; and
- (13) assessing the aggressiveness or indolence of ovarian cancer.

ACTIVITY - Cytostatic.

No biological data given.

MECHANISM OF ACTION - Gene Therapy; Antisense Therapy.

USE - The method is useful for detecting or diagnosing human ovarian cancers, monitoring the progression of ovarian cancer in a patient, assessing the efficacy of a test compound for inhibiting ovarian cancer in a patient, or assessing the efficacy of a therapy for inhibiting ovarian cancer in a patient. The marker genes may also be used for screening compositions for inhibiting or treating ovarian cancer in a patient.

Dwg.0/0

DOC. NO. CPI: C2003-095491
 TITLE: Assessing the presence of ovarian cancers in humans, as well as efficacy of a **cancer therapy**, by determining the level of expression of ovarian cancer marker gene(s), e.g., mesothelin, matrix metalloproteinase.
 DERWENT CLASS: B04 D16
 INVENTOR(S): KOVATS, S G; LILLIE, J; MORRISSEY, M P; SEN, A
 PATENT ASSIGNEE(S): (MILL-N) MILLENNIUM PHARM INC
 COUNTRY COUNT: 1
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2003003479	A1	20030102	(200334)*		47

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2003003479	A1 Provisional	US 2001-285443P	20010419
		US 2002-126227	20020419

PRIORITY APPLN. INFO: US 2001-285443P 20010419; US 2002-126227 20020419

L3 ANSWER 6 OF 7 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
 TI Assessing whether patient is afflicted with breast cancer comprises comparing level of expression of marker in patient sample to marker expression in control non-breast cancer sample.
 AN 2001-381919 [40] WPIDS
 AB WO 200146697 A UPAB: 20010719
 NOVELTY - Assessing whether a patient is afflicted with breast cancer comprising comparing the level of expression of a marker fully defined in the specification in a patient sample to the normal level of expression of the marker in a control non-breast cancer sample, where a significant difference between the two is an indication that the patient is afflicted with breast cancer, is new.
 DETAILED DESCRIPTION - Assessing (M1) whether a patient is afflicted with breast cancer comprising comparing the level of expression of a marker (I) fully defined in the specification in a patient sample to the normal level of expression of the marker in a control non-breast cancer sample, where a significant difference between the level of expression of the marker in the patient sample and the normal level is an indication that the patient is afflicted with breast cancer, is new.
 INDEPENDENT CLAIMS are included for the following:
 (1) monitoring (M2) the progression of breast cancer in a patient comprising:
 (a) detecting in a patient sample at a first point in time, the expression of (I);
 (b) repeating (a) at a subsequent point in time; and
 (c) comparing the level of expression detected in (a) and (b);
 (2) assessing the efficacy of a test compound for inhibiting a breast cancer in a patient comprising comparing the expression of (I) in a first sample obtained from the patient and maintained in the presence of the test compound and expression of (I) in a second sample obtained from the patient and maintained in the absence of the test compound, where a significantly altered level of expression of (I) in the first sample relative to the second is indicative that the compound is efficacious for inhibiting breast cancer in the patient;
 (3) assessing the efficacy of a therapy for inhibiting breast cancer comprising comparing expression of (I) in the first sample obtained from the patient prior to providing at least a portion of the therapy to the

patient and expression of (I) following provision of the therapy, where a significantly altered level of expression of (I) in the first sample relative to the second is indicative that the therapy is efficacious for inhibiting breast cancer in the patient;

(4) selecting (M3) a composition for inhibiting breast cancer in a patient comprising:

- (a) obtaining a cancer cell containing sample from the patient;
- (b) separately maintaining sample aliquots in the presence of test compositions;
- (c) comparing expression of (I) in each aliquot; and
- (d) selecting one of the compositions which induces an altered level of expression of (I) relative to the other compositions;

(5) inhibiting breast cancer in a patient comprising administering the selected composition of M3;

(6) making (M4) an isolated hybridoma which produces an antibody useful for assessing whether a patient is afflicted with breast cancer comprising:

(a) immunizing a mammal using an isolated protein corresponding to (I);

(b) isolating the splenocytes from the mammal;

(c) fusing the splenocytes with an immortalized cell line to form hybridomas; and

(d) screening individual hybridomas for production of an antibody which specifically binds with the protein;

(7) an antibody produced by M4;

(8) assessing the breast cell carcinogenic potential of a test compound comprising maintaining separate breast cell aliquots in the presence and absence of the test compound and comparing expression of (I) in each of the aliquots, where a significantly altered level of expression of (I) in the aliquot maintained in the presence of the compound relative to the aliquot maintained in the absence of the compound is an indication that the compound possesses human breast cell carcinogenic potential;

(9) treating (M5) a patient afflicted with breast cancer comprising providing a protein corresponding to (I) or an antisense oligonucleotide complementary to a polynucleotide corresponding to (I) to the cells of the cancer;

(10) inhibiting breast cancer in a patient at risk for developing breast cancer comprising inhibiting expression of a gene corresponding to (I);

(11) a system (II) for identifying selected polynucleotide records that identify a breast cancer cell comprising a digital computer, a database coupled to the computer, a database coupled to the database server with stored data records containing a polynucleotide corresponding to (I) and a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of polynucleotide records which match the desired selection criteria; and

(12) detecting a breast cancer cell comprising using (II).

ACTIVITY - Anticancer. No supporting data is given.

MECHANISM OF ACTION - Gene therapy.

USE - The methods are useful for:

(1) assessing:

- (a) whether a patient is afflicted with breast cancer;
- (b) the stage and grade of breast cancer;
- (c) the benign or malignant nature of breast cancer;
- (d) the histological type of neoplasm (e.g. ductal or lobular);
- (e) the presence of breast cancer cells; and
- (f) the efficacy of a test compound or therapy for inhibiting breast cancer;

(2) making an isolated hybridoma which produces an antibody useful for assessing whether a patient is afflicted with breast cancer;

(3) monitoring the progression of breast cancer in a patient;

(4) selecting a composition or therapy for inhibiting breast cancer;

(5) treating breast cancer or inhibiting breast cancer (in a patient at risk from breast cancer; and

(6) assessing the carcinogenic potential of a test compound.

Dwg.0/0

ACCESSION NUMBER: 2001-381919 [40] WPIDS
DOC. NO. NON-CPI: N2001-280071
DOC. NO. CPI: C2001-117049
TITLE: Assessing whether patient is afflicted with breast cancer
comprises comparing level of expression of marker in
patient sample to marker expression in control non-breast
cancer sample.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): ELIAS, J; LILLIE, J; PALERMO, A; STEINMANN, K; WANG, Y
PATENT ASSIGNEE(S): (MILL-N) MILLENNIUM PREDICTIVE MEDICINE INC
COUNTRY COUNT: 93
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG

WO 2001046697	A2	20010628	(200140)*	EN	115
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ					
NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM					
DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC					
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE					
SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW					
AU 2001025969	A	20010703	(200164)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

WO 2001046697	A2	WO 2000-US35214	20001221
AU 2001025969	A	AU 2001-25969	20001221

FILING DETAILS:

PATENT NO	KIND	PATENT NO

AU 2001025969	A Based on	WO 2001046697

PRIORITY APPLN. INFO: US 2000-219865P 20000720; US 1999-171406P
19991221; US 2000-176423P 20000114; US
2000-190471P 20000317; US 2000-193482P
20000329; US 2000-205231P 20000515; US
2000-213236P 20000620

L3 ANSWER 7 OF 7 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
TI New isolated nucleic acid for diagnosing and treating cervical cancer and
for assessing and detecting compounds for treating the cancer.
AN 2001-375006 [39] WPIDS
AB WO 200142467 A UPAB: 20010716

NOVELTY - An isolated nucleic acid (I) comprising:

- (a) a nucleotide sequence 90 % identical to one of 4 tables of
sequences (S1) given in the specification;
- (b) a fragment of one of (S1); or
- (c) one of or a complement of (S1), is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the
following:

- (1) a vector containing (I);
- (2) a host cell containing (I);
- (3) an isolated polypeptide encoded by (Ia);
- (4) an antibody that binds (3);
- (5) producing (3) comprising culturing (2);
- (6) detecting the presence of (3) in a sample comprising contacting
the sample with a compound that binds (3) and determining binding;

(7) detecting the presence of (I) in a sample comprising contacting the sample with a nucleic acid probe or primer that hybridizes to (I) and determining binding;

(8) kits comprising a compound that binds (3) or (I);

(9) assessing if a patient is afflicted with cervical cancer or has a pre-malignant condition, comprising comparing the level of expression of a marker (M) that is 1 of (S1) in a patient sample and the normal level of expression of (M) in a control non-cervical cancer sample, where a significant difference between the expression levels in the 2 samples is an indication that the patient is afflicted;

(10) monitoring the progression of cervical cancer or a premalignant condition in a patient comprising:

(a) detecting in a patient sample at a point in time, the expression of (M);

(b) repeating (a) at a subsequent point in time; and

(c) comparing the level of expression detected in (a) and (b);

(11) assessing the efficacy of a compound or therapy for inhibiting cervical cancer in a patient comprising comparing:

(a) expression of (M) in a patient sample exposed to the compound or a sample obtained following a portion of the therapy; and

(b) expression of (M) in a second patient sample not exposed to the compound or a sample obtained prior to the portion of therapy, where a significantly lower level of expression of (M) in the first sample relative to the second sample, is an indication that the compound or therapy is efficacious for inhibiting cervical cancer;

(12) selecting a composition for inhibiting cervical cancer comprising:

(a) separately exposing aliquots of a sample of cancer cells from a patient in the presence of compositions;

(b) comparing expression of (M) in each of the aliquots; and

(c) selecting one of the compositions which induces a lower level of expression of (M) in the aliquot containing that composition, relative to other compositions;

(13) inhibiting cervical cancer in a patient comprising:

(a) 12(a)

(b) separately maintaining aliquots of the sample in the presence of compositions;

(c) 12(c); and

(d) administering to the patient one of the compositions which induces a lower level of expression of the marker in the aliquot containing the composition, relative to other compositions;

(14) kits for assessing:

(a) if a patient is afflicted with cervical cancer or a pre-malignant condition, comprising reagents for assessing expression of (M);

(b) the presence of cervical cancer cells or pre-malignant cervical cells or lesions, comprising a nucleic acid probe that specifically binds with a transcribed polynucleotide corresponding to (M) or an antibody that binds a protein corresponding to (M);

(c) assessing the suitability of compounds for inhibiting cervical cancer, comprising the compounds and a reagent for assessing expression of (M);

(15) making an isolated hybridoma which produces an antibody used for assessing whether a patient is afflicted with cervical cancer or a pre-malignant condition, comprising:

(a) isolating a protein or fragment corresponding to (M);

(b) immunizing a mammal using the protein or fragment;

(c) isolating splenocytes from the immunized mammal;

(d) fusing the splenocytes with an immortalized cells line to form hybridomas; and

(e) screening individual hybridomas for production of an antibody which binds the protein or fragment to isolate the hybridoma;

(16) an antibody produced by the hybridoma of (15);

(17) assessing the cervical cell carcinogenic potential of a compound comprising:

(a) maintaining separate aliquots of cervical cells in the presence and absence of the compound;
(b) comparing expression of (M) in each of the aliquots, where a significantly enhanced level of expression of (M) in the aliquot maintained in the presence of the compound, relative to the aliquot in the absence of the compound, is an indication that the compound possesses the potential;
(18) a kit for assessing the carcinogenic potential of a compound comprising cervical cells and a reagent for assessing expression of (M);
(19) treating a patient afflicted with cervical cancer comprising providing to a patient an antisense oligonucleotide complementary to a polynucleotide corresponding to (M); and
(20) inhibiting cervical cancer in a patient at risk for developing cervical cancer comprising inhibiting expression of a gene corresponding to (M).

ACTIVITY - Cytostatic. No biological data is given.

MECHANISM OF ACTION - Gene therapy.

USE - (I) and a polypeptide encoded by (I) are used:

(a) to assess if a patient is afflicted with cervical cancer or has a pre-malignant condition;

(b) to monitor the progression of cervical cancer or a premalignant condition in a patient; and

(c) to assess the efficacy of a compound or therapy, or select a composition, for inhibiting cervical cancer in a patient.

(I) is used to produce a polypeptide in a host cell. A compound which binds to the polypeptide, such as an antibody, is used to test for cervical cancer in a patient sample. A protein or fragment corresponding to (I) is used to make an isolated hybridoma which produces an antibody used for assessing whether a patient is afflicted with cervical cancer or a pre-malignant condition. An oligonucleotide complementary to (I) is used to treat a patient afflicted with cervical cancer (claimed).

Dwg.0/0

ACCESSION NUMBER: 2001-375006 [39] WPIDS
DOC. NO. NON-CPI: N2001-274388
DOC. NO. CPI: C2001-114664
TITLE: New isolated nucleic acid for diagnosing and treating cervical cancer and for assessing and detecting compounds for treating the cancer.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): BERGER, A; DEEDS, J; SCHLEGEL, R; ZHAO, X
PATENT ASSIGNEE(S): (MILL-N) MILLENNIUM PREDICTIVE MEDICINE INC
COUNTRY COUNT: 93
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG

WO	2001042467	A2	20010614	(200139)*	EN
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW					
AU	2001020742	A	20010618	(200161)	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

WO	2001042467	A2	WO 2000-US33312 20001208
AU	2001020742	A	AU 2001-20742 20001208

FILING DETAILS:

PATENT NO	KIND	PATENT NO

AU 2001020742	A	Based on
		WO 2001042467

PRIORITY APPLN. INFO: US 2000-220114P 20000721; US 1999-169681P
19991208; US 1999-171350P 19991221; US
2000-189315P 20000314; US 2000-203791P
20000512; US 2000-210600P 20000609

=> e fiscella/au